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Ag  Antigen 
Amplicon  PCR product 
bp Base pair 
BLAST  Basic Local Alignment Search Tool 
BSA  Bovine serum albumin 
ClustalW2 ClustalW2 multiple sequence alignment tool 
cPCR Conventional PCR 
CRS Composite reference standard 
Ct Cycling threshold 
DCP  Department of Clinical Parasitology 
DDJB  DNA Databank of Japan 
∆∆ Ct  Delta delta Ct 
DIS Disseminated infection syndrome 
ELISA  Enzyme-linked immunosorbent assay 
EM  Taqman® Environmental master mix 2.0 
FECT Formalin: triton x-100/ ethyl acetate concentration technique for stool 
microscopy 
gfp Green fluorescent protein of the jellyfish Aequorea victoria 
GIT Gastrointestinal tract 
HIS Hyperinfection syndrome 
HPA Health protection agency, now known as Public Health England 
HRMC High resolution melt curve 
HS  Hotstart Taq® polymerase 
HTD  Hospital for Tropical Diseases 
IDEA study  Infectious diseases in Europe and Africa study 
LAMP 
LAMP time  
Loop mediated isothermal amplification 
Detection of turbidity produced by amplification of target DNA 
MgCl2 Magnesium chloride 
PBS Phosphate Buffered Saline, pH 7.2 
PCR  Polymerase chain reaction 
PHE  Public Health England 
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qPCR  Real-time PCR 
SDS  Sodium dodecasulphate 
S. fuelleborni  Strongyloides fuelleborni fuelleborni 
S. fuelleborni kellyi  Strongyloides fuelleborni kellyi 
S. stercoralis  Strongyloides stercoralis 
SPSs  In-house developed LAMP primer set (inner, outer and loop primers) for the 
detection of S. stercoralis DNA 
Stro18S  qPCR primer set and double-labelled probe for the detection of S. stercoralis 
DNA (Stro18S-1530F, Stro18S-1630R and Stro18S-1586T) 
UCLH  University College London NHS Foundation Trust 
UK  United Kingdom 
WTM Western Travel Medicine 
WSs  Published LAMP primer set (inner, outer and loop primers) for the detection 
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The laboratory diagnosis of Strongyloides stercoralis (S. stercoralis) at the Department of Clinical 
Parasitology (DCP) by the routine methods of microscopy and Strongyloides culture is not sensitive 
due to the, usually, low parasite load and intermittent larval excretion of the parasite. Serology 
(enzyme-linked immunosorbent assay) suffers from a lack of specificity because Strongyloides 
antibodies are known to cross- react with schistosomal, filarial and other helminthic antibodies in 
serological tests. Moreover, antibody levels are slow to decline after successful treatment therefore 
serology cannot be used to monitor point of cure. A missed diagnosis of strongyloidiasis in 
immunocompromised patients or those about to undergo iatrogenic immune suppression may 
have severe, even fatal, consequences.  The disease is poorly studied because of the lack of 
sensitive, specific and cost-effective tests. Therefore, the decision was made to evaluate and 
validate nucleic acid amplification techniques (NAATs) for the diagnosis of S. stercoralis for use in a 
well- resourced specialist referral parasitology laboratory. A novel loop mediated isothermal 
amplification (LAMP) assay was also developed for use in resource- limited regions. The study was 
conducted over two years (2014-2016) and examined 284 residual diagnostic samples. The cohort 
was drawn from patients attending a central London western travel medicine (WTM) clinic.  
The NAATs chosen for this study were a published real- time PCR (qPCR) assay (ten Hove et al., 
2009) and a novel LAMP assay. The NAATs were compared to the combined reference standard of 
microscopy, culture and serology for the diagnosis of S. stercoralis in stool samples. The 
development of the novel LAMP assay for use in resource- limited areas included the investigation 
of methods for rapid, simple and cost- effective DNA extraction. The qPCR and LAMP assays detect 
target DNA within areas on either side of the S. stercoralis 18S rRNA genome hypervariable region 
(Hasegawa et al., 2009). In this study the LAMP and qPCR assays demonstrated a limit of detection 
of 10-3 and 10-4, respectively for S. stercoralis DNA detection in clinical samples. Specificity was 
determined for the LAMP and qPCR assays to be 100% and 94.83%, respectively and the cost per 
test was calculated as £4.80 and £8.21, respectively. In this study, persistence of S. stercoralis DNA 
in clinical samples was improved when the samples were stored at -20oC.  
While the LAMP assay has a shorter turnaround time and is less costly than qPCR, the superior 
efficiency of qPCR detection of S. stercoralis DNA in clinical samples established that the qPCR assay 
was a more suitable addition to the diagnostic repertoire at a high- throughput WTM clinic. The 
LAMP assay showed promise for deployment in resource- limited areas and as a point- of- care test 
but further work is required to optimise the LAMP assay for these purposes. 
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CHAPTER 1: INTRODUCTION 
1.1. STRONGYLOIDES STERCORALIS 
Strongyloides stercoralis is a soil transmitted helminth infection endemic to tropical, subtropical 
and temperate climates with poor sanitation and high humidity (Basile et al., 2010, Bonn et al., 
2010, Buonfrate et al., 2015, Cimeno and Krowlewiecki, 2014, WHO, 2010).  
There are more than 50 species of Strongyloides, but only 3 are capable of causing disease in 
humans: S. stercoralis, Strongyloides fuelleborni fuelleborni and Strongyloides fuelleborni kellyi 
(WHO, 2010, Requena-Méndez et al., 2013, Taylor et al., 2014). S. fuelleborni, generally infects non-
human primates, is rare in humans and causes a sporadic zoonotic disease in Africa. S. fuelleborni 
kellyi is only found in Papua New Guinea and if left untreated can cause fatal “swollen belly” 
syndrome in new-borns in Papua New Guinea. It is thought to have derived from a local zoonotic 
source and is now considered a separate species from S. fuelleborni on the basis of small subunit 
ribosomal RNA gene sequences (Dorris et al., 2002, Getaneh et al., 2010, Taylor et al., 2014, Makker 
et al., 2015). Neither S. fuelleborni nor S. fuelleborni kellyi is thought to cause auto-infection as they 
shed eggs rather than larvae in faeces (Olsen et al., 2009). 
Strongyloides stercoralis, the major human pathogen, is capable of causing a disease ranging from 
asymptomatic or chronic non-specific gastro-intestinal or respiratory symptoms to life-threatening 
hyperinfection syndrome (HIS). This is due to the unique lifecycle by which the disease can persist 
in humans for decades due to auto-infection by infectious L3 larvae penetrating the perianal skin or 
gut wall.  This can lead to persistence of infection in immunocompetent hosts or uncontrolled 
multiplication and invasion of organs outside the gastro-intestinal tract if the patient becomes 
immunocompromised (WHO, 2010, Requena-Méndez et al., 2013). Human strongyloidiasis from 
pet origin is rare and this is thought to be due to the diversification of S. stercoralis into strains 
adapted to human and non-human hosts (Hasegawa et al., 2009). Jaleta et al. (2017) described two 
genetically different types of S. stercoralis carried in dogs in Northern Cambodia. One genetic type 
of S. stercoralis was found in both humans and dogs, indicating that dogs may be an important 
reservoir for zoonotic strongyloidiasis. 
Strongyloides stercoralis was first described in 1876 in French soldiers returning from Indochina by 
Louis Normand and the full life-cycle, pathology and clinical features were described in the 1930’s 
(Schär et al., 2013b).  Looss, (in the 1900’s) after infecting himself and observing the larvae 64 days 
later, commented that there were still gaps in the knowledge of strongyloidiasis that hampered the 
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control of the disease (Looss, 1905). This is still the case because of the lack of suitably sensitive and 
specific diagnostic tests (Taylor et al., 2014). 
Strongyloides  stercoralis is increasingly found in patients attending western travel medicine (WTM) 
and gastro-intestinal clinics due to the changing patterns of travel, migration and working practices 
(Gorospe and Oxentenko, 2012, Kramme et al., 2011, Libman et al., 1993, ten Hove et al., 2009).  
Strongyloidiasis is common in migrants from South East Asia and Africa (Biggs et al., 2009) and this 
trend was also seen in this current study. In developed countries the disease is mainly found in 
immigrants and returning soldiers (Schär et al., 2013b). In previously endemic countries (e.g. Italy 
and Spain) older individuals may harbour the disease for decades (Requena-Méndez et al., 2014). 
Imported neglected tropical diseases have become an important issue in western travel medicine 
(ten Hove et al., 2009, Whitty et al., 2000). 
1.2. LIFECYCLE 
S. stercoralis has a complicated life-cycle (Figure 1.1) with host-mediated (homogonic) and free-
living environmental (heterogonic) life-cycles (Taylor et al., 2014).  
The stimuli favouring the free-living or parasitic life-cycles are unknown.  Shiwaku et al. (1988) 
showed that temperature and faecal dilution have an effect on larval development and Minato et 
al. (2008) demonstrated the development of adult worms at temperatures <15oC and the 
development of infectious L3 larvae at temperatures > 15oC in Strongyloides ratti. A chemical agent 
is likely involved in the development of S. stercoralis larvae (Taylor et al., 2014). Siddiqui et al. 
(2000) suggested a parasite receptor that triggers steroid mediated HIS by affecting the 





Figure 1.1: Lifecycle of Strongyloides stercoralis detailing the parasitic (homogonic) life-cycle (1, 6 -
10) and the free-living (heterogonic) life-cycle (1-6) and the auto- infection cycle (1, 7 and 10) (CDC, 
n.d.) 
Strongyloides  stercoralis is a soil- transmitted helminth that can also be transmitted by the faecal-
oral route and infected breast milk (Montes et al., 2010, Requena- Méndez et al., 2013). Infectious 
filariform larvae (L3) penetrate the skin (mostly the soles of the feet) and travel via the bloodstream 
to the alveolar spaces. The larvae are expectorated and travel via the trachea to the oesophagus 
and are swallowed. They become embedded in the lamina propia of the small intestine 
(duodenum) where they mature into adult worms. All parasitic worms are female (2.2 x 0.5 mm) 
and reproduce parthenogenically, producing up to 40 embryonated eggs per day. The eggs hatch 
inside the gut lumen and release rhabditiform larvae (L1) in the faeces (Barros and Montes, 2014, 




The rhabditiform larvae (250 µm x 20 µm) may develop into infectious filariform larvae (600 µm x 
20 µm) and cause auto-infection by penetrating the lumen of the gut or the perianal skin to 
continue the infectious cycle causing a disease that may persist for decades (Barros and Montes, 
2014, Mejia and Nutman, 2012, Repetto et al., 2010) or go directly into the free-living cycle in the 
soil where they can survive without a mammalian host (Montes et al., 2010). Adult males (0.9mm) 
fertilise the eggs in the environment. There is a possibility that pseudogamic reproduction (where 
the sperm stimulates the egg cell to produce an embryo but no genetic material is transferred) 
occurs in S. stercoralis or that S. stercoralis is a complex of related species or sub species but more 
work is required in this field (Schär et al., 2014).   
Research is hampered by the fact that S. stercoralis has only one free-living heterogonous life cycle 
in culture and this makes it difficult to study in a laboratory environment (Olsen et al., 2009, Taylor 
et al., 2014) 
1.3. MORBIDITY AND MORTALITY 
More than half of the infections in immunocompetent people are asymptomatic. Becker et al. 
(2011) showed no difference between infected and non-infected individuals in terms of 
asymptomatic presentation and Sudarshi et al. (2003), in a study carried out at the Hospital for 
Tropical Diseases (HTD); found that a third of travellers and a third of migrants with confirmed 
strongyloidiasis were asymptomatic. The development of symptoms appears to be related to the 
parasite load and immune status (Makker et al., 2015, Khieu et al., 2013). Chronic diarrhoea is a 
feature of strongyloidiasis in HIV positive individuals but strongyloidiasis is no longer categorised as 
an AIDS-defining disease (Montes et al., 2010). Chronic clinical manifestations include abdominal 
discomfort, vomiting, diarrhoea, gastro-intestinal haemorrhage, anorexia, cough, shortness of 
breath, asthma and a fleeting serpingous urticarial rash at the entry of larvae into the skin and 
during auto-infection known as larva currens (Montes et al., 2010). Larva currens occurs on the 
trunk, upper leg and buttocks and moves rapidly at 2-10 cm/ hour. It is a localised allergic response 
to parasites migrating through the skin. It is indurated, has a red flare and disappears within hours 
and is pathognomic for strongyloidiasis (Checkley et al., 2010, Fischer, 2015, Ganesh and Cruz, 
2011). Loeffler’s syndrome (fever, malaise, cough, wheezing and shortness of breath) may occur 
when the larvae are migrating through the lungs in acute or disseminated infection. Larvae are 
detected in faeces only if the parasite load is high enough to be detected microscopically (Requena-
Méndez et al., 2013). 
Immunocompromised individuals are most at risk of developing severe, life-threatening disease 
where large numbers of S. stercoralis larvae invade multiple organs, frequently involving the 
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musculoskeletal system (Barros and Montes, 2014, Levenhagen and Costa-Cruz, 2014). Larvae can 
be found in cerebrospinal fluid, bronchial lavage, sputum, faeces and organs outside of the gastro-
intestinal tract (GIT) (Basile et al., 2010, Bisoffi et al., 2011, Buonfrate et al., 2013). The mortality 
rate for disseminated infection (DIS), found in extra-GIT or respiratory sites, is 85-100% and the 
mortality rate for HIS where increased numbers of larvae are found in the GIT and lungs is 60-85%. 
It is easy to diagnose HIS and DIS because of the high parasite numbers but it is difficult to treat 
(Kassalik and Mönkemüller, 2011). HIS/ DIS may occur 3 months after kidney transplant and carries 
a mortality of 50%, post-haemopoietic transplant HIS/ DIS may occur immediately after 
transplantation and has a mortality rate of 85% which may be due to a higher immunosuppressive 
treatment regime (Roxby et al., 2009). Iatrogenic immune suppressive therapy in patients with 
undiagnosed strongyloidiasis has a fatality rate of up to 87% when corticosteroids are administered. 
This is not as pronounced with the administration of cyclosporine A immunosuppressive therapy 
(Mejia and Nutman, 2012, Montes et al., 2010, Olsen et al., 2012). This may be due to a parasite 
receptor that triggers development of the L3 infectious larvae (Siddiqui et al., 2000). Larval 
penetration of the gut wall can lead to severe Gram-negative bacterial sepsis, pneumonia and 
meningitis.  
1.4. PREVALENCE AND RISK FACTORS 
Strongyloides stercoralis is found in parts of Europe, South Eastern United States, Asia, Africa and 
Latin America (Becker et al., 2015, Bisoffi et al., 2011, Bisoffi et al., 2013). More recently the 
parasite has been reported by Taylor et al. (2014) in endemic populations in the arid Australian 
outback associated with faulty or poorly maintained air-conditioning units. The geographical range 
for the disease is worldwide with the exception of Antarctica (Schär et al., 2013a). 
Previous prevalence rates of 30-100 million S. stercoralis infected individuals were known to be 
under-estimated (WHO, 2010) and more recent estimates based on serological data has put the 
prevalence at over 350 million infected individuals (Requena-Méndez et al., 2014). There is an 
under-appreciated economic and public health burden with no Disability Adjusted Life Years 
(DALYs) for the disease  as there are no distinct clinical markers to use (Krowlewiecki et al., 2013) 
and this is impeding the progress of strongyloidiasis control in endemic areas (Becker et al., 2011, 
Glinz et al., 2011). Prevalence depends on parasite/ host and environmental interactions so 
targeted control measures may prevent transmission (Norman et al., 2010) and the development of 
life-threatening disease (Saugar et al., 2015). There are no suitable diagnostic tests to determine 
prevalence and monitor disease control in endemic areas and this has led the World Health 
Organisation (WHO) to declare S. stercoralis a neglected tropical disease (WHO, 2010). Knopp et al. 
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(2008) and Khieu et al. (2013) noted that the highest prevalence rate was observed when different 
parasitological and serological diagnostic methods were combined. Many studies have been 
performed in endemic areas using different diagnostic methods and study protocols to determine 
the prevalence of the disease, but these are difficult to compare because of the different testing 
protocols used (Table 1.1). 
Table 1.1: Prevalence and risk of infection: S. stercoralis. 




Persistence of strongyloidiasis increases with 
length of exposure 
Under-representation from some areas so 
could not extrapolate to all cases of 
strongyloidiasis 
Use of low sensitivity methods 
Thailand 62.5% Prolonged exposure 
carries  a higher risk of 
infection (migrants/living 
in endemic areas/visiting 
friends and 






Different prevalence around the world  
Dependent on area and monitoring tests, 








20 year review of community, hospital and 
migrant studies. Studies in China and India 
(areas with the highest populations) are scarce 
and do not cover the whole geographical 
region 
63.3% of studies used low sensitivity methods 
(community studies) 
28.6% used moderate sensitivity methods 
(hospital studies) 
9.9% used high sensitivity tests (PCR) (migrant 
studies) 
South East Asia 17-26% one 
study as low as 0.02% 
Ghana 11.6% slightly higher in 
males 
Japan 5.5-30.2% (dependent 
on age) 
Africa 0.1-91.8% 
Central and South America 1-
75.3% 
Migrant studies suggest that 
10-40% of population in 
endemic areas is infected 
Males and older age group 
Areas in Europe and the 
United States of America- 
farming, mining, migrants 
and returning soldiers 
Trend to a higher risk in 




Review of S. stercoralis prevalence rate in 
different countries and different diagnostic 
methods 
 
Kenya 80%  
Gabon 92%  
Namibia 99% 
Dominican Republic 98%  
Peru 75%  
PNG: 99% 
Immunocompromised or 
HTLV1 co-infection at risk 




Reviewing the literature underlined the need for strongyloidiasis to be recognised so that those at 
risk of developing severe disease can be treated (Gorospe and Oxentenko, 2012, Kramme et al., 
2011, Libman et al., 1993, ten Hove et al., 2009). The ability of S. stercoralis to cause severe, life-
threatening disease in immunocompromised hosts, in both endemic and non-endemic areas, 
means that missing a diagnosis of strongyloidiasis can have fatal consequences (Barros and Montes, 
2014, Levenhagen and Costa-Cruz, 2014) 
In an attempted meta-analysis of the global distribution and risk factors Schär et al. (2013b) found 
associations for risk of disease using pooled odds-ratios (OR) with HTLV1 co-infection (OR 2.48, 95% 
BCI:0.70-9.03), HIV positive (OR 2.17, 95% BCI: 1.18-4.01), alcoholics (OR 6.69, 95%BCI: 1.47-33.8) 
and patients with malignancies and/or immunocompromising conditions (they were unable to 
perform the meta-analysis because of the diverse reporting of studies in the literature, 
nevertheless an association was noted in the studies). An analysis of studies in children could not 
be performed, but the literature suggests that children have a lower prevalence rate than adults. 
Norman et al. (2010) found that infection with S. stercoralis was cumulative in travellers and that 
single exposures were unlikely to lead to infection. This coupled with the possibility of increased 
access to warm moist soil due to a change in life-style (child to adult) may suggest a reason for this 
trend in children. 
1.5. DIAGNOSIS 
Laboratory diagnosis is important for the detection of asymptomatic disease and a diagnostic test 
may be employed for more than one purpose. Diagnosis of infectious diseases may be used for:  
I. Patient management and treatment follow-up; 
II. Screening for asymptomatic diseases; 
III. Surveillance;  
IV. Monitoring public health intervention;  
V. Detection of drug resistance markers (Peeling et al., 2007).  
It is known that there is a need for more sensitive tests for the diagnosis of strongyloidiasis in 
clinical samples (Requena-Méndez et al., 2013).  There are limited methods available for the 
detection of S. stercoralis and these methods lack suitable and adequate sensitivity and specificity 
(Requena-Méndez et al., 2013). The requirement for costly, high maintenance equipment and 
technical expertise makes these methods unsuitable for use in resource- limited areas (Olsen et al., 
2009, Requena-Méndez et al., 2013). This has led to a lack of knowledge regarding the prevalence 
and epidemiology of the disease. (WHO, 2010, Requena-Méndez et al., 2013).   
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Diagnosis is problematic as microscopy has a sensitivity of 15-30% using single stool samples (from 
migrants or travellers) and the formalin: triton x-100/ ethyl acetate concentration technique (FECT) 
(Requena-Méndez et al., 2013). Low larval loads and intermittent secretion make this an insensitive 
method although the sensitivity can be improved to nearly 100% if 7 stool samples are examined. 
However, collection of 7 consecutive stool samples is not always feasible. Microscopic expertise is 
required to correctly identify Strongyloides larvae and this may not be available outside of endemic 
areas and even in endemic areas training may not be available (Figure 1.2). It is important to 
remember that microscopy detects all parasites and multiple infections are common amongst 




Figure 1.2: The microscopic identification of hookworm. (A: rhabditiform larva-250µm, B: filariform 
larva-700µm, striated sheath) and S. stercoralis larvae (C: rhabditiform larva-250µm, D: filariform 

















filariform tail (black arrow) and the prominent genital primordium of S. stercoralis (red arrow). 
(Adapted from: CDC, n.d.) 
 
The Baermann technique is recommended for microscopic analysis as it relies on the hydrophilic 
and thermophilic nature of larvae to exit the stool and collect in the bottom of a warm-water-filled 
flask. This method is 3.6 to 4 fold more sensitive than FECT (Becker et al., 2015) which is used in 
routine diagnosis at DCP. It is, however, a technique that carries a high risk of laboratory acquired 
infection and is laborious and time- consuming making it unsuitable for use in a busy diagnostic 
laboratory (Basuni et al., 2011, Becker et al., 2015, Biggs et al., 2009, Requena-Méndez et al., 2013) 
Culture of a single stool sample has a sensitivity of 30-70%, using fresh samples (Requena-Méndez 
et al., 2013). The sample size of stool used in this method is up to 10 fold greater than for FECT and 
this makes it more sensitive than FECT. Sensitivity for culture can also be improved by examining 
multiple stool samples (Gonzaga et al., 2011, Rayan et al., 2012, Requena-Méndez et al., 2013). 
Large fresh stool samples (≥ 5 grams; Figure 1.3) are required and the large numbers of viable 
infectious larvae pose a risk of laboratory acquired infection (Bonn et al., 2010).  
 
 
Figure 1.3: In-house Strongyloides Charcoal culture 
 
The importance of using fresh stool samples that have not been refrigerated was shown by Inēs et 
al.(2011) when comparing recovery rates of S. stercoralis from fresh stools and stools that had been 
stored at 4oC for 24, 48 and 72 hours. The authors showed a loss of recoverable larvae of up to 50% 
Stool and charcoal 
mixture 
Larvae are harvested 




after 24 hours. DCP uses an in-house modified charcoal culture method, described in Appendix 1 
(Minato et al., 2008). 
Serology is more effective at detecting strongyloidiasis than parasitological techniques. Animal 
studies have suggested the role of an innate (where eosinophils serve as the antigen presenting 
cells for an antibody response) and adaptive immune response (the production of specific IgG and 
IgE and granulocyte attack to kill the larvae) to S. stercoralis. Helminth infections induce the TH2 cell 
response and stimulate the regulatory system to avoid tissue damage (Montes et al., 2010). 
Acquired immunity is demonstrated by rising antibody levels, but these antibodies only limit and do 
not eradicate the disease (Krowlewiecki et al., 2013). Antibodies develop 4-12 weeks after infection 
(Checkley and Sanderson, 2009) but serology is unable to distinguish between past and current 
infection and is not suitable for use as a test of cure because antibody decay can take up to 12 
months. Various methods have been investigated to resolve this issue; a drop in optical density to 
≤0.5 post-treatment or a post- and pre-treatment ratio of <0.6 have been used to determine 
successful cure (Biggs et al., 2008). It is also not known whether antibody levels correlate with the 
level of parasite present in the body (Basuni et al., 2011, Biggs et al., 2009, Bonn et al., 2010, 
Krowlewiecki et al., 2013). 
Patients who are immunosuppressed may not develop an antibody response and so a diagnosis of 
potentially severe disease may be missed (Buonfrate et al., 2015). HTLV-1 depresses the TH2 
response and so patients with HTLV-1 and S. stercoralis co-infections are susceptible to 
disseminated infection (Zammarchi et al., 2015). Cross-reactions may be seen with other helminth 
infections, most notably filariasis and schistosomiasis (Requena-Méndez et al., 2013). A reason for 
this may be found in an examination of helminth genomics; a rooted cladogram determined from a 
maximum likelihood analysis of 18S rRNA from 18 helminth species determined that nematodes 
(e.g. Strongyloides species, filaria, Ascaris species) and platyhelminths (e.g. Schistosoma species) 
share a common ancestor (Brindley et al., 2009). An enzyme- linked immunosorbent assay (ELISA) 
is, nonetheless, recommended by WHO (2010) for serological diagnosis of strongyloidiasis. These 
tests have a specificity of 29-93% and a sensitivity of 73-100% depending on the source and type of 
antigen used to detect antibodies in the serum, the population studied and the type of 
immunoglobulins used (Requena- Méndez et al., 2013). Sudarshi et al. (2003) in a study of travellers 
and migrants with proven strongyloidiasis determined a sensitivity of 73% in travellers and 98% in 
migrants. These differences may be due to the length of exposure and possibility of re-infection in 
migrants (Norman et al., 2010).  
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A combination of methods and multiple stool samples are required to improve the sensitivity of 
these diagnostic tests for S. stercoralis detection (Saugar et al., 2015). 
Nucleic acid amplification techniques exist for the detection of S. stercoralis in clinical samples. The 
most sensitive method for the detection of S. stercoralis DNA, using real-time PCR, in stool samples 
was shown with the use of primers targeting the 18S rRNA gene (Verweij et al., 2009). Therefore, 
the decision was taken to investigate NAATs for the detection of S. stercoralis DNA using primers to 
target the 18S rRNA gene for this study. This study focussed on the diagnosis of strongyloidiasis in 
human faecal samples as the aim of the study was to evaluate and validate NAATs for introduction 
into the diagnostic repertoire in a specialist parasitology referral laboratory.  
Processing of stool samples to extract DNA is exacting as the samples contain inhibitors to PCR and 
S. stercoralis has a resistant cuticle that needs to be broken down to release the DNA 
(Moghaddassani et al., 2011, Levenhagen and Costa-Cruz, 2014). DCP uses a modified tissue 
extraction protocol on stool samples with the Qiagen®QiaSymphony SP magnetic bead based 
extraction system. This process has a turnaround time of 48 hours, which includes setting up 
worksheets and templates (Table 1.2). The turnaround time is an important consideration when 
evaluating and validating new diagnostics tests for addition to, or replacement for, a current 
diagnostic protocol. Turnaround times have been used as markers for laboratory performance and 
are associated with clinical outcomes (Hawkins, 2007). 
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Table 1.2: Comparison of diagnostic methods for the detection of S. stercoralis at DCP 
METHOD SENSITIVITY ADVANTAGES DISADVANTAGES PROCESSING 
TIME 
MICROSCOPY 
(Manser et al., 
2015) 
15-30% (can be 
improved to 98% plus 




syndrome as large 






Can’t detect low larval load or intermittent excretion and it is 
impractical to collect 7 stool samples from a patient 
Laborious, risk of laboratory acquired infection in 
hyperinfection syndrome 
Specificity and identification relies on well-trained, experienced 
microscopists as hookworm larvae may be present in older 
stool samples 





et al., 2008) 
Sensitivity- 30 -70% if 
more than 1 stool 
sample is examined 
Stool sample size 
is larger by up to 
a factor of 10 so 
culture is more 
sensitive than 
microscopy as 
more of the 
sample is 
examined 
Laborious, risk of laboratory acquired infection 
False negative if the stool is not fresh and the method has a low 
sensitivity if the parasite load is low. Final results are available 
after 7 – 10 days. This method is only for the detection of S. 
stercoralis larvae, although hookworm larvae may be seen and 















Will cross-react with other helminthic antibodies e.g. filaria, 
Schistosoma sp., hookworm  
Immunocompromised patients may not develop an antibody 
response 
Can’t be used to determine effective therapeutic treatment as 
the antibodies persist for up to 12 months 
Can’t distinguish between past and current infection 







(Notomi et al., 
2000, Watts et 
al., 2014) 
Analytical sensitivity 
10-3 (at DCP) using 
stool samples (250µg) 
spiked with 1 S. 







Can be used in a 
high-throughput 
format 
In this study LAMP detected slightly more positive cases than  
microscopy 
Primers are costly 
Processing of stool samples is laborious and can take 48 hours 
Only detects the parasite being investigated 
2 days 
(Preparation of 
sample for PCR) 
1.5 hours (assay 
and analysis of 
results) 
qPCR (Verweij 
et al., 2009) 
Analytical sensitivity 
10-4 (at DCP)  
Sensitive and 
specific 




Primers are costly and expensive automation and 
thermocyclers are required 
Stool samples contain PCR inhibitors and so an internal control 
is required to determine if the samples need to be diluted 1:10 
and the assay repeated 
Processing of stool samples is laborious and can take 48 hours 
Only detects the parasite under investigation 
2 days 
(Preparation of 
sample for PCR) 
3.5hours (assay 





The development of real-time PCR (qPCR) primers has enabled sensitive detection of S. stercoralis 
in stool samples (Verweij et al., 2009, ten Hove et al., 2009). Verweij et al. (2009) compared primer 
sets targeting the cytochrome c oxidase (cyto c), 18S rRNA and S. stercoralis specific repeat 
sequence DNA and determined that the 18S rRNA gene showed superior efficiency to cyto c oxidase 
or S. stercoralis specific repeat sequence DNA. ten Hove et al. (2009) showed an improvement in 
the detection rate from 0.1% (number of positives found by routine microscopy) to 0.8% (number 
of positives found by qPCR) using primers and a probe targeted to the 18S rRNA gene. PCR only 
detects targeted DNA and in this study 0.5% additional parasites were detected by microscopy. The 
qPCR assay has a turnaround time of 3.5 hours, post extraction, at DCP (Table 1.2). 
The 18S rRNA gene is highly conserved in the Strongyloides genus (Hasegawa et al., 2009) and exists 
in various copy numbers, but the exact copy number is not known (Kramme et al., 2011). Fitch et al. 
(1995) reported that little is known of the copy number in the Rhabditida order (of which S. 
stercoralis is a member), but a free-living species Caenorhabditis elegans has 55 copies of a 
repeating unit in the genome comprising of one gene each for 18S, 28S and 5.8S RNA. The 
Caenorhabditis elegans 18S gene is similar in length to the S. stercoralis 18S gene but has a 
sequence match of only 69%. Viney and Blaxter (2002) stated that the 18S rRNA gene had proved a 
useful tool for separating members of the family into different genera, but not necessarily into 
different species. Later, Hasegawa et al. (2009) described four hyper-variable regions in the 18S 
genome that were able to distinguish between species.   
Loop mediated isothermal amplification has become an established nucleic acid amplification 
technique (NAAT) since it was first described by Notomi et al. (2000). LAMP is recommended for 
use in rural endemic areas due to the isothermal nature of the assay and the requirement for low 
cost simple equipment (Mori and Notomi, 2009). Lyophilised reagent kits are already available for a 
number of parasitic diseases e.g. Trypanosoma cruzi (Thekisoe et al., 2010) and malaria (Polley et 
al., 2013). A LAMP protocol has been published using the 28S rRNA gene of S. stercoralis as a target, 
this study had an analytical sensitivity of 10-2 for a single S. ratti larva spiked into stool and diluted 
(Watts et al., 2014). LAMP primers to the 18S rRNA gene had been designed at DCP (unpublished, 
2011) for use in this study. LAMP has not previously been reported using primers to target the 18S 
rRNA gene and the LAMP assay has not yet been tested on a statistically significant cohort of clinical 
samples.  
1.6. TREATMENT 
Strongyloidiasis is treated with ivermectin 200µg/ kg (Sudarshi et al., 2003) and without treatment 
the infection may last for life (Checkley et al., 2010, Feely et al., 2010, Moghaddassani et al., 2011). 
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Therefore, complete eradication of S. stercoralis is required for the treatment to be effective.  The 
most effective dose for ivermectin is not known because the persistence of antibody means that 
serology cannot be used for monitoring treatment (Requena- Méndez et al., 2013). Drug efficacy 
trials using new sensitive and specific diagnostic techniques are needed to investigate this 
(Requena- Méndez et al., 2013, Krowlewiecki et al., 2013).  
Ivermectin binds to the glutamate- gated chloride ion channels in invertebrate nerve and muscle 
cells and leads to neuro-muscular cell death that affects parasite motility (Biggs et al., 2009). 
Ivermectin is superior to albendazole in terms of safety efficacy and adverse effects, but should be 
avoided in pregnancy and its use is restricted to children > 3-5 years of age because of the lack of 
data in these groups (Biggs et al., 2009, Ganesh and Cruz, 2011, Pottie et al., 2011, Krowlewiecki et 
al., 2013, Requena- Méndez et al., 2013, Henriquez-Camacho et al., 2016 ). Ivermectin should not 
be used in patients with a high Loa loa microfilaraemia due to the potential for serious adverse 
neurological events that occur in microfilaria patients with a high Loa loa parasite load (>50 000/ 
ml) (Boussinesq et al., 2003, Pottie et al., 2011). Loa loa and S. stercoralis are known to be endemic 
in the same areas in parts of Africa (Pottie et al., 2011). Prolonged or repeated treatment with 
ivermectin is indicated in disseminated disease. Albendazole and ivermectin combined therapy may 
also be used to treat disseminated disease. Resistance to ivermectin has not been seen and this 
may be due to the fact that larvae are effectively clones of the adult female worm, however, long-
term use of ivermectin as a control strategy has not yet been investigated (Ganesh and Cruz, 2011, 
Henriquez-Camacho et al., 2016).  
The use of ivermectin at HTD was introduced on the basis of a systematic literature review in 1995. 
The treatment regime was changed from albendazole 400 mg b.d. (twice daily) for 3–7 days to two 
doses of ivermectin 200 µg/ kg (Sudarshi et al, 2003). The treatment regime for strongyloidiasis at 
HTD currently consists of 2 doses of ivermectin (200µg/ kg) on day 1 and day 14 for uncomplicated 
disease and in severe disease ivermectin (200µg/ kg) is administered on day 1, day 2, day 15 and 
day 16 and continued as necessary. A diagnosis of strongyloidiasis is required for informed 
treatment and post-treatment monitoring of in-patients and out-patients who are at risk of being 
infected with S. stercoralis. The current laboratory diagnostic strategy suffers from a lack of 
sensitivity and specificity and the inability to detect the clearance of parasites after treatment. The 
optimal dosage for treatment of S. stercoralis has never been extensively investigated due to the 
absence of a point of cure test, nor is it known whether the above regimes will eliminate extra-
intestinal larvae (Olsen et al., 2009, Requena- Méndez et al., 2013, Krowlewiecki et al., 2013).The 
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current study will evaluate the potential of NAATs for future use in monitoring successful treatment 
of strongyloidiasis. 
1.7. JUSTIFICATION FOR THE STUDY 
Improvement in medical care in the developed world means that there is an increased interest in 
the diagnosis and detection of S. stercoralis, especially in patients that are immunosuppressed (e.g. 
HTLV1 co-infection, alcoholism, old age or auto-immune diseases) or are to undergo iatrogenic 
immune suppression by the administration of immune- suppressive drug regimens (Basile et al., 
2009, Checkley and Sanderson, 2009, Olsen et al., 2009, Smith et al., 2010, Ganesh and Cruz, 2011, 
Kassalik and Möntemüller, 2011, Schär et al., 2013b).  
This has led to the need for reliable and sensitive tests that can be introduced into high-throughput 
systems to diagnose and follow the disease (ten Hove et al., 2009). Daar et al. (2002), in a study 
which sought consensus opinion amongst 28 scientific experts ranked “modified molecular 
diagnostics for affordable, simple diagnosis of infectious diseases” amongst the most promising 
biotechnologies for improving health and healthcare in developing countries.  New NAATs have 
shown promise as sensitive and specific methods for the detection of many parasitic diseases. 
These techniques have revolutionized the diagnosis and treatment of such gastro-intestinal 
infections as amoebiasis, giardiasis, cryptosporidiosis and microsporidiosis at DCP. It is hoped that 
the increased sensitivity of NAATs will detect chronic S. stercoralis infections (the existence of 
which may only be shown by later severe infections in immunocompromised patients) and 
appropriate treatment can be prescribed before immunosuppression leads to severe 
strongyloidiasis (Basile et al., 2010).  
Real-time PCR is run in a closed system and obviates the need for gel electrophoresis to visualize 
the amplification product thereby eliminating the potential for DNA product contamination of the 
laboratory environment. The results are available within 3.5 hours (post-processing) and amplicon 
detection and data analysis can be performed automatically using commercial software packages 
making this technique suitable for high-throughput techniques. This technique is suitable for use in 
WTM clinics but it is costly and requires a high level of technical expertise which limits the use of 
this technique in endemic areas. A published qPCR method to detect the 18SrRNA gene of S. 
stercoralis is already available and is being used to detect S. stercoralis DNA in clinical samples (ten 
Hove et al., 2009). The qPCR assay is amenable to a multiplex format to include the detection of 
other important parasites in WTM clinics (ten Hove et al., 2009). 
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The LAMP assay is an alternative NAAT that is more resistant to inhibition than qPCR and shows 
great promise as a rapid and simple, yet sensitive, diagnostic technique. LAMP has been developed 
for use as commercially available kits (Source Eiken, Japan) for the detection of Trypanosoma cruzi 
and malaria in blood samples (Thekisoe et al., 2010, Polley et al., 2013). The isothermal nature of 
LAMP means that no sophisticated equipment is required, as the amplification may be run in a 
simple water-bath or heated block to produce visually identifiable amplification within one hour 
(post-processing, refer to Table 1.2) or within 1 hour from direct DNA extraction (using manual 
methods) to visualisation of LAMP product (WHO, 2013, Perera et al., 2017). Primers to detect S. 
stercoralis 18S rRNA have been designed by Polley et al. at DCP (unpublished, 2011) but have not 
yet been tested in clinical samples. This technique has the potential to be useful to funded studies 
carried out in endemic areas. 
The follow-up of treatment to determine point of cure is not currently feasible by either microscopy 
or culture because of the low sensitivities of these methods. Conversely, the follow-up of treatment 
by ELISA is seldom reliable as the antibody levels may take 6-12 months to decline and, indeed, may 
never have been positive in immunocompromised patients (Buonfrate et al., 2013, Requena- 
Méndez et al., 2013). 
These limitations, coupled with the ability of S. stercoralis infections to persist for decades in 
infected individuals make a valid case for the development, evaluation and deployment of new 
diagnostic methods with improved sensitivity and specificity. 
This prospective study has the potential to both identify parasite clearance (post-treatment) and 
enhance the sensitivity and specificity of the diagnosis of strongyloidiasis. The data from this study 
can be used to develop a targeted diagnostic and treatment strategy that will benefit the patients 
and the clinicians charged with patient management at HTD and University College London NHS 
Foundation Trust (UCLH).  
Any tests that subsequently improve the sensitivity and specificity of the routine diagnostic services 
will provide the data necessary to allow clinicians to improve the clinical management strategy of 
strongyloidiasis and to determine the persistence of S. stercoralis post-treatment in individuals 
attending at HTD and UCLH. As such, the diagnostics would significantly improve the patient 
experience at UCLH (Whitty et al., 2000, WHO, 2010, Requena- Méndez et al., 2013). 
Chemotherapy- based control, in addition to improved sanitation, was shown to reduce 
strongyloidiasis infection risk in a study in rural Cambodia carried out over two years using the 
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Baermann and Koga agar techniques (Forrer et al., 2016). An addition to the diagnostic monitoring 
array would be useful in establishing an accurate baseline for prevalence in these types of studies. 
1.8. AIMS AND OBJECTIVES  
The study aimed to clinically evaluate the sensitivity and specificity of qPCR (ten Hove et al., 2009) 
and a novel LAMP assay against existing diagnostic procedures to detect S. stercoralis infection. The 
study also aimed to investigate the development of the LAMP assay for use in endemic areas. 
The objective of this study was the development of a “fit for purpose” (CPA standards F1, ISO 
15189:2012) (UKAS, n.d., ISO 15189:2012, 2012) diagnostic screening strategy and the introduction 
of tests to a specialist referral laboratory in the UK that will improve the quality of service supplied 
to service users and improve patient care in a specialist referral centre by increasing the sensitivity 
and specificity of detection of S. stercoralis.  
The primary outcome will be the development, evaluation and validation of new NAATs for use in 
the S. stercoralis diagnostic repertoire. The microscopy, culture and serology techniques were 
individually validated at DCP when the tests were introduced. 
This study also investigated whether LAMP might be a simpler and more rapid assay than qPCR for 
the sensitive and specific detection of S. stercoralis DNA in clinical samples using primers developed 
at DCP. Simplified methods for DNA extraction suitable for use in resource-limited areas were 
piloted to determine whether the LAMP assay could be performed on DNA extracted by these 
methods on stool samples without inhibition of the LAMP reaction. 
This will feed back as an improved diagnostic service that clinicians can use to screen patients and 
determine treatment options. It will also enhance the specialist knowledge- base for a referral 




CHAPTER 2: MATERIALS AND METHODS 
Strongyloidiasis is prevalent in humid tropical, sub-tropical and temperate regions with poor 
sanitation and has the potential to persist undetected in the human host for decades (CDC, n.d.). 
The potential for severe disease and even death occurs when the human host becomes 
immunocompromised. This may occur decades after the host has been in an area that is endemic 
for S. stercoralis (Barros and Montes, 2014). The decision was taken to investigate NAATs at DCP as 
a suitable replacement for the current diagnostic repertoire or as an addition to the service 
provided. The current study focussed primarily on human strongyloidiasis, but the techniques 
investigated have been used in other disciplines e.g. veterinary practice to detect S. stercoralis 
(Yang et al., 2013, Jaleta et al., 2017) and other parasites (Melville et al., 2014). The LAMP assay has 
been used for the detection of micro- organisms in human, livestock and plant diseases (Wong et 
al., 2017). The development of a novel NAAT (LAMP) for use in resource- limited areas was also 
explored. 
Raymaekers et al. (2009) describe the verification and validation procedures required by the 
international quality standard for medical laboratories (ISO 15189:2012, 2012). This chapter 
describes the study design and the protocols used for the study founded on international quality 
guidelines. It includes a technical description of the sample preparation and NAATs assessed in the 
research. The development of a novel LAMP assay using primers designed at DCP (unpublished) is 
defined and methods for confirmation of the NAAT products are also described. Where methods 
for NAAT product confirmation were chosen that were not in routine use at DCP, the procedure 
was described in more detail 
The rationale for the choice of statistical analysis used to demonstrate the aims of this study 
(Chapter 1, Section 1.8) is discussed in Section 2.8. 
2.1. PATIENT COHORT 
The patient cohort comprised of travellers and migrants (> 18 years. Range in this study 26-90 
years) who attended the travel clinic at HTD or patients at UCLH who were being investigated for 
strongyloidiasis. Patients who were part of the Infectious diseases in Europe and Africa (IDEA) study 
(Knopp et al., 2014) were also included.  
2.2. ETHICAL APPROVAL 
All human studies are subject to the ethical principles concerning human experimentation. The 
Declaration of Helsinki (1975) was developed by the World Medical Association (World Medical 
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Association, 2013) for human research ethics. All research studies pertaining to patients, human 
volunteers and human material require ethical approval (World Medical Association, 2013). Local 
ethical approval was sought from the local ethics committee, Clinical Innovation and Research 
Techniques (CIRT), at UCLH and an ethics approval application was submitted to the National 
Research Ethics Service (NRES) after local ethical approval was obtained. Ethical approval was 
granted in October 2014 on the basis of a proportionate review by the Integrated Research 
Application System (IRAS) Research Office 1406LC for study number 14/0169 and designated the 
IRAS protocol number 151217.The samples were residual diagnostic samples surplus to diagnostic 
requirements used for validation of new diagnostics and therefore patient consent was not 
required. 
2.3. STUDY DESIGN 
2.3.1. NULL HYPOTHESIS 
The null hypothesis states that there is no difference between current diagnostic testing 
(microscopy, culture and serology) and NAATs (LAMP or qPCR).  
2.3.2. COMPOSITE REFERENCE STANDARD 
When no “gold standard” exists for diagnostic tests biased accuracy estimates will occur. Bias can 
be reduced by using a composite reference standard (CRS) as the statistical approach (Baughman et 
al., 2008). This study used the routine diagnosis for strongyloidiasis at DCP (microscopy, culture and 
serology) as the CRS. Microscopy and culture denoted proven disease and serology denoted 
probable disease. A positive result in any of the CRS tests was scored as positive. However, 
statistical analysis was performed in two parts: 
I. On the basis of parasitological positivity (proven diagnosis by microscopy and/ or culture). 
II. On the basis of the CRS that included serology (probable diagnosis).  
This was done to determine the sensitivity and specificity of NAATs against an imperfect CRS. The 
results of these analyses are discussed in Chapters 3 (LAMP) and 4 (qPCR). 
2.3.3. SAMPLE SIZE CALCULATION  
A test with a high specificity is required for diagnosis of the disease and a test with high sensitivity is 
required for screening for disease. Treatment monitoring however requires a test with a high 
sensitivity and specificity (Kirkwood and Sterne, 1988, Jones and Payne, 1997). The evaluation and 
validation of NAATs for the diagnosis of strongyloidiasis was performed for screening, diagnosis and 
treatment monitoring. A sample size for McNemar’s test with a power of 90% and a significance 
level of 5% was chosen to demonstrate the potential of the qPCR and LAMP assays to be used for 
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diagnosis, screening and treatment monitoring for strongyloidiasis. A sample size of 286 (Figure 2.1) 
was calculated to give a power of 90% to detect a change between the routine diagnostic 
repertoire (CRS) and NAATs with a 5% significance level (MedCalc®, n.d.) 
 
Figure 2.1: Calculation of sample size for comparison of two proportions to detect a difference of at 
least 10 in a dichotomous dependent variable between two related groups (MedCalc®, n.d.) 
Residual diagnostic samples were collected from 287 patients (over 18 years of age) over a 5 year 
period (2011- 2016). Patients were investigated for strongyloidiasis at HTD or at UCLH or were part 
of the IDEA study (Knopp et al., 2014). Stool samples stored for the IDEA study (Knopp et al., 2014) 
were included with permission from the IDEA Study Lead Researcher (Dr M Brown, Consultant at 
HTD). Cross- reactions are known to occur in Strongyloides serological assays with filarial and 
schistosomal antibodies (Requena-Méndez et al., 2013) and so samples with positive filarial or 
schistosomal serology results were excluded.   
Stool samples sent for microscopic examination of ova, cysts and other parasites (OCP) and culture, 
i.e. care as usual, to DCP were analysed by qPCR and LAMP once routine diagnostic screening had 
been performed.  
Serological testing was performed on serum samples at the request of the clinicians overseeing 
patient care.  
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The standards for microbial investigations guidelines (HPA UK protocols, 2013) deal with the 
accuracy and completeness of the study. A flow chart adapted from the guidelines was used to 















Figure 2.1: Flow chart of the number of true positive and true negative samples determined by the 
composite reference standard (n=284). Flow chart adapted from HPA UK protocols (2013) for the 
study design at DCP. 
Three samples were excluded from this study. The LAMP and qPCR assays and the microscopy and 
culture results were negative. Serology was positive (ELISA) for Strongyloides and filarial or 
Strongyloides and schistosomal antibodies. These samples were excluded as the possibility of cross- 
reactions (Brindley et al., 2009) in the serological tests could not be determined. 
STUDY GROUP 
Residual diagnostic stool samples (n=287) 
Travellers, migrants, travel history varied 
 
SPECIFICITY BANK 
Negative stool from a S. stercoralis negative donor (n=1) 
Archived stool/ blood samples positive for human protozoal and 
helminthic parasites, bacterial and viral pathogens and known 
positive S. stercoralis stool samples  
qPCR negative 
(n=216) 













LAMP negative (n=233) 
LAMP positive* (n=1) 
 
*10% of LAMP and qPCR assay positive and all LAMP and/ or qPCR samples that were CRS negative and assay positive were sequenced to 
confirm product identity. Different methods were used to determine sequence identity in all samples for LAMP or qPCR 
I. pJET® 1.2 cloning and sequencing of cPCR product using the LAMP outer primers or the forward and reverse qPCR primers 
II. Direct sequencing of study samples for sequencing using ABI Big® Dye version 3.1 of cPCR product using forward or reverse 
primers for LAMP or qPCR 
III. pGEM® -T-Easy cloning and sequencing of cPCR product using T7 or SP6 (forward and reverse) primers 
qPCR positive* (n=29) 
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2.3.4. SAMPLE STORAGE 
Two aliquots of approximately 200-250 mg of stool (if the original stool sample was large enough) 
were taken and stored at 4oC (aliquot 1) or -20oC (aliquot 2) until DNA extraction was performed on 
a Qiagen® Qiasymphony SP using a magnetic bead based extraction system (Halstead et al., 2013). 
Stool samples contain inhibitors to DNA extraction and amplification (Monteiro et al., 1997, 
Murphy et al., 2007, Moghaddassani et al., 2011). Larger aliquots, whilst this may have increased 
the sensitivity, were not considered for this study due to the potential for inhibition of the NAATs. 
Stored samples for investigation by NAATs are usually stored at -20oC as long-term storage without 
pre-treatment at 4oC is not optimal for DNA survival (Qiagen, n.d.). However, the two storage 
temperatures were chosen as the IDEA study samples had been collected and stored at these 
temperatures previously and the study continued this practice for all samples. The introduction of a 
new test into the diagnostic repertoire at DCP would ideally harmonise with existing laboratory 
protocols. Diagnostic samples for NAAT identification of other faecal parasites are stored at 4oC, 
without preservatives, for up to three weeks.  Once the DNA had been extracted the DNA was 
stored at -20oC until qPCR or LAMP was performed, as per existing laboratory protocols. 
2.3.5. ANONYMISATION AND DATA STORAGE 
The aliquots were entered onto a sample study sheet and identified with a random study number 
(numbers between 100 and 1200 were randomly allocated using an Excel® spreadsheet) so that the 
researcher could not match the study number to the original stool sample. A database curator (not 
the researcher) entered the study number and identification of the stools onto a password 
protected computer file and the sample code was only broken at the end of the study (April 2016) 
so that the researcher could perform the study analysis. Data collected for the study analysis 
included age (years), gender, microscopy result, culture result, Strongyloides serology result and a 
travel history or details of the country of residence. Further data collected for the study included 
length of time the samples were stored before DNA extraction, the temperature at which the 
aliquots were stored and the volume of stool deposit that was extracted. Routine diagnostic test 
results (microscopy, culture and serology) were performed within the departmental turnaround 




Table 2.1: Departmental turnaround times at DCP for the current routine diagnosis of S. stercoralis  
DIAGNOSTIC TEST TURNAROUND TIME* 
Microscopy (ova, cyst and parasite concentration) (Manser  et al. 2015) 2 working days 
Strongyloides charcoal culture (Minato et al., 2008, Requena-Méndez et al., 2013) 10 working days 
Serology (Sudarshi et al., 2003, Bisoffi et al., 2013, Requena-Méndez et al., 2013) 7 working days 
Real-time PCR for faecal Protista infections  (ten Hove et al., 2007) 





*available from: www.uclh.nhs.uk/OurServices/ServiceA-Z/PATH/PATHMICRO/PARA/Pages/Home.aspx 
**an established qPCR protocol at DCP included for turnaround time comparison only 
1
Samples, showing possible inhibition, are diluted 10
-1
 and re- tested in the next assay run. This adds an additional 7- 14 
days to the turnaround time if the sample requires re- extraction.  
2.3.6. NEGATIVE, POSITIVE, NO TEMPLATE AND INTERNAL CONTROLS USED FOR THIS STUDY  
UK standards for microbial investigations guidelines, for the development and validation of NAATs 
for the detection of DNA from clinical samples, recommend that controls are included in all stages 
of the process (processing, extraction and amplification). This ensures that appropriate DNA has 
been extracted and added to the reaction to exclude false negative reactions and to eliminate the 
possibility of false positive reactions from contamination or process failure (HPA UK protocols, 
2013). 
2.3.6.1.  NEGATIVE CONTROL 
Five grams of a known negative stool sample (sample from a donor who is Strongyloides serology 
and microscopy negative) was added to 10 ml phosphate buffered saline pH 7.2 (PBS) to form a 
negative slurry. Aliquots of 250 µl of negative slurry were stored at -20oC to be used as the negative 
extraction and amplification control. 
2.3.6.2.  POSITIVE CONTROL 
2.3.6.2.1. HARVESTING S. STERCORALIS LARVAE FROM A POSITIVE CULTURE 
Stool samples for Strongyloides culture (Figure 1.3) were performed as per the in-house protocol 
(Appendix 1).  The infectious S. stercoralis larvae were harvested by decanting the positive stool 
culture water into a 50ml centrifuge tube (Source VWR, International), followed by centrifugation 
(Eppendorf Centrifuge 5702, Source Meadowrose Scientific Ltd.) at 2000 revolutions per minute 
(rpm) for 5 minutes. The deposit was stored at 4
o
C and the supernatent was used to continue the 
culture. This process was repeated until the culture was negative; in this study three harvests were 
usually obtained. The final pellet was stored at -20oC until required. 
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2.3.6.2.2. PREPARING THE POSITIVE CONTROL 
The pellet stored at -20oC (Section 2.3.6.2.1) was used to prepare aliquots of positive control stool 
sample as follows: the stored pellet of S. stercoralis larvae was thawed to room temperature and 
reconstituted in 1ml PBS, mixed by vortex (VWR Analog vortex mixer) for 3 seconds and the 
number of S. stercoralis larvae seen in 50 µl under a 22x22 mm coverslip (Source CellPath Ltd.) at 
x100 magnification (Nikon Eclipse E400) was recorded. The positive culture used throughout this 
study on the clinical and optimisation samples contained 548 S. stercoralis larvae in 50 µl PBS. (50 x 
2 = 100, 100 x 10 = 1000 µl i.e. multiplication factor = 20). The positive culture contained 548 x 20 = 
10 960 S. stercoralis larvae per 1000 µl or 10.96 S. stercoralis larvae per µl. 
One ml of the positive culture was added to 9 ml of negative slurry (Section 2.3.6.1., this Chapter) 
to give a positive control containing approximately one S. stercoralis larva/ µl. Aliquots of 250 µl of 
the positive spiked stool sample were stored at -20oC until used as extraction and amplification 
controls. The extracted DNA from the positive stool controls was tested in the qPCR or LAMP assays 
at serial 10- fold dilutions of the positive control DNA.  
Routine laboratory practice stores samples at 4oC, for up to 3 weeks, without a preservative. A pilot 
study compared DNA persistence in samples stored at 4oC and -20oC to determine whether sample 
aliquots for S. stercoralis NAAT could be stored using current laboratory protocols. A new positive 
control was made up to test storage survival time at 4oC and -20oC. The new positive control stool 
contained 66 larvae in 50µl with a final concentration of 0.1 S. stercoralis larvae/ µl. Inēs et al. 
(2011) demonstrated a 50% drop of viable S. stercoralis larvae in stool when investigating the effect 
of storage temperature on the S. stercoralis culture result (Section 1.5). This lower concentration of 
S. stercoralis larvae per µl was used to determine a drop in efficiency earlier than a positive control 
containing a higher concentration of larvae would be able to. 
A further pilot study compared the DNA extraction efficiency between manual and automated DNA 
extraction methods. The extracted DNA was analysed by the LAMP assay to determine whether a 
DNA extraction method suitable for use in resource- limited areas could be developed.  
2.3.6.3. NO TEMPLATE CONTROL 
Nuclease free water (Source Thermo Fisher Scientific, UK) was used as the no template control 
(NTC) for qPCR and LAMP 
2.3.6.4. USE OF AN INTERNAL CONTROL 
Stool samples contain complex polysaccharides and enzymes that are known to cause inhibition of 
target cell lysis and nucleic acid degradation or direct inhibition of PCR (Monteiro et al., 1997, 
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Murphy et al., 2007, Moghaddassani et al., 2011). To monitor qPCR inhibition, an internal control 
derived from the green fluorescent protein (gfp) gene, found in the jellyfish Aequorea victoria, 
which had been incorporated into an Escherichia coli (E. coli) genome (Source Public Health 
England- PHE) was used. The internal control (gfp) was added to the stool sample before 
automated DNA extraction was performed to monitor the reliability of nucleic acid extraction, 
amplification and product detection (Kinson, 2012). The internal control, gfp, does not naturally 
occur in human stool samples and so can be used to detect the presence of inhibitors in human 
stool samples (Murphy et al., 2007). 
2.3.7.  SPECIFICITY BANK 
The specificity bank comprised of 200-250 mg aliquots of positive stool samples, that had been 
previously stored at -20oC (a DCP collection of positive stool samples), a blood sample containing 
Loa loa, cultures from bacterial human intestinal pathogens and an adenovirus DNA sample. The 
stool, blood and bacterial culture samples were extracted and the DNA was stored at -20oC until 
required. Viral, bacterial and other parasitic organisms (Table 2.2) were tested to determine 
analytical specificity using primers targeted to S. stercoralis DNA in the qPCR and LAMP assays. 
Strongyloides species DNA was not available to determine the detection of other Strongyloides 
species DNA using the LAMP or qPCR assays. However, qPCR has been reported to detect other 
Strongyloides species DNA (Requena-Méndez et al., 2013, Requena-Méndez et al., 2014). In 2013 
Sultana et al. showed detection of Strongyloides DNA using S. ratti spiked stools and S. stercoralis 
positive clinical samples. A LAMP assay using primers to target the 18S rRNA gene has not yet been 
shown to detect Strongyloides species DNA. This study was able to obtain S. stercoralis DNA but 
was not able to obtain Strongyloides species DNA, although a free-living (non-human pathogen) 
rhabditiform larva (isolated by microscopy from a diagnostic sample) was included in the specificity 
bank (Table 2.2). Cross-reactions between S. stercoralis LAMP and qPCR primers and free- living 




Table 2.2: Human Pathogens (viral n=1, bacterial n= 4, S. stercoralis aliquots n=8 and other parasitic 
species n=20) tested to determine the analytical specificity of the primers targeted to S. stercoralis 
DNA in qPCR and LAMP 
 Organism Pathogen type 
1 Adenovirus DNA   Virus* 
2 Campylobacter sp. NCTC 12850   Bacteria** 
3 Escherichia coli  0157 NCTC 13126  Bacteria** 
4 Peptone water (negative culture control)  Negative culture 
control** 
5 Shigella sonnei NCTC1132   Bacteria** 
6 Vibrio cholera (diagnostic sample)  Bacteria** 
7 Cryptosporidium sp.  Protista 
8 Cryptosporidium sp.  Protista 
9 Cryptosporidium sp.  Protista 
10 Cryptosporidium sp.  Protista 
11 Cryptosporidium sp.  Protista 
12 Cyclospora cayetanensis  Protista 
13 Cystoisospora belli  Protista 
14 Cystoisospora belli   Protista 
15 Sample containing mixed Protista-Entamoeba histolytica , Entamoeba coli  and Entamoeba 
hartmanni  
Protista 
16 E.  histolytica  Protista 
17 E.  histolytica  Protista 
18 E.  histolytica  Protista 
19 E.  histolytica  Protista 
20 E.  histolytica  Protista 
21 Encephalitozoon intestinalis  Fungi 
22 Enterocytozoon bienusi  Fungi 
23 Enterocytozoon bienusi  Fungi 
24 Enterocytozoon bienusi  Fungi 
25 Giardia lamblia Blastocystis hominis  Protista 
26 G. lamblia  Protista 
27 G. lamblia  Protista 
28 G. lamblia  Protista 
29 G. lamblia  Protista 
30 G. lamblia  Protista 
31 Dicrocoelium dendriticum  Trematode 
32 Schistosoma mansoni  Trematode 
33 Bertiella studeri  Cestode 
34 Taenia saginata  Cestode 
35 Sample containing mixed nematodes-Ascaris lumbricoides Hookworm, T. trichiura  Nematode 
36 Sample containing mixed nematodes-Ascaris lumbricoides, Hookworm, T. trichiura  Nematode 
37 Free-living Rhabditiform larvae (unable to identify further at DCP)  Nematode 
38 Hookworm  Nematode 
39 Hookworm  Nematode 
40 Hookworm  Nematode 
41 Loa loa in blood  Nematode 
42 Trichostrongylus sp.  Nematode 
43 Trichuris trichiura  Nematode 
44 S. stercoralis culture larvae x1 (various aliquots from the same positive culture- neat or 
spiked into a negative stool sample) 
Nematode 
45 Negative stool controls (various aliquots) Negative stool control 
*   supplied by the Virology Department at UCLH 
**Supplied by the Microbiology Department at UCLH 
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2.3.8. EXTRACTION USING THE QIAGEN®QIASYMPHONY SP 
2.3.8.1. PRE-PROCESSING OF STOOL SAMPLE 
The volumes of the stool deposit varied greatly as the amount of supernatant removed depended 
on the appearance of the stool (Lewis and Heaton, 1997). The volume of type 1 stools was harder 
to aliquot into smaller samples, while the type 6 and type 7 samples had large volumes of 
supernatant removed (Table 2.3). 
Table 2.3: The effect of appearance of the stool sample on aliquot size in samples used for DNA 
extraction in this study. 
STOOL 
APPEARANCE 
DESCRIPTION APPROXIMATE* VOLUME 
SUPERNATENT REMOVED (µl) 
Type 1 Separate hard lumps, like nuts (hard to pass) 0-0.1 
Type 2 Sausage shaped, but lumpy 0.1-0.3 
Type 3 Like a sausage, but with cracks on the surface 0.2-0.4 
Type 4 Like a sausage, smooth and soft 0.3-0.5 
Type 5 Soft blobs, clear-cut edges, passed easily 0.4-0.7 
Type 6 Fluffy pieces, ragged edges, mushy stool 0.5-0.8 
Type 7 Watery, no solid pieces, entirely liquid 0.8-0.99 
*Approximation by eye only, as stool samples varied greatly by appearance. The length of storage may also have 
contributed to dehydration of the sample. Adapted from: The Bristol Stool Chart, developed at the University of Bristol, 
by Lewis and Heaton (1997). 
 
Samples were removed from storage (-20oC) and brought to room temperature. The samples were 
centrifuged at 13000 rpm (16.2 rcf) for 5 minutes on a MSE Micro Centaur centrifuge. The 
supernatant, containing potential cell free inhibitors to NAATs, was removed and the deposit was 
weighed on a balance (Oertling HB63). This procedure also allowed the improved recovery of 
parasites from watery diarrhoeal samples. Qiagen® DNA tissue lysis buffer (ATL) and proteinase k 
(Source Thermo Fisher Scientific, UK) were added to the stool deposit to give a dilution of 1 in 2 
(approximately) of ATL buffer containing a 10-1 volume of proteinase k. Samples were well-mixed 
and incubated overnight at 56oC. The following day the samples were mixed by vortex and pulse-
centrifuged to remove any droplets that might be adhering to the top of the tube lid.  The addition 
of 200µl L6 lysis buffer (Source Thermo Fisher Scientific, UK) and 400µl of an internal control (gfp) 
was added to 200µl of stool sample. The gfp internal control (Source LSHTM, UK) was diluted in 
sterile PBS pH 7.2 to give a 1 in 50 dilution before being added to the L6 buffer and sample mixture. 
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The sample was then mixed on a Vortex Genie 2 before being placed in the Qiagen® Qiasymphony 
SP work station. 
 
2.3.8.2. DNA EXTRACTION USING THE QIAGEN®QIASYMPHONY SP WORKSTATION 
DNA was extracted on the Qiagen® Qiasymphony SP work station, using magnetic particle-based 
nucleic acid purification and the tissue extraction program (Kruhøffer et al., 2010) from the 
QIAsymphony®DSP Virus/Pathogen Kit as per the manufacturer’s instructions (Qiagen, n.d.). The 
protocol was modified by the addition of the internal control, gfp directly to the samples instead of 
the carrier RNA mixture. This method was already established at DCP for the extraction of DNA 
from stool samples. The effectiveness of the method using magnetic particle-based nucleic acid 
purification to produce DNA with fewer inhibitors present was determined previously for a 
multiplex stool Protista PCR (Verweij et al., 2004, ten Hove et al., 2007) in routine use at DCP. In the 
magnetic particle-based nucleic acid purification method the target DNA (RNA can also be extracted 
by this method) is lysed and then bound to the magnetic particles, the bound DNA is then washed 
before being eluted (Halstead et al., 2013). The Qiagen® Qiasymphony SP work station is employed 
for rapid, reliable and high-throughput extraction (up to 96 samples in 4 hours) and is, therefore, 
useful for routine well-resourced diagnostic settings and was considered suitable for this study. 
2.3.8.3. DNA EXTRACTION USING A MANUAL METHOD “BAKE AND SHAKE” 
LAMP is less sensitive to inhibition of amplification in blood samples than qPCR due to the use of 
the Bst DNA polymerase (Notomi, 2000, Wong et al., 2017) and a method for the direct extraction 
of DNA from samples has been described for the rapid and easy DNA extraction from sputum, 
blood and soil samples (WHO, 2013, Perera et al., 2017). The PURE® device is a series of 
interlocking plastic components comprising a heating tube containing lysis buffer, an absorption 
tube containing absorbent powder to remove inhibitors present in the samples and an injection cap 
that directly dispenses extracted DNA into reaction tubes in a closed system. The LAMP assay was 
performed using the rapid ultrapure DNA extraction kit (PURE®) for malaria (Figure 2.3) and a 
Loopamp- LF 160 (Source Eiken, Japan), a homoeothermic heating and LAMP amplification block 
with UV lamp, (Figure 2.4). A parallel DNA extraction was performed (PURE® vs. Qiagen® 
Qiasymphony SP). The PURE® method requires a constant power source. Positive stool controls 
were stored at -20oC until parallel extraction of DNA was performed using the PURE® method or the 
Qiagen® Qiasymphony SP. S. stercoralis has a thick cuticle that may affect the efficiency of DNA 
extraction by this method (Repetto et al., 2010, Levenhagen and Costa-Cruz, 2014) and so some 
samples were pre-treated to investigate this issue. The samples to be extracted using the PURE® 
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method were used direct (neat or at a dilution of  1 in 2 in nuclease free water) or pre-treated using 
one of the following methods before addition to the buffer in the heating tube (figure 2.3 A): 
I. pre-incubation at 56oC in ATL plus proteinase k for 2 hours 
II. pre-incubation at 56oC in ATL plus proteinase k overnight 
III. extreme temperature shock for 5 minutes in liquid nitrogen  
Loading sample (60 µl stool sample) was added to PURE® buffer (WHO, 2013, Perera et al., 2017) in 
the heating tubes. The tubes were heated at 75oC for 15 or 30 minutes on a Loopamp- LF 160.The 
adsorbent tube (Figure 2.3 B) was screwed onto the heating tube and the resultant tube was 
shaken vigorously to combine the sample with the absorbent powder and remove any inhibitors 
present in the samples. The ultrapure DNA was delivered (Figure 2.3 C) into a reaction tube which 
may be used immediately or stored at -20oC. The extracted DNA (Figure 2.3 D) was diluted in a 
serial 10-fold dilution series to determine the end-point at which DNA could be detected by the 
LAMP assay. The DNA was used neat or at dilutions made in nuclease free water (10-1, 10-2, 10-3,   
10-4 and 10-5) in the LAMP assay. The positive control used during the study for optimisation of the 
assay and testing of diagnostic samples contained 1 S. stercoralis larva/ µl. Further testing using 10, 
20, 50, 80 or 100 µl for the loading sample was performed using PURE® technology to determine 
the volume of loading sample that is required to eliminate inhibition of the LAMP assay.  
 
Figure 2.3: PURE® rapid ultrapure DNA extraction kit (Eiken, Japan) 
A: Heating tube containing buffer                 B: Absorbent tube with powder                           C: Injection cap 








Figure 2.4: Loopamp- LF 160 
The Loopamp- LF 160 can perform the DNA extraction, the LAMP assay and direct visualisation of 
the end- point within one hour (Eiken Chemical Co. Ltd., 2005). In this study results were available 
within 2 hours. 
2.3.8.4 DNA EXTRACTION USING A MANUAL METHOD “BOIL AND SPIN” 
A method has been evaluated and described by FIND whereby DNA can be directly extracted from 
blood (FIND, 2012). This method was investigated in this study for the extraction of DNA from stool 
using a hot- block at 95oC, a vortex (optional), a micro- centrifuge, a timer and a stable power 
source (Polley et al., 2013).  
A loading volume of stool (100, 80, 50, 25 or 10 µl) was added to an equal volume of SDS buffer 
(400 mM NaCl, 40 mM Tris pH 6.5, 0.4% SDS) in an extraction tube. The sample was mixed by 
vortex for 10 seconds. Before being placed in a heating block and heated at 95oC for 5 minutes. 
Overheating may degrade the DNA and reduce the sensitivity of the test (FIND, 2012). The sample 
was then centrifuged at 10, 200 rpm (9.6 rcf) for 3 minutes. Following this the clear supernatant 
was transferred to a dilution tube containing 345 µl of nuclease free water and mixed (by pipette 
ten times or by vortex for 3 seconds). The DNA was used neat or diluted in nuclease free water   
(10-1, 10-2, 10-3, 10-4 and 10-5) in the LAMP assay. The extracted DNA was used immediately or 









2.3.8.5. DETERMINATION OF PERSISTENCE OF DNA IN SAMPLES STORED AT 4oC. 
Routine diagnostic samples for DNA extraction at DCP are stored at 4oC for one week before DNA 
extraction is performed. Some samples requiring re-extraction may be stored at 4oC for up to three 
weeks. Storage at 4oC without a preservative is less successful for the detection of DNA than 
storage at -20oC (Qiagen®, 2013).  
A pilot study was performed to determine if this protocol could be applied to routine diagnostic 
samples so that the addition of NAAT testing for S. stercoralis DNA could be synchronised into the 
existing routine work-flow of the laboratory.  
Aliquots of 250 µl of positive stool controls (containing 0.1 S. stercoralis larvae/ µl) and negative 
stool controls were stored at 4oC and -20oC for different lengths of time until extraction of DNA was 
performed using the Qiagen® Qiasymphony SP. A 10- fold dilution series of the extracted DNA was 
performed and qPCR and LAMP assays were carried out to determine the effect of prolonged 
storage at 4oC on the persistence of S. stercoralis DNA. The qPCR and LAMP assays were performed 
in parallel on DNA extracted from duplicate samples stored at 4oC or at -20oC.   
2.3.9. NUCLEIC ACID AMPLIFICATION TECHNIQUES AND TARGETS CONSIDERED FOR THE 
DETECTION OF S. STERCORALIS DNA IN CLINICAL SAMPLES 
The introduction of a method that can detect a low parasite load and determine eradication of S. 
stercoralis post-treatment (point of cure) is urgently required (Requena-Méndez et al., 2013).  
Based on the, previously mentioned, evidence published by Verweij et al. (2009) for the detection 
of S. stercoralis using the 18S rRNA gene in a real-time PCR format the 18S rRNA gene was 
determined to be a suitable target for this research.  
LAMP is available for the detection of parasite DNA (T. cruzi and malaria) and has been successfully 
deployed in endemic areas for these infections (Thekisoe et al., 2010, Polley et al., 2013). This study 
investigated the development of LAMP for the detection of S. stercoralis DNA in clinical samples 
using primers, designed at DCP, to detect to detect target DNA in the S. stercoralis 18S rRNA gene.  
2.4. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) 
2.4.1. PRIMER DESIGN 
Primer design for LAMP is crucial and primers were designed for this study using the software LAMP 
primer designing software PrimerExplorer V.3 (Eiken Chemical Co. Ltd., 2005). A BLAST (Basic Local 
Alignment Search Tool) search was performed against the EMBL database on the EBI and NCBI 
website (NCBI, n.d.) for the S. stercoralis 18S rRNA gene. A number of potential primer sets were 
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Figure 2.5 LAMP primers and the target DNA binding sites. F3 and B3: Forward and reverse outer 
primers, FIP (comprised of two segments-F2:F1c) and BIP (comprised of two segments-B2:B1c): 
Forward and reverse inner primers). http://loopamp.eiken.co.jp/e/lamp/primer/html and “A guide 
to LAMP primer designing (Primer ExplorerV4)” (Eiken Chemical Co. Ltd., 2005) 
LAMP reactions were set up using the protocol supplied by Eiken Chemical Company, Ltd (2005). 
The LAMP assay was performed in a LA 320C turbidometer and heating block (Source Eiken, Japan) 
for one hour at 63oC.  
The reaction mix contained 20mM Tris-KCl reaction buffer(20 mM Tris-HCl, 10 mM KCl, 8 mM 
MgSO4, 10 mM (NH)2SO4), 0.1% Tween 20, 0.8M Betaine, 25mM each of dNTPs, 40 pmol each of 
forward and back inner primers, 20 pmol each of forward and back loop primers, 5 pmol each of 
forward and back outer primers, 8 units/ µl Bst DNA polymerase, 2.5 mM NaCl and nuclease free 
water to make up the volume to 20µl to which was added 5 µl of extracted DNA (Eiken Chemical 
Co. Ltd., 2005). 
A positive result (LAMP time in minutes) was determined by the development of turbidity detected 
by production of insoluble magnesium pyrophosphate released by the specific binding of the S. 
stercoralis specific outer and inner primers and amplification of DNA at a pre-determined cut-off. 
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Real-time turbidity was measured by the LA 320C turbidometer and the results were analysed using 
a program available from the Eiken Chemical Co. Ltd., (2005). Personal communication with Dr van 
Lieshout regarding the qPCR method (ten Hove et al., 2009) noted that S. stercoralis DNA (for a 
qPCR assay) deteriorated with repeated freeze-thaw cycles and this was thought to be the case 
with the LAMP assay as well. Repeated use of the positive control dilution series was consistently 
positive at a dilution 10-2 but not at 10-3. A consistent loss in the sensitivity of the detection of DNA 
was demonstrated with the positive control after more than one freeze-thaw cycle and the positive 
control extracted DNA dilution series was, therefore, kept at 4oC for future use and the problem of 
deterioration of DNA was mostly eliminated. Whilst the analytical sensitivity was determined as 1 x 
10-3 S. stercoralis larvae/ µl for LAMP assays (Table 3.10), the assays were performed using the 
control at a dilution of 10-2 to eliminate the effect of a possible loss of sensitivity in storage at 4oC.  
2.4.2. CONFIRMATION OF LAMP PRODUCT 
Conventional PCR (cPCR) was used to generate a product, using the outer LAMP primers, which 
could be used to determine the sequence of the product and confirm LAMP assay product identity. 
The master mix consisted of 25 mM MgCl2, 5 mg/ml of bovine serum albumin, 5 pmol each of LAMP 
forward and back outer primers, 12.5 µl of Hotstart Taq® polymerase and water to make up a 
volume of 20 µl to which was added 5 µl of DNA. The program on a Hybaid thermocycler was: 95oC 
for 15 minutes followed by 50 cycles of- 95oC for 15 seconds, 60oC for 30 seconds and 72oC for 20 
seconds. This was followed by 1 hold cycle of 10oC. 
2.5. QUANTITATIVE REAL-TIME PCR (qPCR) 
The qPCR assay collects data in real-time so that the amplification and visualisation steps are 
combined into a single step. This eliminates contamination of the laboratory with amplified DNA as 
there is usually no need to open the sealed reaction tubes.  
A qPCR assay is available for the detection of S. stercoralis. Verweij et al. (2009) published a method 
that has been referenced in other publications (Requena- Méndez et al., 2013) using primers to the 
18S rRNA gene for S. stercoralis and a double-labelled probe (Chapter 4, Section 4.3). The samples 
were run on a Rotagene Q and results were analysed using Rotor-Gene 6 software, version 6.1, 
Corbett Research (Source Corbett Life Sciences). 
2.5.1. PRIMERS AND PROBES 
Published primers and a probe for the qPCR assay were chosen (Verweij et al., 2009) on the basis of 
a literature review (Requena- Méndez et al., 2013) and the protocol was received from Dr van 
Lieshout at Leiden University, to ensure that the most up to date protocol was used. An NCBI BLAST 
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search (NCBI, n.d.) confirmed the sequence (AF 279916) reported by Verweij et al. (2009) and 
displayed a sequence match of 100% for S. stercoralis. Verweij et al. (2009) reported that the 
forward primer on the 18S rRNA gene sequence also showed a sequence match of 100% with other 
Strongyloides species.  
A qPCR protocol of 95oC for 15 minutes, followed by 55 cycles of 95oC for 15 seconds, 60oC for 30 
seconds, and 72oC for 20 seconds was used for the study.  
The master mix contained 12.5 µl Hotstart Taq® polymerase, 5 mg/ml BSA, 25 mM MgCl2, 2.5 pmol 
each of forward and reverse S. stercoralis primers, 1.25 pmol of S. stercoralis probe, 3.95 pmol each 
of forward and reverse gfp primers, 1.33 pmol gfp probe and water to make a final volume of 20 µl 
to which was added 5µl of DNA.  
The product is 101 base pairs (bp) and the sequences of the published primers and probe for qPCR 
are: 
Forward primer Stro18S-1530F 5ˈ -GAATTCCAAGTAAACGTAAGTCATTAGC-3ˈ 
Reverse primer Stro18S-1630R 5 ˈ -TGCCTCTGGATATTGCTCAGTTC-3ˈ 
Probe Stro18S-1586T FAM-5 ˈ -ACACACCGGCCGTCGCTGC-3 ˈ -BHQ1 
2.6. CONFIRMATION OF PCR PRODUCT 
All tubes that were qPCR positive were run on a 2% agarose gel with 5µl of Safeview® nucleic acid 
stain for 1.5 hours at 100V to demonstrate separation of the S. stercoralis (101bp) and gfp (97bp) 
bands. Furthermore, the products of LAMP and qPCR were sequenced to confirm the identity of S. 
stercoralis and to confirm target detection where the CRS was negative and LAMP and/ or qPCR 
was positive. Samples that produced anomalous band sizes were also sent for sequencing reactions 
to determine the identity of these bands. 
A proportion of the positive samples were also amplified using cPCR and the thermo-cycler protocol 
described for cPCR confirmation of the LAMP product was used. The Stro18S-1530F and Stro18S-
1630R primers replaced the LAMP primers. The probe is excluded from this reaction to prevent 
problems occurring downstream in the sequencing process by remaining probe sequence. The 
amplified product was run on a 2% agarose gel with 5µl of Safeview® nucleic acid stain for 1 hour at 




2.7.1. PREPARATION OF DNA PRODUCT FOR SEQUENCING REACTION (a) 
DNA generated by cPCR using Str18S forward (F) and reverse (R) primers (used in qPCR) or LAMP 
SPSs (Appendix 2)  inner forward (F) and back (R) primers was purified and ligated to a pJET® 1.2 
plasmid vector using a GeneJET® gel extraction kit (Source Thermo Fisher Scientific, UK).  The 
ligation reaction was then used to transform competent TOP10 Escherichia coli (E. coli) cells 
(chemically treated to accept DNA). The ligation reaction and the TOP10 E. coli were incubated at 
37oC (with shaking at 300 rpm for 1.5 hours) in SOC buffer (Brown, 2006). The transformed E. coli 
was plated out onto LB agar plates containing a 10-3 dilution of ampicillin and incubated overnight 
at 37oC. Four colonies were chosen and incubated overnight in LB broth containing a 10-3 dilution of 
100 mg/ ml ampicillin. The plasmid DNA was purified using an Invitrogen Quick plasmid minikit 
(Source Thermo Fisher Scientific, UK). The Bgl II restriction enzyme was used to confirm the 
presence of a cloned insert by gel electrophoresis. DNA concentration was performed on a 
Nanodrop spectrophotometer at 260 nm. The inserts were sent to Thermo Fisher Scientific, UK for 
sequencing. The sequence results were used to perform a nucleotide database search (BLASTn) to 
confirm product identity (NCBI, n.d.). 
2.7.2. PREPARATION OF DNA PRODUCT FOR SEQUENCING REACTION (b) 
Reactions were set up using cPCR products and primers Stro18S F and R or LAMP outer primers 
(Forward-F3 and Back- B3).  
The DNA was purified using a QIA®quick PCR purification kit (Source Thermo Fisher Scientific, UK). A 
2% agarose gel, plus 5µl Safeview® nucleic acid dye (Source NBS Biologicals Limited, UK) was run for 
one hour at 100V to determine the DNA concentration against a 100bp Hyperladder IV marker 
(Source Bioline, UK). Hyperladder IV contains known DNA concentrations in the restriction bands. 
This method was used when a UV spectrophotometer was not available for the estimation of DNA 






Figure 2.6: DNA concentration using Hyperladder IV after DNA purification. The Hyperladder IV 
band sizes contain different known concentrations of DNA (Lanes 1 and 18). cPCR product (Lanes 2-
5, 7, 11, 13-15). Lane 17 an anomalous band at approximately 500 bp. Negative cPCR (Lanes 6, 8-10, 
12 and 16)  
The DNA, purified using the QIAquick PCR purification kit, was amplified using single primers, either 
Stro18S F or Stro18S R or LAMP F3 or LAMP B3 using the protocol supplied for the ABI Big®Dye 
version 3.1 cycle sequencing kit (Source Thermo Fisher Scientific, UK). The amplicons were sent to 
The London School of Hygiene and Tropical Medicine (LSHTM) for sequencing on an ABI Prism 310 
genetic analyser.  
2.7.3. SEQUENCING USING ABI BIG®DYE VERSION 3.1 FOR PERFORMING FLUORESCENCE –
BASED CYCLE SEQUENCING REACTIONS USING THE ABI PRISM 310 GENETIC ANALYSER 
The ABI Big®Dye version 3.1 cycle sequencing kit terminates the elongation of single stranded DNA 
by the addition of a fluorescence tagged nucleotide so that a mixture of DNA strands of different 
lengths is available for sequence analysis. Single primers are used to generate the DNA strands so 
that only one DNA product is sequenced (Thermo Fisher Scientific Inc., 2016). A laser allows the 
four nucleotides (thymine, adenine, cytosine and guanine) to radiate different colours of the visible 
light spectrum (Life Technologies Corp., 2011). The DNA migrates through a capillary with a 50 
micron bore and a laser detects any fluorescent tagged nucleotides and transfers the data to a 
computer for data analysis of the raw data peaks to automatically generate a sequence of the DNA 
template. An electropherogram of the resulting sequence with the different nucleotides generating 
four different coloured peaks is produced.   
2.7.4. SEQUENCING USING ABI BIG®DYE VERSION 3.1 FOR PERFORMING FLUORESCENCE –
BASED CYCLE SEQUENCING REACTIONS USING THE ABI PRISM 310 GENETIC ANALYSER ON 
CLONED SAMPLES USING pGEM® T- EASY VECTOR SYSTEM TO CLONE THE PCR PRODUCTS 
Further sequencing reactions were performed using cloned sequences in the ABI®BigDye version 
















previously in Section 2.7. Chen et al. (2000) confirmed that blunt-edged ligation was less efficient 
than sticky-ended ligation. A vector that included 3’-T (thymidine) overhangs that improve the 
efficiency of ligation, by preventing re-circularization of the high-copy number vector and allowing 
ligation of PCR product, was chosen. TOP10 E. coli competent cells were used for the 
transformation. The vector contains T7 and SP6 RNA polymerase promoters that flank the multiple 
cloning regions, within the alpha-peptide coding region of the enzyme beta-galactosidase. In this 
study ampicillin resistance was used to isolate the transformed cells.  
The pGEM® T-Easy kit was used as described by the manufacturer (Source Thermo Fisher Scientific, 
UK).  The purified plasmids were restricted using the EcoR1 restriction enzyme and the presence of 
DNA inserts was confirmed on a 1% agarose gel. The plasmid DNA was purified using an Invitrogen 
Quick plasmid minikit (Source Thermo Fisher Scientific, UK). DNA concentration was performed on a 
Nanodrop spectrophotometer at 260 nm. Samples that contained inserts were amplified using the 
T7 primer or the SP6 primer to generate a single- stranded product that was sent to LSHTM for 
sequencing using an ABI Prism 310 genetic analyser.  
2.7.5. SEQUENCE ANALYSIS 
All sequences generated were analysed using a nucleotide basic local alignment search tool 
(BLASTn) to determine sequence homology. Where sequence matches to published sequences is 
determined, a statistical value (E expected) is generated to determine statistical significance of a 
match, the lower the E value the more significant the sequence similarity is (NCBI, n.d.). The 
sequences generated from the LAMP and qPCR assays were analysed by the ClustalW2 multiple 
sequence alignment tool (ClustalW2) to align the S. stercoralis sequences with the sequence of the 
published 18S rRNA genome (Larkin et al., 2007) 
2.8. STATISTICAL ANALYSIS 
Statistical analysis on the comparison of two NAATs was chosen to detect whether the assay was 
able to exclude the disease with a high sensitivity (a screening test) or to detect the disease with a 
high specificity (a diagnostic test) (Kirkwood and Sterne, 1988). The use of an imperfect reference 
test was addressed by the use of statistical analysis methods recommended in the Food and Drug 
Administration guidelines (FDA, 2007). Statistical analysis was performed only once on each patient, 
although multiple samples were received on some patients, as repeat samples could not be 
categorised as new episode/ re-infection, failure of treatment or past infection.  
Once the study code was broken the results of the LAMP and qPCR assays were compared with the 
results for the composite reference standard. The results were separated into samples stored at 4oC 
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or at -20oC to determine if the final statistical analysis would be performed on the results obtained 
at both storage temperatures or only at -20oC.  
Friedman’s non-parametric test can be used when the same parameter (LAMP or qPCR) is 
measured under different conditions (temperature) on the same subject. This test was performed 
to confirm the effect of the temperature of sample storage on the LAMP and qPCR assays 
(Medcalc®, n.d.).  
McNemar’s test was performed to determine the difference between paired proportions of the 
composite reference standard and the LAMP or qPCR assay results. This assumes that the sum of 
the rows equals the sum of the columns when the null hypothesis is true. The definitive tests in the 
CRS (microscopy and culture) are insufficiently sensitive to enable determination of disease 
frequency and serology indicates probable disease only. Statistical analysis was performed on CRS 
result (including serology positive only, which denotes probable disease) or microscopy/ culture 
result (proven disease) for the determination of non-equivalence of tests using McNemar’s test on 
paired proportions (Medcalc®, n.d.). Fischer’s Exact test was used to determine initial statistical 
significance of the results.  
Logistic regression was chosen to determine whether the characteristic of interest would have an 
effect on the result of the LAMP or qPCR assays (1= positive or 0= negative). Stepwise logistic 
regression was performed to determine if the storage temperature, aliquot size, length of storage, 
country of travel/ origin, age (years) or gender had a statistically significant effect on the LAMP or 
qPCR assay results. (Medcalc®, n.d.). Data was not available to determine the immune status of the 
patient samples in this study. 
Contingency (2x2) tables were used to allow a comparison (plus 95% confidence intervals to 
determine significance) between two tests. The sensitivity (proportion of true positives detected), 
specificity (proportion of true negatives detected), positive and negative predictive values 
(probability that person is infected if they have a positive test or is truly disease-free if they have a 
negative test) were calculated (Banoo et al., 2007).  
Likelihood ratios provide useful clinical information as a positive likelihood ratio >1 indicates a 
positive result is more likely to occur in those with strongyloidiasis than in those without the 
disease. A ratio of <1 indicates that a positive result is less likely to occur in those with 
strongyloidiasis than in those without the disease and the same holds true for the likelihood of a 
negative result. The greater than 1 the likelihood ratio is, the stronger the association with the 
58 
 
disease, ratios between > 10 and <0.1 provide strong evidence to determine, or exclude, the 
diagnosis.  
However, in this study, quantities such as positive predictive value, negative predictive value, and 
the positive and negative likelihood ratios must be interpreted with care since the subjects’ 
condition status (as determined by the composite reference standard) is unknown (Kirkwood and 
Sterne, 1998). The formulae for all the above indices are shown in Table 2.4.  
Table 2.4: 2x2 contingency table and associated formulae. 
TEST STATUS TRUE STATUS TOTAL 
 POSITIVE NEGATIVE  
POSITIVE True positive TP False positive FP TP+FP 
NEGATIVE False negative FN True negative TN FN+TN 
TOTAL TP+FN FP+TN TP+TN+FP+FN 
Sensitivity= TP/(TP+FN) 
Specificity= TN/(TN+FP) 
Positive predictive value= TP/(TP+FP) 
Negative predictive value= TN/(TN+FN) 
Positive likelihood ratio= sensitivity/ 1- specificity (probability that that a person who has the disease testing 
positive over the probability of a person without the disease testing positive) 
Negative likelihood ratio= 1-sensitivity/ specificity ( probability of the person who has the disease testing 
negative over the probability of the one who does not have the disease testing negative) 
Κ= (Total number of agreements- expected number of agreements) (total number of observations-expected 
number of agreements). Value of K Strength of agreement- < 0.20=  Poor; 0.21 - 0.40=  Fair; 0.41 - 0.60=  
Moderate; 0.61 - 0.80=  Good; 0.81 - 1.00=  Very good  
Prevalence index=([TP-TN])/(TP+TN+FP+FN) 
Bias index=([FP-FN])/ (TP+TN+FP+FN) 
 
The Food and Drug Administration (FDA) guidelines for statistical analysis (FDA, 2007) recommends 
using positive and negative percent agreement for tests without a suitable reference standard and 
using the overall percent agreement between the reference standard and the test under 
investigation. When a new test is compared to a non-reference standard rather than to a reference 
standard, the usual sensitivity and specificity type calculations from the 2x2 table will produce 
biased estimates of sensitivity and specificity. This is because the non-reference standard is not 
always correct.  However, being able to describe how often a new test agrees with a non-reference 
standard may be useful. The estimated sensitivity is the proportion of subjects with the condition of 
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interest (reference standard positive) that are new test positive. Estimated specificity is the 
proportion of subjects without the condition of interest (reference standard negative) that are new 
test negative. The differences between sensitivity and percent positive and specificity and percent 
negative is that the results do not represent whether the subject has the condition of interest as 
determined by the reference standard and so the results must be interpreted differently. Two 
commonly used measures are the overall percent agreement and Cohen’s kappa. Clinical and 
analytical sensitivity is discussed in Chapter 3 for the LAMP assay and in Chapter 4 for the qPCR 
assay. 
The sensitivity and specificity data provides information on how often the new test is correct; 
whereas, percent positive and negative data provides information on how often the new test 
agrees with a non-reference standard. The simplest measure is overall percent agreement (OPA): 
the percentage of total subjects where the new test and the non-reference standard agree. The 
FDA (2007) guidelines state that it is more useful to report a pair of agreement measures, positive 
percent agreement (PPA) and negative percent agreement (NPA), the overall percent agreement 
(OPA) will always lie somewhere between the positive percent agreement and the negative percent 
agreement. The positive percent agreement is the proportion of non-reference standard positive 
subjects that are new test positive (similar to a sensitivity calculation) (Table 2.5). The limitations 
are that agreement measured by overall percent agreement or kappa may not be correct as 
agreement depends on prevalence (relative frequency) of the disease in a specific cohort (pre-test 
probability). Prevalence is unknown in the current study cohort.  
Table 2.5: Calculations required for positive and negative percent agreement 
 NON-REFERENCE STANDARD 
NEW TEST  + - 
 + A B 
 - C D 
TOTAL  A+C B+D 
Positive percent 
agreement (PPA) 
Proportion of non-reference standard positive samples where the new 
test is positive = 100% x A/A+C 
Negative percent 
agreement (NPA)  
Proportion of non-reference standard  negative samples where the new 
test is negative = 100% x D/B+D 
Overall percent 
agreement (OPA)  
Proportion of samples where new test and non-reference standard agree 




Cohen’s kappa coefficient was performed to determine the level of agreement between the LAMP 
and qPCR assays with the composite reference standard to give a better indication of concordance 
as it accounts for agreements due to chance. Interpretation of kappa is influenced by bias (bias 
index = number of false positive and false negative/ number of observations) and prevalence 
(prevalence index= true positive - true negative/ number of observations) (Table 2.4). The 
difference between kappa and maximum obtainable kappa (Kmax), after marginal possibilities and 
cell frequencies were adjusted, was used to obtain the greatest possible agreement plus 95% 
confidence intervals (95% CI) (McHugh, 2012). Kappa assumes independence and factors affecting 
independence were considered for the interpretation of kappa on factors that could affect 
independence by stepwise logistic regression analysis, as previously described. 
Intraclass correlation and multiple variable clustered graphs were used to demonstrate the 
influence of the CRS on the LAMP and qPCR assay results. Cicchetti (1994) gives the following 
guidelines for intraclass correlation interpretation: <0.4 = poor; 0.4-0.59 = fair; 0.6-0.74 = good and 
0.75-1.00 = excellent.  
The Youden index was used to determine the cut off Ct, at which a qPCR result was a reliable 
indicator of strongyloidiasis. Ct values of ≥ 40 may be subject to primer dimer and false positive 
reactions (Caraguel et al., 2011).  
Box and whisper plots were used to determine the number of cycle runs for the qPCR assay 
(Medcalc®, n.d.). 
All statistical analysis was performed using the Medcalc® statistical program version 16.2.0 
(MedCalc®, n.d.) or on an Excel® spreadsheet. 
This chapter was designed to meet the requirements for evaluation and validation of new 
diagnostic tests (ISO 15189:2012, 2012) and to serve as a standard operating protocol for the 
addition of tests to the diagnostic repertoire in a specialist parasitology diagnostic laboratory (HPA 




CHAPTER 3: DEVELOPMENT, EVALUATION 
AND VALIDATION OF A NOVEL LOOP- 
MEDIATED ISOTHERMAL AMPLIFICATION 
(LAMP) ASSAY 
3.1 INTRODUCTION 
This chapter describes the development of an assay suitable for use in the diagnosis of 
strongyloidiasis in resource- limited and well- resourced settings for use in the diagnosis of human 
strongyloidiasis. As previously discussed, development of rapid, accurate and sensitive diagnostics 
is essential for treating, controlling and eradicating infectious disease (WHO, 2010). This technique 
has been used for the detection of other parasitic diseases in blood. Perera et al. (2017) described 
the development of a high- throughput assay which was suitable for use in resource- limited areas 
for the detection of malaria. Stool inhibition of the LAMP assay was investigated in this study as 
stool has more potential inhibitors than blood and this had the potential to limit the sensitivity of 
the LAMP assay (Murphy et al., 2007). LAMP has also been used in veterinary medicine for the 
control and cost-effective management of parasites in livestock. Melville et al. (2014) described the 
development of a rapid specific and sensitive LAMP assay for the detection of Haemonchus 
contortus nematode eggs in faecal samples requiring only crude DNA for detection. While it is true 
that large amounts of Haemonchus contortus DNA is available in the faecal samples (Melville et al., 
2014), the techniques described could also be applied to the detection of S. stercoralis DNA in 
human faecal samples in this study.   The detection of S. stercoralis DNA in canine stool samples has 
been previously described by Jaleta et al. (2017) using conventional PCR and primers to the 
hypervariable region of the 18S rRNA gene followed by sequence analysis. This method may be 
adapted to LAMP using the methods described in the current study for the deployment of a cost- 
effective technique for control and animal management (Melville et al., 2014). 
The requirements for verification and validation of new diagnostic techniques is discussed in ISO 
15189.2012 standards (UKAS, n.d., ISO 15189:2012, 2012) and in the standards for reporting 
diagnostic accuracy studies (STARD) guidelines (HPA UK protocols, 2013, Bossuyt et al., 2015). 
STARD guidelines were used to establish and confirm performance characteristics and accuracy 
measures for the diagnostic assays evaluated in the current study (Bossuyt et al., 2015). 
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Standardisation and quality assurance is required and the study was also designed to detect the risk 
of bias and sources of variation. For the purposes of this study QADAS 2 guidelines (discussed in 
Section 6.1) were used to design a protocol to address the lack of quality assurance in studies noted 
in a systematic review by Whiting et al. (2014).   
The criteria chosen for the verification of the assays in the study were analytical sensitivity (the 
limit of detection), analytical specificity (Saah and Hoover, 1997), LAMP efficiency and assay 
precision (Reed et al., 2002, Salimetrics®, n.d.).  
Analytical sensitivity was determined by the lowest detection level for S. stercoralis using serial 10-
fold dilutions of DNA extracted from a positive stool control containing 1 S. stercoralis larva/ µl. 
Analytical specificity was determined using a specificity bank comprised of known negative stool 
samples and human viral, bacterial and parasitic pathogens and a free- living rhabditiform larva 
(Table 2.2). LAMP efficiency was determined by the limit of detection of the method using serial 10- 
fold dilutions of DNA extracted from a positive stool control or a known concentration of purified 
DNA. 
The LAMP assay is a rapid, sensitive technique that can be used in well-resourced laboratories in a 
high-throughput or point of care format when an urgent result is required (Wong et al., 2017). 
LAMP can also be transferred to resource-limited areas as the requirement for complex machinery 
and technical expertise is not as high as that for real-time PCR (Mori and Notomi, 2009). The 
reaction is described in detail in Section 3.4.  
3.2. AIMS 
There were three main aims to this part of the study: 
1. To develop and evaluate the sensitivity and specificity of a novel LAMP assay and compare 
to the CRS (this Chapter) and the qPCR assay (Chapter 5) for the detection of S. stercoralis DNA 
from clinical samples. 
2. To evaluate the sensitivity and specificity of DNA extraction using the routine method at 
DCP compared to simplified DNA extraction methods to determine if a simplified method suitable 
for resource- limited areas could be introduced (this Chapter). 
3. To determine the cost and suitability of LAMP and qPCR assays for introduction to the 
diagnostic NAAT repertoire at DCP (this is discussed further in a comparison of the LAMP and qPCR 
assays in Chapter 5) 
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3.3 METHODS FOR THE DEVELOPMENT, EVALUATION AND VALIDATION OF A NOVEL LAMP ASSAY 
FOR THE DETECTION OF S. STERCORALIS DNA IN CLINICAL SAMPLES 
This section of the study investigated the development of LAMP to detect S. stercoralis DNA using 
novel primers to target the 18S rRNA gene. LAMP needs to be clinically validated before this 
technique can be introduced as a diagnostic method (Requena-Méndez et al., 2014) and 284 
residual diagnostic stool samples from a cohort of returning travellers or migrants from endemic 
areas were tested were used to determine LAMP performance as a diagnostic technique for the 
diagnosis of strongyloidiasis. The composite reference standard consisted of microscopy and 
culture (parasitological definitive diagnosis) and serology (serological probable diagnosis). As 
previously discussed, a composite reference standard may be used when no “gold standard” exists 
to eliminate bias in accuracy estimates (Baughman et al., 2008).  Statistical analysis was performed 
using an online statistical program (MedCalc®, n.d.).  
Optimisation of the LAMP assay and sequence determination of the LAMP assay product was 
performed to determine whether this assay would be suitable for the detection of S. stercoralis 
DNA in clinical samples. The results of the LAMP assay are presented in Section 3.4. 
Mori and Notomi (2009) stated that LAMP is suitable for use in resource- limited areas. The 
automated DNA extraction method used in this study requires costly equipment and highly trained 
laboratory staff and is unsuitable for use in resource- limited areas (Minetti et al., 2016). To 
determine the usefulness of LAMP as a screening test in resource-limited areas a pilot study was 
carried out using the manual method of heating at 75oC for 15 minutes followed by removal of 
assay inhibitors with absorbent buffer and the rapid extraction of ultrapure DNA for the LAMP 
assay. DNA extraction was performed in parallel using Qiagen® Qiasymphony SP magnetic bead 
resonance technology to serve as a comparison control, a method which is currently in use at DCP. 
A manual method to extract DNA using only heating at 95oC for 5 minutes and a centrifuge was also 
compared to the Qiagen® Qiasymphony SP magnetic bead resonance technique for suitability of 
use in resource- limited areas. To investigate the issue of stool inhibition of the LAMP assay a range 
of stool volumes were compared to determine whether the loading volume of stool sample would 
have an effect on the sensitivity of detection for S. stercoralis DNA in clinical samples 
The current NAAT protocol for the determination of human protists in stool samples at DCP may 
require that stool samples are stored for up to 3 week at 4oC. ten Hove et al. (2009) recommends 
the storage of stool samples for S. stercoralis DNA extraction at -20oC . Consequently, DNA survival 
in stool samples stored at 4oC or -20oC was investigated. Aliquots of positive and negative stool 
control samples were stored at 4oC and at -20oC before DNA extraction and the LAMP assay were 
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performed.  The investigation was performed to determine a storage technique that would be 
suitable for integration in the current workflow at DCP. 
3.4 LOOP- MEDIATED ISOTHERMAL AMPLIFICATION 
LAMP, first described by Notomi et al. (2000), is recommended for use in monitoring control 
strategies in resource- limited regions (Figure 3.1). Mori and Notomi (2009) suggest that the 
technology can also be used in point of care testing in well-resourced laboratories.  
 
 
Figure 3.1: Standard procedure for loop-mediated isothermal amplification using blood or 
microbial cultures* (Eiken Chemical Co. Ltd., 2005). 
*The extraction of S. stercoralis DNA from stool samples is said to require a more rigorous protocol 
(Moghaddassani et al., 2011, Levenhagen and Costa Cruz, 2014). 
The mechanism for LAMP is in two stages: first the production of a stem loop structure that serves 
as the starting point for the second stage, the cycling amplification stage. The cycling amplification 
stage is dependent on the strand displacement activity of the Bst DNA polymerase. Bst DNA 
polymerase is less susceptible than Taq polymerase to PCR inhibition (Notomi, 2000). 
The inner primers bind first, the outer primers in a lower concentration bind more slowly. Binding 
of the outer primer triggers Bst DNA polymerase strand displacement and the rest of the primers 
bind to single stranded DNA. This generates a stem loop structure and starts the cycling 
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amplification stage. The inner primers bind to the stem loop structure and generate a 
complementary stem loop structure and an elongated new stem loop structure. The generation of 
alternating stem loop and complementary stem loop structures forms the elongated product 
(measured as turbidity due to the release of magnesium pyrophosphate). An animation of the 
process is available from: www/loopamp.eiken.co.jp/e/lamp/anim.html. 
It is a one-step amplification of target DNA with high sensitivity and specificity at one temperature 
(range usually between 60-65oC) using a water-bath or heating block. A DNA polymerase with 
strand displacement activity and four to six primers that recognise six to eight distinct regions of 
the target DNA are required. The production of insoluble magnesium pyrophosphate can be 
visualised by an attached turbidometer, the use of fluorescent dyes- e.g. calcein® (fluorescence is 
quenched by the binding of free magnesium ions which is released by the amplification of product) 
or other intercalating dyes that can be viewed under UV light and turbidity which can also be 
viewed directly by eye. The turnaround time is shortened to one hour by the fact that temperature 
ramping and elongation times are eliminated (Mori and Notomi, 2009, Nagamine et al., 2001, Njiru, 
2012, Polley et al., 2013). 
The lyophilisation of primers and reagents has led to the development of kits to test various viral, 
bacterial and other parasitic organisms (e.g. T. cruzi and malaria) without the need for a cold chain 
for storage (Njiru, 2012, Polley et al., 2013, Thekisoe et al., 2010). This suggests a use for the LAMP 
assay in rural or resource- limited endemic areas (Eiken Chemical Co. Ltd., 2005).  
3.4.1 DEVELOPMENT AND OPTIMISATION OF THE LAMP ASSAY 
3.4.1.1. PRIMERS DESIGNED TO DETECT S. STERCORALIS DNA FOR LAMP ASSAY 
Four primer sets, (St18s:1, St18s:4, St18s:12 (SPSs) and Po18s:299, (Appendix 2) were designed at 
DCP in 2011 for the detection of S. stercoralis DNA targeting the 18S rRNA genome. The primers 
(Source Eurofins Scientific, UK) were designed using Primer Explorer v3.0 (Eiken Chemical Co. Ltd., 
2005). To increase sensitivity and specificity of the LAMP assay, four to six primers are required to 
target a small segment of the DNA and primer design is restrictive and problematic (Wong et al., 
2017) and the four resulting primer sets were tested to determine the primer set that was optimal 
for the detection of S. stercoralis DNA. Primer set St18s:12 was chosen for the study on the basis of 
the results of the LAMP assay using the study protocol (Table 3.1) and was designated primer set 
SPSs.  
In 2014, Watts et al. published a LAMP method for the detection of S. stercoralis DNA targeting the 
28S rRNA genome. A review by Wong et al. (2017) found LAMP to be at least 1000 more sensitive 
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than conventional PCR for the detection of Strongyloides, Necator americanus and Trichomonas 
vaginalis. The Watts et al. (2011) primers were ordered (designated primer set WSs) to establish 
which primer set (SPSs or WSs) would be the most efficient primer set to use in this study. The 
results obtained by Watts et al. (2014) could not be duplicated in this study. In this study, the 
published protocol (Watts et al., 2014), could not be successfully optimised for the detection of S. 
stercoralis DNA. However, the published primer set (WSs) did successfully detect S. stercoralis DNA 
when used with this study protocol for the LAMP assay.  Primer set SPSs demonstrated greater 
sensitivity than primer set WSs for detection of S. stercoralis DNA (Table 3.1).   
Table 3.1: Results of primer sets St18s:1, St18s:4, Pol18s:299, SPSs and WSs when run at the 
optimised reaction temperature of 63oC using the LAMP assay study protocol (I- V). Results for the 
LAMP assay described by Watts et al., 2014 for the primer set WSs using the published protocol 
(VI). 
PRIMER SET AND PROTOCOL USED LAMP (TIME IN MINUTES) 
NEGATIVE CONTROL 
LAMP (TIME IN MINUTES) 
POSITIVE CONTROL (DILUTION 10-2) 
I.  18S rRNA St18s:1 using this study protocol 20.30 16.54 
II. 18S rRNA St18s:4 using this study protocol 50.36 23.42 
III.18S rRNA St18s:12 (SPSs) using this study  protocol Negative 24.24 
IV. 18S rRNA Po18s:299 using this study  protocol 18.12 18.3 
V. WSs 28S rRNA (Watts et al., 2014) using this study  
protocol 
Negative 34.30 
VI.WSs 28S rRNA using the published protocol 
described by Watts et al.(2014) 
Negative Negative (repeat assays below limit 
of detection) 
 
In the primer sets designed at DCP primer set SPSs (III) did not detect amplified product in the 
negative control, while primer sets St18s:1, St 18s:4 and Pol 18s:299 detected S. stercoralis DNA in 
the negative control.  Primer set WSs (V) demonstrated detection of S. stercoralis DNA in the 
positive control only. The LAMP time for primer set WSs was increased when compared to the 
LAMP time for primer set SPSs.  Primer set SPSs detected S. stercoralis DNA in the positive stool 
control with a LAMP time of 24.24 minutes and was therefore chosen for this study (III). 
To determine the target site for the primer set chosen, the primer set sequences (Table 3.2a) and a 
sequence determined by a BLAST search (Table 3.2b) were compared. Table 3.2a shows the primer 
sequences for primer set 12 (SPSs).  The binding sites are colour- coded for F3 (forward outer 
primer- yellow), B3 (back outer primer- no colour), FIP (forward inner primer- green), BIP (back 
inner primer- complex primer blue complementary sequence F2 and pink B1c) and LB1 (loop back 
primer-complementary sequence red, direct sequence in dark green) primers on a sequence from 
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the NCBI website (BLAST ID: AB453314- Strongyloides stercoralis gene for 18S rRNA, partial 
sequence, host: Pan troglodytes) for the S. stercoralis 18S rRNA gene (Table 3.2a and Table 3.2b). 
The sequence alignment of the LAMP assay product generated by cPCR and the outer primers for 
BLAST ID: M84229.1 (Strongyloides stercoralis 18S ribosomal RNA gene, complete cds) is appended 
in Appendix 3a. There is an overlap between the product generated by the LAMP assay back primer 
(B3) and the HVRI and HVRIV hyper variable regions described by Hasegawa et al. (2009) (Appendix 
3a).  
Table 3.2a: Identification of primers Primer set St18s:12 (SPSs) (colour- coded to determine their 





NUCLEOTIDE SEQUENCE  (LENGTH) 
 













ACCATCGAAAGTTGATAAACCAGATATATTGGTTGACTCAAAATATCCTC (50)  








 Complementary B2 CATAACCGGATGGTACCAACACACCATCGGCAAAGAGTCC 








Table 3.2b: Primer set SPSs- Position of Forward outer primer (F3) Forward inner primers (F2:F1c), 
reverse inner primer (B2; B1c) and loop reverse primer (LB1) 



























3.4.2. SODIUM CHLORIDE CONCENTRATION, TEMPERATURE AND TEMPLATE VOLUME 
OPTIMISATION 
The Eiken website (Eiken Chemical Co. Ltd., 2005) describes a protocol for the LAMP assay without 
the addition of sodium chloride (NaCl). To fully optimise the method for use at DCP, the NaCl 
concentration, reaction temperature and template volume was investigated. Optimisation of the 
LAMP assay was performed using a negative stool sample as the negative amplification control and 
a stool sample spiked with S. stercoralis larvae (1 larva/ µl) as the positive amplification control. The 
concentration of NaCl and the reaction temperature at which S. stercoralis DNA was consistently 
detected in the positive stool control (at dilutions of 10-1, 10-2 and 10-3) determined the optimal 
LAMP assay conditions. Table 3.3 shows the results obtained for the concentration range 0mM to 
7.5mM NaCl using the study protocol and primer set SPSs to perform a LAMP assay on a negative 
stool control and positive stool control dilutions of 10-1 to 10-3. A positive result is given in time 
(minutes) at which turbidity is detected to demonstrate that product had been amplified. 2.5mM 
NaCl was the most sensitive (rapid) concentration at which S. stercoralis DNA was detected.   
LB1 (B2) loop 
reverse primer  
F1c 

















Negative stool control Negative Negative Negative Negative 
Positive stool control (10
-1
) 21.06 20.0 22.18 25.42 
Positive stool control (10
-2
) 24.0 24.72 25.42 25.06 
Positive stool control (10
-3
) 27.12 25.0 29.12 36.06 
 
Optimisation of the temperature at which LAMP was performed was determined from the results 
generated at 60oC, 63oC or 65oC. Table 3.4 shows the results obtained for the temperature range 
60oC, 63oC or 65oC using the study protocol and primers SPSs to perform a LAMP assay on a 
negative stool control and positive stool control dilutions of 10-1 to 10-3. A positive result is given in 
time (minutes) at which turbidity is detected to demonstrate that product had been amplified. The 
optimum temperature at which to perform LAMP was determined to be 63oC in this study. 
Table 3.4: Results of the temperature range optimisation for the LAMP assay (Positive result in 
minutes) 
 60oC 63oC 65oC 
Negative stool control Negative Negative Negative 
Positive stool control (10
-1
) 33.0 19.36 30.36 
Positive stool control (10
-2
) 46.12 20.06 32.42 
Positive stool control (10
-3
) 45.36 23.42 37.54 
 
The Eiken website (Eiken Chemical Co. Ltd., 2005) describes using 12.5 µl of DNA as the template 
volume. A DNA template range from 2.5 to 12.5 µl was tested to optimise the amount of DNA 




Table 3.5: Determination of the volume of template DNA for the LAMP assay. (Positive result- LAMP 
time in minutes) 















Negative stool control Negative Negative Negative Negative Negative 




16.18 20.36 23.42 23.3 27.06 




27.42 21.54 25.36 24.06 29.24 
 
Analysis of the results generated using different DNA template volumes determined that 5µl of DNA 
template was the optimal volume to use in this LAMP assay. There was a 25% improvement in the 
detection time at a 10-1 dilution and a 24% improvement in the detection time for the 10-2 dilution 
when compared to the detection time for the DNA template volume of 12.5µl.  
A smaller DNA template volume (2.5µl) demonstrated an improvement to the detection time of 
40% in the 10-1 dilution, but an improvement of only 6% was demonstrated for the detection time 
in the 10-2 dilution. This may have been due to very little DNA template present in the reaction 
(Morrison et al., 1998) and indicated that a significant loss of sensitivity to the LAMP assay was 
likely when using a 2.5µl DNA template. These results were duplicated on repeat LAMP assays (data 
not shown).  
3.4.3 CONFIRMATION OF DETECTION OF S. STERCORALIS DNA 
To develop the assay confirmation of the sequenced product was performed on DNA amplified 
from the positive stool control using the inner or outer SPSs LAMP primers in a cPCR reaction 
(Figure 3.2) to confirm product identity and to generate a product sequence. LAMP product may 






Figure 3.2: Gel electrophoresis (2% agarose run at 100V for 1 hour) of LAMP products generated by 
cPCR using LAMP SPSs outer or inner primers (Lanes 3 or 6). Lanes 1 and 4 contained the negative 
control and Lane 2 contained the no template control. Lane 5 shows the cPCR product, generated 
using qPCR Stro18S primers.  
 
The product was cloned using the pJET® 1.2 plasmid vector kit and sent for sequencing. The cPCR 
product using the outer primers repeatedly failed to produce an insert with sequence identity. The 
insert produced using the inner primers failed to give sequence identity on a BLASTn search and 
could not be used to confirm product identity or to determine the limit of detection of the method. 
The insert sequence that was generated is shown in Table 3.6 and demonstrated that the pJET® 1.2 
plasmid vector method was processed correctly according to the manufacturer’s protocol.   
  















Table 3.6: Sequences generated by cPCR from a positive stool control using Fip and Bip (LAMP 
forward and back inner primers) failed to generate identifiable sequences after cloning and 
sequencing reactions using the pJET®1.2 plasmid vector 









No identity obtained 
 
It is not known why the cPCR product generated by the outer primers failed on two separate 
occasions to produce an insert using a blunt-ended plasmid vector (pJET® 1.2). The Corning Cellgro 
troubleshooting guide (Corning Cellgro, 2012) suggests that residual restriction enzyme or 
phosphatase might inhibit ligation, but this was not the case in this study as all the cPCR products 
that were sent for ligation had been purified. Another cause for concern is that the cells may have 
been contaminated allowing the cells to grow in the broth and on the LB agar plate containing 
ampicillin, but no confirmation was obtained for this in the study. Further investigation found that 
the ampicillin was in date and used at the correct concentration and so the detection reagent used 
could not be attributed to the failure of the sequencing reaction to generate a sequence identity. 
The lack of sequence identity may be due to the sequence of the product or the amount of cloned 
DNA produced. Table 3.6 demonstrates the sequences obtained and the result of a mega BLAST 
search using the pJET®1.2 plasmid vector where no sequence identity could be determined. 
The DNA product was also sequenced using a direct sequencing method (Section 2.7.2) or by 
sequencing of the cloned insert using the pGEM® T-Easy plasmid vector, a vector with 3’ T 
overhangs. These methods generated a sequence with matches of 77 to 100% with the S. 
stercoralis 18S rRNA subunit. The samples were sent to LSHTM for sequencing using an ABI Prism 
310 genetic analyser. The sequences were analysed using the Seqman® program (Source DNASTAR® 
Inc., USA). The results of sequencing reactions on the purified product generated by cPCR were 
used to confirm the product identity for the LAMP assay from the direct sequence reactions (Table 




Table 3.7 Sequences generated using an ABI Prism 310 genetic analyser 



















Table 3.8 Sequence identity generated by direct sequencing reactions performed on amplicons 
generated with LAMP forward outer or LAMP back outer primers using the ABI Big®Dye version 3.1 
protocol. Sequence identity was determined using the BLASTn search tool (NCBI, n.d.). 
PRIMER USED PRODUCT BLAST RESULT SIZE E value 
Sequence 
generated using 




Product sent for 
direct 
sequencing 
100% homology to the 
Strongyloides stercoralis 
gene for 18S small subunit 
ribosomal RNA, partial 
sequence. NCBI accession 
bank numbers: 
AB923888.1, KF926660.1 , 
KF926659.1, KF926658.1 
and AB453316.1 
172bp 8e-47 to 9e-86 
Sequence 
generated using 













168bp 2e-68 to 7e-67 
 
Further confirmation of the amplified product was performed by sequencing of the cloned insert 
using the pGEM® T-Easy plasmid vector, a vector with 3’ T (thymidine) overhangs, to prevent 
recircularization of the vector and improve ligation of the target. The direct and pGEM® T-Easy 
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sequences align in the same region of the 18S rRNA genome. The pGEM® T-Easy sequence showed 
a 99% sequence match (239/240bp) with the forward outer primer (F3) but no sequence identity 
was found using the back outer primer (B3). Gel electrophoresis of the EcoRI digestion product 
confirmed the presence of the insert before the PCR reactions (using only T7 or SP6 primers) were 




AACGCACCACTAATGTGGAAT (240bp).  
This was identified on a BLASTn search as S .stercoralis with a sequence match of 99% and with an E 
value of 8e-123 for a sequence size of 239/240bp.  
Future transformation reactions will use cPCR and T7 and SP6 as the forward and back primers as a 
screening method for multiple colonies. A single colony (proven by cPCR to contain the target 
insert) is subsequently picked from a purity plate (after overnight incubation at 37oC) and placed 
into LB broth for a further overnight incubation at 37oC. Multiple colonies can be more easily 
screened using this method. This has the added benefit of confirmation of the presence of the 
insert before cloning and enzyme digestion is performed.  
A final product sequence identity and alignment on the 18S RNA genome for the results of direct 
(F3 or B3 primers) or pGEM®T-Easy (T7 primer) sequencing reactions was obtained using the 
BLASTn and ClustalW2 tools (Larkin et al., 2007) and is shown in Appendix 3a. The ClustalW2 
sequence alignment illustrated that the LAMP and qPCR assay primers do not target the same 
region of the 18S rRNA genome.  
3.5 SENSITIVITY AND SPECIFICITY OF LAMP 
The standards for reporting of diagnostic accuracy guidelines recommends validation of a new 
diagnostic method using analytical sensitivity and specificity to assess the performance and 
accuracy of new diagnostic methods (Saah and Hoover, 1997, Bossuyt et al., 2015).  
3.5.1. ANALYTICAL SENSITIVITY 
Analytical sensitivity determines the smallest amount of substance that can be detected in an 
assay. This differs from diagnostic sensitivity, which is the ability to determine disease in the 
infected population (Saah and Hoover, 1997). Analytical sensitivity was determined by serial 10- 
fold (10-1 to 10-7) dilution of S. stercoralis DNA in nuclease free distilled water. S. stercoralis DNA 
was extracted from an aliquot of stool containing 1 S. stercoralis larva/ µl. 
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Dilutions of the positive control diluted in negative stool slurry were well-mixed before DNA 
extraction was performed to ensure that the stool sample was as homogenous as possible but the 
results were not consistent. A consistent comparable result was obtained when DNA was serially 
diluted after extraction from a spiked stool positive control sample and this was the method chosen 
for the current study. The dilution series also diluted any stool inhibitors of the LAMP assay that 
may have been present in the DNA aliquots. Table 3.9 demonstrates the results for 10- fold dilution 
series of the positive control. The sample size of stool extracted is included as it was assumed that 
the sample size would have an effect on the LAMP results. However, stepwise logistic regression 
analysis showed that the sample size of stool extracted did not have an effect on the result of the 
LAMP assay. The results of the statistical analysis are discussed in more detail in Section 3.9.  
Table 3.9 Performance of LAMP using serial 10- fold dilutions of DNA extracted from positive 
control stool samples (Positive LAMP time in minutes) 




CONTAINING 1 S 
STERCORALIS 
LARVA/ µl) 
LAMP RESULT (TIME IN MINUTES) 
DETERMINED BY THE DEVELOPMENT OF 
TURBIDITY USING AN LA 320C 
TURBIDIMETER 
10-1 Positive stool control (*10-fold dilutions performed on extracted 





10-1 Positive stool control (*10-fold dilutions performed on extracted 





10-1 Positive stool control (*10-fold dilutions performed on extracted 







A dilution series was performed on the positive stool samples that were extracted with each 
Qiagen® Qiasymphony SP run and used to monitor the DNA extraction process. The resulting 
dilution series was also used as an amplification control in the LAMP assays. Table 3.10 shows the 
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average results obtained from the dilution series of eight positive stool controls that were used in 
this study and were positive for dilutions 10-1 to 10-3. 
Table 3.10 Determination of the analytical sensitivity or limit of detection (LOD) using negative stool 
slurry spiked with L3 (infectious stage) S. stercoralis larvae from a positive stool culture- final 
concentration: 1 S. stercoralis larva/µl. 
 LAMP DILUTION SERIES S. STERCORALIS  
NEGATIVE STOOL SAMPLE 
Neat (1 S. 
stercoralis 
larva/µl) 





23.4 25.40 27.37 32.38 Negative Negative Negative Negative 
 
Watts et al. (2014), using primers targeted to the 28S rRNA gene, found an analytical sensitivity of 
10-2 (dilution of 1 larva of S. ratti/ 50µl of water diluted 1 in 5 in a known negative stool sample). 
This study showed an analytical sensitivity of 10-3 (with a final dilution of 1 larva S. stercoralis/ µl 
diluted in a known negative stool control sample).  
The analytical sensitivity for LAMP assays was determined to be 1 x 10-3 S. stercoralis larvae/ µl, 
using the limit of detection of an aliquot containing a known concentration of DNA. The amount of 
DNA in samples (after EcoRI digestion) sent for sequencing, using the pGEM®T-EASY plasmid vector, 
was measured using a Nanodrop spectrophotometer (Source Thermo Fisher Scientific, UK). The 
Nanodrop spectrophotometer gave a reading of 117.2 ng at a wavelength of 260nm and one serial 
10- fold dilution series was performed in duplicate in a LAMP assay. The limit of detection for the 
LAMP assay was 117.2 x 10-9 ng of DNA. Table 3.11 demonstrates the results obtained from 




Table 3.11 Determination of the LOD using EcoRI digested DNA. 
LAMP DILUTION RESULT LAMP ASSAY RUN 1  
(TIME IN MINUTES) 
RESULT LAMP ASSAY RUN 2  
(TIME IN MINUTES) 
Neat (1 S stercoralis larva/ µl) 12 12 
10-1 13 14 
10-2 14 15 
10-3 17 18 
10-4 19 21 
10-5 21 27.06 
10-6 22 27.36 
10-7 25 30.42 
10-8 31 32 
10-9 44.00 52.12 
10-10 Negative Negative 
10-11 Negative Negative 
10-12 Negative Negative 
 
The values for the LAMP assay (time in minutes) were determined from the analysis of the 
justification results to determine true positive results. Where the time is reported in whole 
numbers a turbidity reading was not reported by the LA 320C turbidometer (Source Eiken, Japan) 
and justification results were used to determine time (minutes) for a true positive result (Figure 
3.3). True positive can be determined by a sharp peak and negative product production is 
determined by wavy lines in the curves and/ or broad peaks and may be the result of non- specific 




Figure 3.3 Justification results for LAMP assay run 1 to determine true positive results.  
A1:  Positive stool control 10-2 dilution, A2: No template control, A3: LOD sample neat, A4: LOD 
sample dilution 10-1, A5: LOD sample 10-2, A6: LOD sample 10-3, A7: LOD sample 10-4, A8: LOD 
sample 10-5, B1: LOD sample 10-6, B2: LOD sample 10-7, B3: LOD sample 10-8, B4: LOD sample 10-9, 
B5: LOD sample 10-10, B6: LOD sample 10-11, B7: LOD sample 10-12, B8: Negative stool control. 
 
3.5.2. DIAGNOSTIC SENSITIVITY 
The determination of diagnostic sensitivity was performed using CRS positive and negative study 
samples compared with the results of the LAMP assay in a 2x2 table (Jacobson, 1998). Prevalence, 
which is required for a complete determination of diagnostic sensitivity and specificity, (Baughman 
et al., 2008) is unknown in the patient population attending DCP.  
The diagnostic (or clinical) sensitivity was calculated as 23.29% (95% CI: 14.19-34.65%) using the 
CRS (indicating proven or possible disease) as a comparator. Diagnostic sensitivity was calculated as 
46.15% (95% CI: 26.59-66.63%) when using only microscopy and culture results (proven disease) as 
a comparator. The 95% CI intervals indicate that sensitivity and specificity results are biased (i.e. the 
interval range is too broad to be significant) and so cannot be interpreted. When using an imperfect 
reference standard, sensitivity and specificity estimates are biased (Baughman et al., 2008) and the 
FDA recommends using overall percent agreement (OPA) between the current and new tests (FDA, 
2007). The positive percent agreement (PPA) for the LAMP assay detection of S. stercoralis DNA in 
clinical samples was determined in this study to be 27.42% with an overall percent agreement 
(OPA) between current (CRS) and new (LAMP assay) tests of 83.8% (95% CI: 73.5-95.2%). As 
discussed in Chapter 2, Section 2.8 this result must be interpreted with care as the values indicate 
only the number of negative or positive agreements between the CRS and the LAMP assay. 
Sharp peaks 




















3.5.3. ANALYTICAL SPECIFICITY 
The ability of an assay to detect only a specific organism/ analyte is termed analytical specificity and 
is defined as the ability to detect “true” negative samples i.e. those without the disease (Saah and 
Hoover, 1997). Analytical specificity was determined by the samples in the specificity bank and 
negative stool control samples.  LAMP had 100% specificity as there were no false positive or false 
negative reactions using the samples in the specificity bank. All known positive S. stercoralis 
samples in the specificity bank using the current stool DNA extraction protocol at DCP were 
detected. The samples in the specificity bank were processed and analysed using the same protocol 
that was used for the study samples. The results of the analytical specificity study are shown in 
Table 3.12.  
Table 3.12 LAMP results for viral, bacterial and parasitic human pathogens (total S. stercoralis 
positive samples = 8, total S. stercoralis negative samples = 58) 
ORGANISM NUMBER OF ORGANISMS TESTED LAMP RESULTS (EXTRACTED 
DNA) 
Negative stool 8 Negative (8) 
 
Positive S. stercoralis stool 
control 
8 Positive (8) 
 
Rhabditiform free-living larvae 
NOT S. stercoralis 
1 Negative (1) 
Nematodes  11- Ascaris lumbricoides (2), Trichuris trichiura(2), 
hookworm (5), Trichostrongylus sp. (1), Loa loa (1) 
Negative (11) 
Trematodes  2- Dicrocoelium dendriticum (1), Schistosoma 
mansoni(1) 
Negative (2) 
Cestodes  2- Bertiella studeri (1), Taenia saginata(1) Negative (2) 
Intestinal protists/ intracellular 
fungi 
29- Cryptosporidium sp. (5), Cystoisospora belli (2), 
Cyclospora cayetanensis (1), Entamoeba 
histolytica/dispar (6), Entamoeba hartmanni (1), 
Entamoeba coli (1), Giardia lamblia (6), Blastocystis 
hominis (1), Enterocytozoon bienusi (5), 
Encephalitozoon intestinalis (1) 
Negative (29) 
Bacteria 4- Campylobacter jejuni (1), Shigella sonnei (1), 
Escherichia coli O157 (1), Vibrio cholera (1) 
Negative (4) 




3.5.4. DIAGNOSTIC SPECIFICITY 
Diagnostic specificity was determined using the results of the LAMP assay and the CRS for the study 
samples in a 2x2 contingency table (Jacobson, 1998).  
The specificity was calculated as 99.57% (95% CI: 97.63-99.99%) using the CRS as a comparator and 
97.86% (95% CI: 95.39-99.21%) when using microscopy and culture as a comparator. The negative 
percent agreement (NPA) is used when there is no “gold standard” and was calculated to be 99.55% 
(FDA, 2007).  
3.6. EVALUATION OF THE LAMP ASSAY FOR THE DETECTION OF S. STERCORALIS DNA FROM 
CLINICAL SAMPLES 
The sample size for this study was calculated for a comparison of two proportions (McNemar’s test) 
to show a difference of at least 10 in the row and column totals of a 2x2 table, for the null 
hypothesis to be disproven (Jacobson, 1998). Test performance was evaluated using McNemar’s 
test, overall percent agreement and Cohen’s kappa co-efficient (MedCalc®, n.d.). The 
reproducibility and reliability was evaluated on samples that were positive for LAMP and qPCR or 
negative for LAMP and positive for qPCR. Furthermore a proportion of the negative samples were 
re-tested with no additional positive samples detected.  
With the exception of a failing batch of primers (these results were excluded and the LAMP assay 
was repeated using a fresh set of primers) only two inconsistent results were obtained. The 
inconsistent results were generated from template DNA at a dilution of 10-1 and these are thought 
to be due to the presence of very little DNA in the samples (Table 3.13). 
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Table 3.13 Reproducibility of LAMP assay for the detection of S. stercoralis DNA in clinical samples 













DNA AT A 


















ASSAY USING DNA 
AT A DILUTION OF 
10-1TO DETERMINE 
IF ANY INHIBITION 
OF THE ASSAY IS 
PRESENT 
(LAMP RESULTS) 
7 out of 9 samples 
positive 
9 out of 9 samples 
positive 
1 out of 2 
samples 
positive*.  
24 out of 24 
negative 
24 out of 24 
negative 
12 out of 12 samples 
negative 
*The positive sample was negative in 2 out of 3 LAMP assays. The LAMP time (minutes) was 52.24 indicating that there was very little 
DNA present in that sample. 
 
The LAMP assay in these samples was tested at a dilution of 10-1 as the qPCR assay indicated that 
possible inhibitors were present in these samples. Any samples that were found by qPCR (Chapter 
4) to have possible inhibitors present (internal control Ct raised above the run mean + 2SD) were 
diluted 10-1 and a repeat LAMP and qPCR assay was performed. Low levels of DNA in faecal aliquots 
may result in false negative results in the LAMP assay (Morrison et al., 1998) and a determination of 
the effect of stool inhibition on low levels of DNA was investigated and discussed in Section 3.7. 
All of the samples that were LAMP assay positive also tested positive by qPCR (Chapter 4). Analysis 
of the results of the gel electrophoresis of the qPCR products showed that no samples with 




Table 3.14: Results of the LAMP assay positive or negative compared with qPCR assay positive and 
CRS (microscopy, culture and serology) results in samples stored at -20oC. Total number of 
samples n=284. 











NUMBER OF ANOMALOUS 
BANDS ON A 2% AGAROSE 
GEL FOR qPCR PRODUCT 
1 CRS negative 40.12 (n=1) 27.15 0 
7 Microscopy/ culture positive 20-52.24 (n=7) 19.5-27.49 0 
4 Serology positive 27.24-58.42 (n=4) 24.06-26.42 0 
6 Full CRS positive 24.06-53 (n=6) 14.98-26.78 0 
18 CRS negative Negative (n= 18) 27.49-35.7 5* 
2 Microscopy/ culture positive Negative (n= 2) 27.49-31.84 0 
5 Serology positive Negative (n= 5) 31.29-40.05 0 
2 Full CRS positive Negative (n= 2) 28.47-33.89 0 
*Repeat qPCR assays generated 2 negative results (Original qPCR Cts 38.15-39.5). Final total 3 anomalous bands detected by qPCR in this 
study. 
In this study the LAMP assay failed to detect S. stercoralis DNA in a number of qPCR positive 
samples (where Ct was >31.46). All qPCR assay positive and LAMP assay negative results were 
repeated and no new positive LAMP samples were detected. The cut-off for detection of S. 
stercoralis DNA by the LAMP assay was a qPCR Ct of ≤31.46 (in samples stored at 4
oC or -20oC) also 
indicating that low concentrations of S. stercoralis DNA will not be detected by the LAMP assay 
(Table 3.15). Clinical samples are not homogenous samples and small aliquots taken from clinical 
samples for analysis may not necessarily detect the parasite (Monteiro et al., 1997). Also very little 
DNA present in samples for molecular analysis may not be detected (Morrison et al., 1998). The 
target site for the 18S rRNA genome was found to be different for the LAMP and qPCR assays 
(Appendix 3a) and this may have contributed to the less sensitive detection of S. stercoralis DNA 
with the LAMP assay. 
Table 3.15: Maximum, minimum, mean and standard deviation values for the LAMP (time in 
minutes) and qPCR (Ct) assays. Samples stored at 4
oC or -20oC. 
  MINIMUM MAXIMUM MEAN STANDARD 
DEVIATION 
qPCR (Ct) 14.98 (LAMP= 29.54) 31.46 (LAMP= 49.36) 31.49 6.75 




While this determines that there is very little improvement over current methods for proven 
disease available in the field (microscopy and culture combined), the decrease in time taken to 
diagnose cases of strongyloidiasis (LAMP= one hour, microscopy with a sensitivity of up to 50% = 
one hour but may contain infectious L3 larvae in cases of hyperinfection and culture with a 
sensitivity of up to 70% = 7 to 10 days, may contain infectious L3 larvae) makes this a useful assay 
for deployment to endemic areas. In addition, this has the added benefit of limiting laboratory staff 
to exposure of infectious L3 larvae that may be abundant in culture techniques. 
Precision between the LAMP amplification runs was tested from the results generated by the 
positive control (at a dilution of 10-2) in amplification runs using the study protocol. A standard 
curve of the positive control DNA at dilutions of 10-1, 10-2 and 10-3 was used during optimisation 
runs for the LAMP assay and so could not be used to calculate percentage coefficient of variation (% 
CV). The % CV for the 10-2 dilution of the positive control was 9.7% over 16 consecutive 
amplification runs. The % CV should be <15% between runs and <10% within runs (Reed et al., 
2002, Salimetrics®, n.d.) and the LAMP assay was shown to have an acceptable level of precision 
(9.7% between runs) for a diagnostic assay. 
3.7 PERSISTENCE OF S. STERCORALIS DNA AT STORAGE TEMPERATURES OF 4oC AND -20oC 
As previously discussed (Section 3.3) faecal samples for S. stercoralis molecular testing should be 
stored at -20oC before DNA extraction if no preservative (e.g equal volume of ethanol) is used. The 
LAMP assay was assessed for the persistence of DNA with short-term storage at 4oC without a 
preservative as this would impact the routine workflow at DCP. To investigate the decreased 
sensitivity in the detection of S. stercoralis in samples stored at 4oC and -20oC a pilot study was set 
up to determine the short-term persistence of DNA in samples stored at 4oC or -20oC. This was 
performed to confirm that S. stercoralis DNA in clinical sample aliquots could safely be stored at 4oC 
for a short-term without a decrease in sensitivity in the detection of S. stercoralis DNA.  
Table 3.16 shows the results obtained using a positive control stool sample stored at 4oC or -20oC 
and tested at various time intervals. A positive control stool sample containing 0.1 S. stercoralis 
DNA/ µl was used in this study so that a drop in efficiency of the LAMP assay could be determined 
within the pilot study time- frame. The DNA was extracted using the Qiagen® Qiasymphony SP and 
the extracted DNA was stored at -20oC until a LAMP assay could be performed. The DNA was 



























LAMP ASSAY (final 
dilution positive) 





Week 1 15-04-2017 Negative Neat Negative 10-4 
Week 2 15-04-2017 Negative Negative Negative 10-3 
Week 3 15-04-2017 Negative Negative Negative 10-3 
Week 4 15-04-2017 Negative Negative Negative 10-3 
Week 5 15-04-2017 Negative Negative Negative 10-3 
Week 8 17-04-2017 Negative 10-1 Negative 10-3 
Week 12 17-04-2017 Negative 10-1 Negative 10-2 
 
The results from the DNA persistence pilot study demonstrated that storage at 4oC was not 
recommended, even for short-term storage, and samples requiring a LAMP assay for detection of S. 
stercoralis DNA in clinical samples must be stored at -20oC.  
Discrepant results demonstrated in the LAMP assay for some of the 10-1 dilutions of aliquots that 
had been stored at 4oC before DNA extraction was performed, may be attributed to poor quality 
DNA (the DNA was extracted on separate Qiagen® Qiasymphony SP runs) or very small amounts of 
DNA present in the sample when DNA may not always be detected in each assay (Morrison et al., 
1998). These results do not alter the conclusion reached from the pilot study that storage at 4oC is 
sub- optimal for the detection of S. stercoralis DNA in the LAMP assay. Storage at -20oC showed 
some deterioration of the stored DNA and samples requiring a LAMP assay for the detection of S. 
stercoralis DNA must be tested as soon as possible.  
While this is not difficult to arrange in busy routine well-resourced laboratories this must be 
considered when choosing an assay for epidemiological monitoring and control studies as it may 
not be possible to test the samples in the field in a timely manner. It may also not be possible to 
store the samples at -20oC in resource- limited areas. Further work is required to determine if 
storage in DNA preservative or on FTA cards (Source Sigma Aldridge) would eliminate the effect of 
sub- optimal storage. FTA cards contain chemicals to lyse cells, denature proteins and protect 
nucleic acids from damage by nucleases, oxidation or UV damage (Mullen et al., 2009) and may 
improve the detection of S. stercoralis DNA in the LAMP assay. 
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3.8 INVESTIGATION OF METHODS FOR DNA EXTRACTION THAT ARE SUITABLE FOR USE WITH 
LAMP ASSAYS IN RESOURCE-LIMITED AREAS 
Automated DNA extraction is expensive and requires complex technology and high technical 
expertise and, as such, is not suitable for use in resource- limited areas. The LAMP assay is reported 
to be more resistant to inhibition than the qPCR assay (Notomi, 2000) and so manual DNA 
extraction methods were examined for the suitability of LAMP assay deployment in resource- 
limited areas. Manual methods of DNA extraction for use in the LAMP assay to detect blood 
parasites have been described that are suitable for use in resource- limited areas (FIND, 2012, 
Lucchi et al., 2016, Perera et al., 2017).  
Strongyloides stercoralis has a thick cuticle that may inhibit successful DNA extraction using 
methods that do not lyse the parasite (Moghaddassani et al., 2011, Levenhagen and Costa Cruz, 
2014). Gasser et al. (1993) demonstrated a reduced yield of DNA from Trichostrongylus sp. worms 
due to the thick cuticle, nevertheless sufficient DNA was extracted using a homogenisation method. 
The pilot study, therefore, included pre- treatment methods to determine whether lysis of the thick 
cuticle of S. stercoralis would improve the manual extraction of DNA from stool samples. 
Aliquots of negative and positive stool control samples were stored at 4oC and -20oC until DNA 
extraction was performed using the PURE® method (Source Eiken, Japan), the “boil and spin” 
method (FIND, 2012) or the Qiagen® Qiasymphony SP automated DNA extraction method.  
Using the magnetic bead resonance DNA extraction method, in this study, purified DNA was 
extracted that was suitable for use in the LAMP assay. To investigate manual methods of DNA 
extraction, 60 µl of positive control stool samples (containing 1 S. stercoralis larvae/ µl) and 
negative control stool samples, stored at -20oC were extracted by the manual method with pre-
treatment of the sample before manual DNA extraction by one of the following methods:   
I. Incubation with a 1 in 2 dilution of the Qiagen® tissue lysis buffer (ATL)  containing a 1 in 50 
dilution of proteinase k (Source Thermo Fisher Scientific, UK) at 56oC for 2 hours;  
II. Incubation with a 1 in 2 dilution of the Qiagen® tissue lysis buffer (ATL)  containing a 1 in 50 
dilution of proteinase k (Source Thermo Fisher Scientific, UK) at 56oC overnight; 
III. Extreme freeze-thaw in liquid nitrogen for 5 minutes.  
The positive stool control was also analysed without pre- treatment: 
I. Neat;  




A parallel automated DNA extraction was performed on the Qiagen® Qiasymphony SP (the 
comparison control) (Section 2.3.8.3). Negative stool controls were extracted using the same 
conditions (FIND, 2012, Perera et al., 2017).  
In this study the aliquots were diluted in a 10- fold dilution series in nuclease free water and stored 
at -20oC until the LAMP assay could be performed using the study protocol.  
Inhibition (shown in red) was determined by comparison of the LAMP time of the DNA extracted by 
the automated method and the LAMP time for the different treatment methods for the DNA 
extracted by the manual method. Where the LAMP time for the manual extraction method was 
greater than the LAMP time for the automated DNA extraction method plus a 1.96 standard 
deviation, sample inhibition of the LAMP assay was suspected. Where the standard deviation could 
not be calculated (too few results) sample inhibition of the LAMP assay was suspected when the 
LAMP time for the manual DNA extraction method was more than 3 minutes greater than the LAMP 
time for the automated DNA extraction method.  
Table 3.17 shows the results obtained using negative and positive stool controls (containing 1 S. 
stercoralis larvae/ µl). The positive stool sample DNA was diluted in a 10- fold dilution series and 




Table 3.17: Comparison of LAMP times for the manual DNA extraction method- PURE® technology 
(Source Eiken, Japan) and the automated Qiagen® Qiasymphony SP DNA extraction method. Results 
in red indicate possible inhibition of the assay. Underlined results indicate that DNA degradation 
may have occurred as a result of the extreme temperature pre- treatment method. 









































































































Negative Negative Negative Negative Negative Negative Negative Negative 
 
The results demonstrated that inhibition of the LAMP assay occurred when large sample volumes 
were used, as shown by the reduced numbers of samples showing inhibition in the LAMP assay 
when the samples were diluted. Extreme temperature (freeze- thaw in liquid nitrogen) pre- 
treatment of samples was unsuitable for the extraction of S. stercoralis DNA using PURE® 
technology. Pre- treatment of the stool samples with ATL plus proteinase k incubated at 56oC 
(overnight or 2 hours) improved the detection of S. stercoralis DNA. This may be due to improved 
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lysis of the larval cuticle recommended by Moghaddassani et al. (2011) and Levenhagen and Costa 
Cruz (2014) for the DNA extraction of whole parasites.  
These results indicated that DNA manual extraction may be performed on neat stool samples with 
ATL and proteinase k pre-treatment but further modification of the method is required as assay 
inhibition was demonstrated when using large sample volumes.  
Therefore, a further study was performed to determine the effect of the stool loading sample 
volume on the manual DNA extraction method. Negative and positive stool control samples, 
without pre-treatment, were extracted using decreasing volumes of stool loading sample: 100, 80, 
50, 20 and 10 µl. These results generated by the LAMP assay are shown in Table 3.18. 
Table 3.18: Effect of inhibition on the LAMP assay using the PURE® manual DNA extraction method. 
Results in red indicate possible inhibition of the LAMP assay. All negative stool control samples 











Negative Negative Negative Negative 30.24 25 
Positive stool 
control 10-1 
Negative 32.18 26.12 26 28.3 23.2 
Positive stool 
control 10-2 
29.42 28 26.48 26.42 24.36 24.36 
Positive stool 
control 10-3 
28.36 25 26.36 24 27.06 24.36 
  
The determination of inhibition of the LAMP assay is reported in red, using the same criteria for the 
determination of inhibition as previously described. A loading volume of 10 µl detected S. 
stercoralis DNA (extracted from an aliquot containing 1 S. stercoralis larva/ µl) in the neat DNA and 
the DNA dilutions 10-1 to 10-3. 
A loading volume of 10 µl detected S. stercoralis DNA in the neat DNA and the DNA dilutions 10-1 to 
10-3 demonstrating that a smaller loading sample volume is required for this technique. Inhibition 
was demonstrated in the 10-3 dilution for this volume. This may be due to the fact that 10 µl only 
contains a small amount of DNA template and this will affect the sensitivity of detection of S. 
stercoralis DNA in the LAMP assay (Morrison et al., 1998). There is a corresponding decrease in 
sensitivity of the LAMP assay when small loading volumes are used. This study concluded that, in 
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the present format, PURE® DNA extraction on untreated stool samples was unsuitable for the LAMP 
assay. 
A simpler method (“boil and spin”) requiring only a vortex, a centrifuge, a stable power supply and 
heating at 95oC was also assessed for efficiency of DNA extraction for use in the LAMP assay. This 
was previously described for the malaria LAMP assay for detection of protist parasites in blood 
(Polley et al., 2013). The results of the “boil and spin” method investigated for the suitability of use 
in extracting DNA in endemic areas are shown in Table 3.19. 
Table 3.19: Effect of inhibition on the LAMP assay using the “boil and spin” manual DNA extraction 










Negative Negative Negative Negative Negative Negative Negative 
Positive stool 
control (neat) 
Negative Negative Negative 42.5 Negative 27.0 
Positive stool 
control 10-1 
41.12 33.06 34.42 34.24 34.24 32.18 
Positive stool 
control 10-2 
36.0 42.3 35.0 35.0 41.18* 34.0 
Positive stool 
control 10-3 
32.0 Negative 33.0 43.0* 42.0* 38.12 
 
Positive (containing 1 S. stercoralis larva/ µl) and negative stool controls were emulsified in SDS 
buffer (Section 2.3.8.4) before DNA extraction was performed. Inhibition of the assay was 
calculated using the same criteria previously mentioned. Inhibition is shown in red in Table 3.19.  
The results demonstrated that a loading volume of 25 µl was optimal for this manual DNA 
extraction method. A smaller loading sample of 10 µl showed possible inhibition of the LAMP assay 
when compared to the comparison control (DNA extraction using the automated Qiagen® 
Qiasymphony SP). The loading sample is small and the increased LAMP time may be due to the fact 
that very little S. stercoralis DNA template was present in this sample (denoted by * in Table 3.19). 
Nevertheless, this method for extraction of DNA for use in the LAMP assay shows promise for use in 
resource- limited areas after further optimisation of the stool sample storage conditions has been 
completed. The SDS extraction buffer is a relatively inexpensive reagent and is easy to prepare and 
store at room temperature making this a suitable reagent to use in resource- limited areas. 
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The LAMP assay detected S. stercoralis DNA extracted using the manual or automated methods 
investigated in this study (Figure 3.4) 
 
 
Figure 3.4: Gel electrophoresis of LAMP assay products (positive study samples, positive stool 
control PURE® manual DNA extraction method and the automated Qiagen® Qiasymphony SP DNA 
extraction method).  Lane 1: negative stool control, Lane 2: no template control, Lanes 3, 4: study 
samples, Lanes 5, 6: PURE® DNA (manual) dilutions 10-1 (Lane 5) and 10-2 (Lane 6), Lane 7: Qiagen® 
Qiasymphony SP DNA (automated) dilution 10-2, Lanes 8, 9: negative study samples. 
 
The LAMP assay also detected DNA extracted directly from cultured larvae. The data is not shown 
as optimisation of the assay was performed on stool samples spiked with S. stercoralis larvae. 
 
3.9 STATISTICAL ANALYSIS OF LAMP 
287 stool samples that had been stored at 4oC and -20oC before DNA extraction were tested by the 
LAMP assay. Only one sample per patient was included in the statistical analysis for this study. 
Duplicate samples were excluded using the criterion that statistical analysis was performed using 
the first sample only (the diagnostic sample). The results of the repeat samples could not be 
determined to be due to failed treatment, active disease or persistent antibody (serology result as 
part of the CRS) and so were removed from the analysis of the data. The microscopy and culture 
assays in the CRS were performed from the same sample that was sent for storage at 4oC or -20oC. 
Standard McNemar’s test for the comparison of proportions and diagnostic sensitivity and 














specificity calculations were carried out (MedCalc®, n.d.) and the results are recorded in Table 3.20.  
The sensitivity results were poor for the LAMP assay as an imperfect reference standard was used 
that denoted proven disease or probable disease and was subject to sensitivity and specificity bias 
(Baughman et al., 2008). The overall percent agreement between the CRS and the new test when 
using an imperfect reference standard was used (FDA, 2007). This is shown in Table 3.20. 
Table 3.20: McNemar’s test and 2x2 contingency table results for the LAMP assay and overall 
percent positive results (including 95% CI) for significance of results 
STATISTICAL TEST  CRS AND 
LAMP -20OC 
 MICRO/CULTURE AND 
LAMP -20OC 
 
   95%CI  95%CI 




 Probability p=<0.0001  p=0.1153  




















 Disease Prevalence 













FDA recommendation when using 
an imperfect reference standard 
(FDA, 2007) 
Positive percent 
agreement PPA (instead 
of sensitivity) 
27.4% - - - 
 Negative percent 
agreement NPA  (instead 
of specificity) 
99.6% - - - 
 Overall percent 
agreement OPA (between 





McNemar’s test showed a significant difference between the CRS and the LAMP assay, but no 
significant difference was shown when using microscopy/ culture as a comparator. The sensitivity 
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calculations were not valid as the 95% CI was too large to demonstrate a significant value. The 95% 
CI for specificity between 97.63-99.99% (using the CRS as a comparator) and 95.39-99.21% (using 
microscopy/ culture as a comparator) and an NPA of 99.6% indicate that the LAMP assay is a useful 
diagnostic test. This indicates that there is a high probability that disease is present when a positive 
result is found. The area under the ROC curve (AUC) demonstrated that the LAMP assay is less 
sensitive than the CRS or serology but is a fair test for the diagnosis of strongyloidiasis. The OPA 
confirms that there is a good overall percent agreement between the CRS and the LAMP assay.  
Further statistical analysis was carried out on those samples where the travel history was known 
(Asia n= 73 and Africa n=73). Analysis could not be performed in those with a known travel history 
to other geographical areas (e.g. Mediterranean) as the numbers were too low for accurate 
analysis. A comparison of LAMP and the CRS or LAMP and microscopy/ culture positive only for 
samples with a travel history in Asia (Table 3.21) or Africa (Table 3.22) demonstrated the effect of 
serological results on the comparison of the usefulness of the LAMP assay when using an imperfect 
composite reference standard.  
Table 3.21: Intraclass correlation of: LAMP and microscopy/ culture positive only or LAMP and CRS 
in samples with a travel history to Asia. 
  LAMP VS. 
MICROSCOPY/ 
CULTURE POSITIVE  
LAMP VS. CRS 
   95% CI  95% CI 
Single measures (degree of consistency among 
measurements) 
0.52 0.413-0.68 0.29 0.144-
0.441 
Average measures (Reliability of averages of kappa 
ratings) 






Table 3.22: Intraclass correlation of: LAMP and microscopy/ culture positive only or LAMP and CRS 
in samples with a travel history to Africa. 
  LAMP VS. 
MICROSCOPY/ 
CULTURE POSITIVE  
LAMP VS. CRS 
    95% CI  95% CI 
Single measures (degree of consistency among 
measurements) 
0.416 0.258-0.570 -0.0104 -0.131-
0.138 







In Tables 3.21 and 3.22 the effect of removal of the serological result alters the interpretation of 
the usefulness of LAMP as an effective screening tool from good to excellent (Table 3.21) and poor 
to good (Table 3.22) (Cicchetti, 1994). Serology is a screening diagnostic test used in the current 
repertoire at DCP and this, along with the percentage of positives detected by both the LAMP assay 
and serology, demonstrates the unsuitability of LAMP as a replacement screening test at DCP. 
LAMP has a low PPA  and cannot rule out the presence of disease in all cases, the false negative 
rate is not suitable for first- line diagnostic screening for disease in a condition where severe 
disease or even death may occur in immunocompromised patients (Pewsner et al., 2004, Pottie et 
al., 2011). As demonstrated in Table 3.23 the percentage of positive LAMP reactions in samples 
stored at -20oC was 6.7 % and that for serology was 26 %.  
Table 3.23: Percentage positive of the total number of samples detected by LAMP, CRS, serology 
only or microscopy/ culture. (Data obtained for samples stored at -20oC). 
ASSAY PERCENTAGE POSITIVE 
CRS % positive 27% 
Microscopy % positive 4.80% 
Culture % positive 3.90% 
Serology % positive 26% 
LAMP assay  % positive 6.70% 
 
While some of the serology positive results may be due to the persistence of antibody there may 
well be serology positive samples that indicate active disease.  
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The consequences in immunocompromised patients of a missed diagnosis (Pottie et al., 2011), 
necessitates the retention of serology as a diagnostic test. Serology is difficult to interpret as a 
positive result reflects past or current disease and may indicate persistent antibodies after 
successful treatment. A negative result may indicate no disease, early disease or a compromised 
immune response. WHO (2010) for this reason recommends a range of tests for the diagnosis and 
monitoring of S. stercoralis infections. 
Microscopy positive samples did not necessarily have cultures performed and this is shown in the 
reduced percentage positive result obtained for the Strongyloides cultures, even though culture is a 
more sensitive method than microscopy for the detection of S. stercoralis. Statistical analysis was 
therefore, in all data analysis divided into two parts: (I) full CRS and (II) microscopy/ culture positive 
only.  
The purpose of this chapter was to ascertain the analytical sensitivity and specificity of a novel 
LAMP assay in order to assess the suitability for diagnostic assay of strongyloidiasis in human faecal 
samples in both resource- limited and well-resourced settings. 
This study concluded that the LAMP assay demonstrated a high probability of disease when the 
LAMP assay is positive. The LAMP assay, which is superior to microscopy and culture (Table 3.23) 
for the detection of strongyloidiasis (in samples stored at -20oC) cannot replace serology in this 
study, although the LAMP assay may be useful as an additional test to determine disease when 
current routine tests are negative in those patients that are at risk of severe disease.  
The LAMP assay in the current format shows a limited use in the high- throughput diagnosis of 
strongyloidiasis in well- resourced settings, but it has the potential to be useful in point of care 
testing for urgent results (Mori and Notomi, 2009). The LAMP assay also has the potential to be 
useful in resource- limited areas once the appropriate sample storage conditions have been 
determined. The LAMP assay has been developed for the detection of other parasitic diseases in 
blood (Thekisoe et al., 2010, Polley et al., 2013, Perera et al., 2017) and this study will provide a 
platform for the development of LAMP assays for the detection of stool parasites. 
Further development is,  therefore,  indicated to determine the protocol that will allow the 
sensitivity (10-3) for the detection of S. stercoralis DNA in clinical samples to approach the limit of 
detection sensitivity (117.2 x 10-9 ng DNA) seen in the detection of S. stercoralis target DNA in 
samples with a known concentration of purified DNA. This is discussed further in Section 6.2. 
While this study was focussed on the evaluation and validation of a diagnostic test for the detection 
of a parasitic disease in humans, LAMP assays have been described for the detection of parasites in 
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veterinary medicine (Savan et al., 2005, Jaleta et al., 2017). Parasitic infection in production animals 
carries an increased financial cost to the producers of reduced productivity, increased treatment 
costs and loss of livestock and is responsible for a reduced quality of life for the animals (Perry and 
Randolph, 1999).The outcomes from this study may be used to develop further assays that will 
provide simple and cost effective diagnostic assays that may be used in the diagnosis and 
management of parasitic diseases in animals in resource- limited or well- resourced areas (Jaleta et 
al., 2017). This is discussed further in Chapter 6.  
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CHAPTER 4: EVALUATION AND VALIDATION 
OF REAL-TIME PCR (qPCR) 
4.1. INTRODUCTION 
Basuni et al. (2011) described a multiplex real- time PCR for the detection of Ancylostoma sp., 
Necator americanus, A. lumbricoides and S. stercoralis with detection of low levels of DNA in faecal 
samples in microscopy negative samples. This indicated that a real- time PCR would be a suitable 
candidate for the detection of S. stercoralis DNA in faecal samples at DCP.  
Verweij et al., 2009 published a method for the detection of S. stercoralis DNA using a qPCR assay 
targeting the 18S rRNA genome. The qPCR assay uses specific primers and a fluorescent double-
labelled internal probe to detect target amplicons that can be analysed and possibly quantitated. 
This reaction can be developed for a multiplex format (using multiple primers and probes in a single 
reaction mix) (Basuni et al., 2011, Verweij and Stensvold, 2014). A multiplex real-time PCR has also 
been developed to detect Ancylostoma duodenale, Necator americanus and Oesophagostomum 
bifurcum by Verweij et al. (2006) demonstrating that real-time PCR detection of S. stercoralis may 
be used in a high- throughput multiplex format (Basuni et al., 2011). Basuni et al. (2011) found a 
limit for the number of target sites that can be detected in a multiplex format with a decrease in 
sensitivity of the assay if five target sites were used. As described above by Verweij et al. (2006), 
the qPCR assay is useful for detecting parasite DNA for up to three target sites with the current 
technology available at DCP. 
The product is detected when the amplification fluorescent intensity rises above the background 
fluorescence intensity, the threshold level can be determined by the user, and is termed the cycling 
threshold (Ct). Detection of DNA starts during the exponential phase (Figure 4.1) (Wong and 





Figure 4.1: Real-time exponential amplification curve 
 
There are a variety of detection methods for qPCR: 
I. Melting curve analysis (MC) can only be performed when the fluorophore remains bound to 
the amplified DNA. The level of fluorescence with SYBER®Green fluorophore increases 
when bound to double-stranded DNA (dsDNA). Applying a melting curve to the amplified 
product immediately after the thermal cycling profile will generate a melting curve for 
single-stranded DNA that is specific to the amplicon and can distinguish primer dimers and 
contaminating nucleotides from amplified DNA. It can also be used to detect point 
mutations when a high resolution melting curve is analysed. (Life Technologies Corporation, 
2012) 
II. Attachment of a short specific probe to the amplicon causes the fluorescent dye to be 
separated from a fluorescent quencher allowing amplification of specific DNA to be 
detected (Wong and Medrano, 2005). 
III. Self-quenching labelled primers, where the secondary structure of the primers reduces 
fluorescence to a minimum until the primer has bound to target DNA. This process is not 
independent of primer binding so gel electrophoresis is required to ensure that a single 
product has been produced (Wong and Medrano, 2005). Refer to Figure 4.2 for a simplified 
guide to DNA detection methods. 
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Figure 4.2: Detection of amplicons produced by real-time PCR using DNA binding dyes (A), short 
specific probes that bind to the amplicon and release fluorescence by hydrolysis or inactivation of a 
fluorescent quencher (B,C,D,E,F), self-quenched labelled primers, does not require a quencher, but 
does require gel electrophoresis to ensure a single product has been amplified (G). (Source: Image 
from Wong and Medrano, 2005). 
 
Once the thermal cycling protocol was completed statistical analysis of the run was performed 




Figure 4.3: Generalised real-time PCR protocol (Wong and Medrano, 2005) 
 
Generally accepted figures for Cts during analysis of the qPCR assay run are that Cts < 29 are strong 
positive reactions indicating large amounts of target DNA in the sample; Cts of 30-37 are indicative 
of moderate amounts of target DNA in the sample and Cts between 38-40 indicate minimal 
amounts of target DNA in the sample or environmental contamination (Caraguel et al., 2011). 
The use of an internal probe is expensive (Verweij and Stensvold, 2014). High resolution melting 
curve analysis (HRMC) can also be performed but an internal control cannot be used as it is limited 
by the number of fluorescent channels available (Wittwer et al., 2003). Two reactions are 
performed for melt curve analysis (MC) one reaction using the specific target primers and another 
reaction using the extraction and amplification control (gfp) primers. HRMC cannot be performed 
on a Rotagene 3000 (available at DCP) but a melting curve analysis (MC) to determine the potential 
use of melting curves was performed at DCP. A pilot study was carried out to determine the 
potential of MC analysis to be used to detect S. stercoralis amplicons in an MC format for 
information only. This technique was not chosen for this study as the standards for microbial 
investigations guidelines (HPA UK protocols, 2013) strongly recommend the use of an internal 
control to monitor the process from extraction to amplification in the UK. However, MC and HRMC 
(Wittwer et al., 2003) may be useful in future studies to detect geographical differences in S. 
stercoralis strains or possible treatment- resistant strains and the results demonstrated that this 
method has the potential for use in epidemiological and resistance monitoring studies. 
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Optimisation of the method and the reaction mix was performed for the evaluation and validation 
of this assay for the detection of S. stercoralis DNA in clinical samples at DCP. A comparison 
between Hotstart ® Taq polymerase master mix (HS) and the Taqman® environmental master mix 
2.0 (EM) was performed (Source Thermo Fisher Scientific, UK). The published protocol by Verweij et 
al. (2009) recommends the use of HS master mix. However, Environmental® master mix (EM) 
(Source Thermo Fisher Scientific, UK) is in use at DCP for a multiplex qPCR for Protista. The 
Environmental® master mix is used for DNA extracted from stool samples for qPCR as it is more 
resistant to PCR inhibition than the HS master mix (Minogue et al., 2014). A composite reference 
standard and samples from viral, bacterial and other parasitic human pathogens and 284 clinical 
samples from patients being investigated at UCLH and HTD for strongyloidiasis were used to 
validate the assay. Chapter 3 describes the validation procedure for LAMP and this was also applied 
to the qPCR assay.  
The analytical verification of this method used analytical sensitivity, analytical specificity and qPCR 
efficiency (determined by statistical analysis of the qPCR runs) using Rotagene software (Source 
Corbett Life Sciences). Statistical analysis was performed using an online statistical program 
(MedCalc®, n.d.) as previously described (Section 2.8). 
 
4.2. AIMS OF THE STUDY 
There were two main aims of this part of the study: 
1. To determine the sensitivity and specificity of a published real-time assay and 
comparison to the CRS (this Chapter) and a novel LAMP assay for the detection of S. 
stercoralis DNA from clinical samples (Chapter 5). 
2. To determine the cost of LAMP and qPCR for introduction of a NAAT to the diagnostic 
repertoire at DCP (Chapter 5, Section 5.3) 
4.3. OPTIMISATION OF REACTION MIX 
The method was optimised for use by the comparison of HotStart®Taq polymerase (HS) or 
TaqMan® Environmental master- mix 2.0 (EM). The EM was tested as this master- mix is said to be 
more resistant to inhibition (Minogue et al., 2014) than the HS master mix. Using DNA extracted 
from a negative stool control and a positive stool control (1 S. stercoralis larva/ µl) with a 10- fold 
dilution series and used neat and 10-1 to 10-5 plus or minus bovine serum albumin (BSA). BSA may 
be added to minimise stool inhibition. The reactions were run using the study protocol. Reaction 
mixtures were also set up in HS or EM (plus or minus added MgCl2).  
101 
 
To further optimise HS and EM, a MgCl2 curve was performed (dilution ranges: 0, 5, 10, 15, 20 mM 
and 0, 3, 3.5, 4, 4.5 mM MgCl2) in each of the reactions.  MgCl2 is required as a cofactor for 
thermostable polymerase activity (Qiagen, n.d.). Primers and probe concentration curves were also 
run using HS and EM. The results demonstrated similar cycling thresholds (Cts) for HS and EM but 
the amplitude of the fluorescence was lower with EM than with HS (Figure 4.4) when run in the 
optimised study protocol. There was a positive reaction using HS in the dilution series from 10-1 to 
10-6. A positive reaction was obtained, using EM, in the dilution series from 10-1 to 10-5 (a 10- fold 




Figure 4.4: Comparison of HotStart®Taq polymerase (HS) and TaqMan® Environmental master- mix 
2.0 (EM) using a ten-fold dilution series of the positive control DNA showing the difference in 
fluorescent amplitude between HS and EM (10-1 = red, 10-2 = green, 10-3 = blue, 10-4 = purple), there 
was very little difference between the Ct values for the two master-mixes. The straight red line 
indicates the cycling threshold, A= fluorescence amplitude for HS, B= fluorescence amplitude for 
EM.  
A pilot study was performed with the SYBR®Green master mix to determine if identification by 
melting temperature could be a feasible option for future detection of geographical variation in S. 
stercoralis strains or detection of treatment resistant strains. Melt-curve analysis depends on the 
melting temperature at which double-stranded DNA with the incorporated intercalating dye 
becomes single-stranded DNA and releases the intercalating dye. A graph of change of fluorescence 
vs. temperature produces a characteristic melt curve that is affected by the sequence of the 
Cycle









































product, the reagents, presence of inhibitors and low concentrations of DNA (which may give rise to 
non-specific products). The melting temperature is determined to be the point at which there is 
50% dissociation of double stranded DNA. Using DNA extracted from a negative stool control and a 
positive stool control at dilutions ranging from: neat to 10-5, the reactions were run using the study 
protocol. Two reactions were set up using either the Stro18 forward and reverse primers to detect 
S. stercoralis DNA or gfp forward and reverse primers to detect the internal control. The internal 
control was added to the positive and negative stool samples prior to DNA extraction and was used 
to monitor the extraction process and the amplification reactions. Melting temperature peaks 
ranged from: 75 – 77.5oC with a peak at 76.3oC (gfp) and 78.8-80.5oC with a peak at 79.75oC (S. 
stercoralis) (Figure 4.5). The addition of BSA showed a dampening effect on the melting curve- i.e. 




Figure 4.5: Melt curve analysis of qPCR S. stercoralis melt curves (green) and gfp amplification 
control (orange) showing a fluorescent peak at 80oC with the intercalating dye SYBR®Green.  The 
gfp reaction is shown in grey and the Stro18S reactions are shown as negative stool control (black), 
positive stool control at dilutions of 10-1 (green), 10-2 (purple) and 10-3 (red). A= primer dimers or 
insufficient DNA, B= gfp peak, C= S. stercoralis peak. 
The threshold for the MC analysis has been set at 0.05 and any fluorescence below the threshold 
(with a melting temperature <74oC) may be due to primer dimer formation as shown in Figure 4.5 A 
or different length amplicons generated from a diluted DNA template. The double- peaks in Figure 
ºc





















4.5 B and C may be due to the ability of SYBR®Green to bind to any double stranded DNA to 
produce a detectable fluorescence. In high dilutions with very little detectable DNA shortened 
amplification products may arise and different melting temperatures may be observed. This 
distinction is also useful in HRMC analysis for single-point mutation detection with the generation 
of distinct peaks with different Tm (Wittwer et al., 2003). However, in this case, further optimisation 
of the method is required so that light infections with very little S. stercoralis DNA may be reliably 
detected. This study demonstrated that this method can be used to detect S. stercoralis DNA, but 
requires further optimisation and no further work was performed using the SYBR®Green master 
mix as this method was investigated for information only. 
4.3.1. FINALISATION OF THE STUDY PROTOCOL 
HS was chosen as the DNA polymerase for the study and optimisation for the primers and probes 
showed no adjustments were necessary from the published protocol (Verweij et al., 2009). The only 
difference to the published protocol was the choice of 55 cycles rather than published 50 cycles so 
that the final cycle number for an assay in use at DCP could be determined at the end of the study. 
A qPCR assay is already available at DCP in a multiplex format for protest parasites (ten Hove et al., 
2007) with a run protocol of 45 cycles and harmonisation of the qPCR assays would be expedient 
for new methods deployed in the routine laboratory. Analysis of the qPCR assay (Table 4.1) was 
interpreted from the results generated by the internal control, the negative stool control, the 
positive stool control (at a dilution of 10-3) and the no template control (nuclease free water). The 
positive control was only run at a full dilution range of neat and 10-1 to 10-6 when testing a new 




Table 4.1: Interpretation of the qPCR assay at DCP. 













Positive Positive Negative Positive Negative Positive, a repeat qPCR assay using 
neat DNA and DNA at a 10
-1
  dilution 
will be performed if the sample gfp 
Ct is above the mean gfp Ct for the 
run 
Positive Negative Negative Positive Negative Possible positive result, validation of 
the run will require a repeat qPCR at 
a 10
-1
 dilution to determine if 
inhibition of the qPCR assay is 
present. Re- extraction of the sample 
may be required. 
Negative Positive Negative Positive Negative Negative 
Negative Negative Negative Positive Negative Repeat sample at a dilution of 1in10 
to determine if inhibition of the qPCR 
assay has occurred. Re- extraction of 
the sample may be required. 
Negative/ 
Positive 



















4.3.1.1. CHALLENGE OF qPCR AND THE DECISION FOR GEL ELECTROPHORESIS OF ALL qPCR 
PRODUCTS 
Once the qPCR method was optimised a set of residual diagnostic samples, from routine qPCR for 
protist and microsporidial (intracellular fungi, formerly protists) parasites, was used to challenge 
the method before the start of the study (n=20). Three unexpected positive results were obtained 
from samples of patients who were not being investigated for strongyloidiasis and so no routine 
diagnostic results for S. stercoralis were available. Repeated qPCR runs were negative, this may 
have been due to contamination of the DNA in the assay but further information regarding 
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strongyloidiasis risk in these patients was unavailable.  On this basis it was decided that all qPCR 
positive results would be further investigated. A European committee comprised of experts in the 
field of molecular and routine diagnostics has ruled that qPCR tubes, as a closed system, must not 
be opened and run on an agarose gel as this could result in DNA product contamination of the 
laboratory (Personal communication with Dr van Lieshout). However, in light of the unexpected 
results it was decided to perform gel electrophoresis on all tubes that were qPCR positive in a 
separate PCR product laboratory. Very little DNA is released as droplets in this procedure and it is 
unlikely that significant DNA contamination of an electrophoresis gel in a designated PCR product 
room will occur. A sodium hypochlorite solution and a UV lamp (15 minutes) were used to clean all 
work spaces and no anomalous results were attributed to the gel electrophoresis of qPCR product.  
All qPCR positive samples were run on a 2% agarose gel for one and half hours at 100V to allow for 
distinction between the S. stercoralis product band and the internal control gfp band. The 
published band size for S. stercoralis is 101 base pairs (bp) (Verweij et al., 2009) and the internal gfp 
control is 97bp (Murphy et al., 2007, Kinson, 2012). All DNA samples that were positive in the qPCR 
assay were also tested by conventional PCR (cPCR) using only the specific Stro18S forward and 
reverse primers (to generate single bands that could be used for sequencing reactions) and the 
resulting products were viewed after gel electrophoresis on a 2% agarose gel run for one hour at 
100V. Three study samples showed anomalous bands approximately 145bp or 500- 525bp and the 
identity of these bands was investigated by sequencing of the cPCR product. The cPCR product was 
purified using a QIAquick PCR clean-up kit (Source Thermo Fisher Scientific, UK). The purified 
product was sequenced using one or more of the following methods: 
I. Sequence reaction of the pJET® 1.2  plasmid vector insert; 
II. Direct sequencing of cPCR product using ABI Big®Dye version 3.1 chemistry on an ABI  
Prism 310 automated sequencer (Source Applied Biosystems, UK) using the forward or 
reverse Stro18S primers;  
III. Sequence of the plasmid vector insert generated by pGEM®T-Easy plasmid vector. A single 
contig was compiled for each product using the Seqman® program (DNASTAR).  
The resultant sequences were identified using a nucleotide BLAST search against the EMBL database 
on the NCBI website (NCBI, n.d.). 
4.4 SEQUENCING OF THE cPCR PRODUCT TO CONFIRM S. STERCORALIS 
The positive control was cloned and sequenced and the product was confirmed to be S. stercoralis 
with a 96% sequence match using the pJET® 1.2 plasmid vector. The sequence results of some of 
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the positive study samples with no anomalous results or bands are shown in Table 4.2 and the 
sequence alignment on an NCBI BLAST reference strain M84229.1 is shown in Appendix 3a.  
Table 4.2: Sequences generated from the cPCR product of the positive stool control and positive 
study samples, using pJet® 1.2 plasmid vector, generated a 111bp or 121bp segment with sequence 
matches to S. stercoralis 18S ribosomal RNA gene Accession number M84229.1 ranging from 93 – 




















































Anomalous bands at 145bp (Figure 4.6) and 500-525bp (Figure 4.7) were cloned but failed to 
generate a cloned insert for sequencing reactions twice using the pJET® 1.2 plasmid vector and a 
direct sequencing method was chosen in an attempt to sequence and identify these products.  
 
Figure 4.6: qPCR products run on a 2% agarose gel run at 100V for 1.5 hours. Lanes 2, 4, 5, 7- 11, 13- 
16: positive 101bp target amplicon and a 97bp internal control, Lanes 3, 6, 12: negative for target 
amplicon, only a 97bp internal control amplicon was demonstrated, Lane 17: 97bp internal control 
and a 145bp anomalous amplicon, Lanes 1 and 18 contain a 100bp DNA marker ladder. 
 
Figure 4.7:  cPCR products run on a 2% agarose gel run at 100V for 1.5 hours. Lanes 1, 13: 100bp 
hyperladder, Lanes 2, 4, 6, 7, 10 and 12: 101bp target amplicon, Lanes 3, 8, 11: Negative, Lanes 5, 
and 9: 500- 525bp anomalous amplicon. Only one band (target DNA) is generated as the gfp 
primers were not added to the mixture. 
The cPCR products were sent for sequencing to confirm product identity, either by using blunt-end 
plasmid vector pJET® 1.2, “sticky end” plasmid vector (pGEM® T-Easy) or direct sequencing. 
1         2      3      4         5       6       7      8        9     10    11       12      13     14     15     16     17    18 
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Watts et al., 2016 stated that samples containing hookworm or Blastocystis hominis have been 
reported to amplify product with species specific primers that generated non-target bands on 
electrophoresis. There have, however, been no reports in the literature regarding the identity of 
these anomalous bands. Samples containing B. hominis were tested by LAMP and qPCR but no non-
target bands were detected in this study. One stool containing hookworm was positive with the 
qPCR in only 1 out 3 assay runs and the qPCR was thought to have been contaminated for the one 
positive result. Direct sequencing was performed on the cPCR amplicons that generated anomalous 
bands to identify the product. Samples that were qPCR positive but CRS negative were determined 
to be anomalous results and were also sent for direct sequencing. 
The results of sequencing reactions on the product generated by cPCR of the positive control stool 
sample (ON2, ON4, 2H2, 2H4) were used to confirm the product identity for the qPCR reactions. 
The results from the sequence reactions generated from the purified cloned DNA are listed in Table 
4.3. The sequences generated from DNA extracted from the positive stool control containing 1 S. 
stercoralis larva/µl showed a 100% sequence match to S. stercoralis M84229.1 on a BLAST search of 
nucleotide identity on the NCBI website (NCBI, n.d.). ON2 was used to perform the limit of 
detection study and Table 4.3 shows the amount of DNA present in the purified DNA digests, 
measured on a Nanodrop spectrophotometer at 260nm.  
Table 4.3: Sequences generated using the pJET®1.2 plasmid vector from a positive stool control 
containing 1 S. stercoralis larva/ µl. 
ID DNA 
ng 


















Study samples with an anomalous results (qPCR positive when the CRS was negative) or band sizes 
different to the published product size of 101bp (anomalous bands) were run on ABI Big®Dye v3.1 
for direct sequencing to determine identity of anomalous results or anomalous bands (Appendix 4). 
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This failed to generate identifiable sequences so the samples were cloned using the pGEM®T-Easy 
vector system protocol and sent to the LSHTM for sequencing. Only one of the 500- 525bp bands 
produced a sequence with a 100% sequence match to S. stercoralis AJ558163.1 (37bp) with the T7 
primer and a sequence with 99% sequence match to S. stercoralis M84229.1 (90bp) with the SP6 
primer. The E value was 3E-11 (for T7 primer) and 8E-40 (for the SP6 primer) indicating that there is 
only a small probability that this sequence would occur in other species. The 500- 525bp anomalous 
band size produced by the qPCR assay was probably S. stercoralis DNA. Three anomalous band sizes 
were detected during this study and only one anomalous band showed sequence matches to S. 
stercoralis. It is possible that there was very little DNA available and the sequencing reaction was 
unable to generate a sequence identification for the anomalous bands where no sequence identity 
was obtained.  It may be that a new species of S. stercoralis is detected by real-time PCR or that the 
primers are detecting hypervariability in this region. However, care must be taken to interpret this 
data as the sequence matches for the 500bp query were only 37 or 90bp. Jaleta et al. (2017) 
examined S. stercoralis species infecting canines and humans in rural villages in Northern 
Cambodia, using comparison of mitochondrial sequences and whole genome analysis of the 18S 
DNA, found that hypervariability in the HVR1 region (Hasegawa et al., 2009) of the genome does 
not indicate different species, rather that S. stercoralis is more variable in this region than other 
nematodes. However, they do state that this does not exclude the existence of a cryptic 
Strongyloides species. Further work is required to confirm the findings in this study. 
This confers a false positive rate (probability of receiving an incorrect positive test) of 0.8% to the 
qPCR assay (5 anomalous bands detected in the qPCR assay of 610 samples). The study was 
designed to detect a difference between the CRS and the NAAT with a power of 90% and a 
probability of 5%. As previously discussed, the development of an assay is designed with a power of 
80-95% and a probability of 5-20%. The choice of power and probability depends on the use of the 
test (Jones and Payne, 1997). The qPCR assay requires a high specificity if it is to be used as a 
diagnostic test and a high sensitivity if it is to be used as a screening test. A false negative result 
could have severe consequences for the patient and in a disease such as strongyloidiasis the 
detection of a false positive would have a less severe impact than a missed diagnosis. The patient 
would have a range of tests (microscopy and serology) to confirm the result and a clinical decision 
would determine whether further testing or treatment was required.   
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4.5 SENSITIVITY AND SPECIFICITY OF qPCR 
4.5.1 ANALYTICAL SENSITIVITY 
Analytical sensitivity was determined by the serial 10- fold dilution of DNA extracted from positive 
control stool samples (1 S. stercoralis larva/ µl) as previously described in Section 3.5 (Saah and 
Hoover, 1997). The analytical sensitivity, or limit of detection (LOD) for the number of S. stercoralis 
larvae/ µl, was determined as 10-4 for qPCR (Table 4.4 and Table 4.5). Stepwise logistic regression 
did not show any effect on the qPCR results using the criterion of sample size of stool extracted. 
The variation in the sample size of stool extracted has been previously discussed in Section 2.3.8.1. 
Table 4.4 Performance of qPCR using serial 10- fold dilutions of DNA extracted from positive control 
stool samples (Positive result in Ct) 















10-7 Not done 








10-7 Not done 





















Table 4.5: Determination of the analytical sensitivity or limit of detection (LOD) using negative stool 
slurry spiked with L3 S. stercoralis larvae from a positive stool culture- final concentration: 1 S. 
stercoralis larva/µl. 
 PCR DILUTION SERIES S. STERCORALIS  































The positive control was not consistently positive at a final dilution of 10-5 so the analytical 
sensitivity for this assay was chosen as 10-4 S. stercoralis larvae/ µl.   
The LOD was also determined by dilution of purified DNA with a concentration of 154.4 ng. The 
concentration was determined by a Nanodrop spectrophotometer. To determine the limit of 
detection by this method cPCR was performed on positive stool control DNA. The resulting product 
was purified using the GeneJET® gel extraction kit and ligated into TOP10 E. coli using cloning vector 
pJET® 1.2 and the resulting clone was sent for sequencing (Source Bioscience, UK). The resultant 
sequences were identified using a BLAST search against the EMBL database on the EBI and NCBI 
website (NCBI, n.d.). The sequence results showed a 100% sequence match to S. stercoralis and a 
93-98% sequence match with Strongyloides species. Once identity had been confirmed one of the 
clones was chosen for the study (ON 2) and a serial 10- fold dilution range of 10-1 to 10-20 was tested 
in triplicate on two separate qPCR runs. An LOD of 154.4 x 10-9 ng was demonstrated (Figure 4.8). 
The qPCR assay was negative, in triplicate, for the neat DNA. The qPCR assay was positive in only 1 
out 3 samples for the 10-1 dilution and this may be due to the fact that excess DNA was present in 





Figure 4.8: Results of the limit of detection for qPCR (DNA extracted and cloned, using pJET® 1.2 
plasmid vector, from a spiked negative stool samples containing 1 S. stercoralis larva/ µl). The 
dilutions 10-2 to 10-10 were run in triplicate over two different qPCR amplification runs. Black, dark 
grey and light grey series indicate the triplicate results. The 10-10 dilution was negative in triplicate 
runs of the qPCR assay. 
 





10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 
0 38.61 10.19 10.79 12.22 15.77 20.67 26.8 27.69 32.77 0 
0 44.59* 10.2 10.71 12.04 15.5 20.71 27.04 27.84 36.59 0 
0 0 10.55 11.33 13.01 16.59 21.42 27.65 28.58 34.82 0 
* Ct= 44.59 was determined in this study to be an equivocal result. 
A consistent positive result was obtained in dilutions 10-2 to 10-9. No reactions were seen in the 
dilutions 10-10 to 10-20. 
4.5.2 ANALYTICAL SPECIFICITY 
Analytical specificity was determined by the samples in the specificity bank (previously described in 
Section 3.5 for the LAMP assay) and qPCR was 94.83% specific (Saah and Hoover, 1997). Viral, 
bacterial, protist and other helminthic human stool pathogens formed the specificity bank to 
determine whether the qPCR assay would detect only S. stercoralis target DNA. Three samples in 
the specificity bank were positive for qPCR S. stercoralis DNA which was confirmed by gel 
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electrophoresis. The specificity bank samples were completely anonymised prior to the start of the 
study (stored positive samples for research purposes) and no further action could be taken (Table 
4.7).  
Table 4.7: qPCR results for viral, bacterial and parasitic human pathogens (total S. stercoralis 
positive samples =8, total S. stercoralis negative samples =58) 
ORGANISM NUMBER OF ORGANISMS TESTED qPCR RESULTS (EXTRACTED DNA) 
Negative stool 8 Negative (n=8) 
Positive S. stercoralis stool control 8 Positive (n=8) 
Rhabditiform free-living larvae 
NOT S. stercoralis 
1 Negative (n=1) 
 
Nematodes  11- Ascaris lumbricoides (2), Trichuris trichiura(2), 
hookworm (5), Trichostrongylus sp. (1), Loa loa (1) 
Negative (n=11) 
Trematodes  2- Dicrocoelium dendriticum (1), Schistosoma mansoni(1) Negative (n=2) 
Cestodes  2- Bertiella studeri (1), Taenia saginata(1) Negative (n=2) 
Intestinal protista/ intracellular 
fungi 
29- Cryptosporidium sp. (5), Cystoisospora belli (2), 
Cyclospora cayetanensis (1), Entamoeba histolytica/dispar 
(6), Entamoeba hartmanni (1), Entamoeba coli (1), Giardia 
lamblia (6), Blastocystis hominis (1), Enterocytozoon 
bienusi (5), Encephalitozoon intestinalis (1) 
Negative (n=26) 
qPCR POSITIVE: 
 1 x C. belli Ct= 35.11 
 1 x E. intestinalis Ct= 35.31 
 1x hookworm Ct= 44.56 
Bacteria 4- Campylobacter jejuni (1), Shigella sonnei (1), Escherichia 
coli O157 (1), Vibrio cholera (1) 
Negative (n=4) 
Viruses 1- Adenovirus (1) Negative (n=1) 
 
Positive results obtained with the protist pathogens with Cts of 35.11 and 35.31 were repeated and 
the results were negative in 2 consecutive qPCR assays. The positive hookworm sample had a Ct of 
44.56 and Cts of > 40 are considered equivocal in this study. In the case of a diagnostic sample a 10
-1 
dilution of re- extracted DNA would be performed in the qPCR assay or a repeat sample would be 
requested. The repeat qPCR for this sample was negative in 2 consecutive runs. It is thought that 
contamination of the qPCR reaction tube occurred. The specificity of qPCR was determined to be 
94.83% because of the false positive results obtained. This is discussed further in Section 6.4. 
4.5.3 DIAGNOSTIC SENSITIVITY 
Diagnostic sensitivity was determined using the results of qPCR and the CRS for the study samples 
in a 2x2 contingency table (Jacobson, 1998). Prevalence is unknown for strongyloidiasis in the 
patient population attending DCP and larger sample sizes are required for a complete 
determination of prevalence. The diagnostic sensitivity was determined to be 39.73% (95% CI: 
28.45-51.86%) using the CRS (indicating proven or possible disease) as a comparator and 74.07% 
(95% CI: 53.72-88.89%) when using only microscopy and culture results (proven disease). When 
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using an imperfect reference standard sensitivity and specificity estimates are biased (Baughman et 
al., 2008) and the FDA recommends using overall percent positive agreement (OPA) between the 
old and new tests (FDA, 2007). The positive percent agreement for the qPCR assay for the detection 
of S. stercoralis DNA in clinical samples was determined, in this study, to be 40.32 % with an overall 
percent agreement (OPA) between old and new tests of 80.63% (95% CI: 70.5-91.8). 
4.5.4 DIAGNOSTIC SPECIFICITY 
Diagnostic specificity was determined using the results of qPCR and the composite reference 
standard for the study samples in a 2x2 table (Jacobson, 1998). The specificity was calculated as 
92.70% (95% CI: 88.58-95.69%) using the CRS as a comparator and 90.68% (95% CI: 86.64-93.82%) 
when using microscopy and culture as a comparator. The negative percent agreement (NPA) is used 
to replace specificity estimation when there is no “gold standard” and was calculated to be 91.89% 
(FDA, 2007). 
The qPCR assay sensitivity and specificity estimates were biased due to lack of a suitable “gold 
standard” and overall percent agreement was chosen to eliminate some of the bias (FDA, 2007). 
The diagnostic overall percent agreement between the CRS and qPCR demonstrated that qPCR is a 
suitable diagnostic test that can be included in a diagnostic repertoire consisting of serology and 
qPCR. Microscopy is a very insensitive test that will nevertheless detect parasites other than S. 
stercoralis. Until the future introduction of multiplex NAATs or microarrays (Requena-Méndez et 
al., 2014) for the diagnosis of parasitic diseases microscopy cannot be excluded from a routine 
diagnostic repertoire. The future use of culture as a diagnostic test for strongyloidiasis, however, 
may require the removal of this test from the laboratory. Although it is more sensitive than 
microscopy, it entails a biological risk to laboratory staff from infectious L3 larvae and is not more 
sensitive than combined serology and qPCR. 
4.6 DETERMINATION OF THE OPTIMUM NUMBER OF RUN CYCLES AND POSITIVE CUT-OFF VALUES 
Once all the samples and controls had been tested the results of the positive samples and controls 
were entered into the MedCalc® statistical program to generate Box and Whisper plots with the 
whiskers indicating the 25th and 75th percentile to determine the cut-off for the number of cycles 
required to detect all cases of S. stercoralis. The cut-off was determined to be 50 cycles (if all qPCR 
positive results were recorded i.e. this included band sizes different to 101bp shown in Figure 4.9). 
The published protocol (ten Hove et al., 2009, Verweij et al., 2009,) has a cycling run of 50 cycles. 
Using only qPCR positives with a band size of 101bp the cut-off was determined to be 45 cycles and 
this is the same number of amplification cycles as for the multiplex protist qPCR protocol already 
deployed in the routine laboratory.  
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The final number of run cycles for this study was chosen as 45 cycles as this identified all the 
samples containing a 101bp product when run on a 2% agarose gel at 100V for 1.5 hours. The qPCR 
HS plot (Ct) was generated from the cycling thresholds (Cts) of all positive qPCR results, regardless 
of the product size visualised on a 2% agarose gel. The qPCR HS plot (Ct and gel 101) was generated 
from the Cts of all positive qPCR results that had a product that generated a band of 101bp on gel 
electrophoresis. 
 
Figure 4.9: Box and Whisper plots for the determination of run cycles for the qPCR protocol. Notch 
indicates the mean and the whiskers indicate the 25th and 75th percentiles. qPCR HS (Ct) indicates all 
the Ct values regardless of product size on a 2% agarose gel, qPCR HS (Ct and gel 101) indicates the 
Ct values of the real-time PCR with a product size of 101 bp. 
The results from sequence identity were used to determine the number of amplification cycles that 
would be used in a diagnostic test. All anomalous band sizes were detected in samples where the 
composite reference standard (CRS) was negative and the qPCR Cts ranged from 35.13 to 48.16. 
Two out of five anomalous bands were negative on repeat cPCR assays and, of those that were still 
positive, only one (the 500- 525bp band) gave a partial sequence identity and was identified as S. 
stercoralis. This sample had a Ct of 35.29 and would be detected by a qPCR assay with 45 
amplification cycles. The results of the repeat qPCR and interpretation of the results is discussed in 
Appendix 4.  
Caraguel et al. (2011) recommend the Youden Index, amongst others, to determine the limit of 




















false positive reactions occur at around 40 cycles. However Caraguel et al. (2011) do admit that the 
determination of the limit of detection cut-off does depend on the consequences of a missed 
diagnosis. In Figure 4.10 a cut-off of 35 cycles would miss true positive results (clear circles). The 
results of the study determined that samples with a Ct of <40 will be considered positive and 
samples with a Ct ≥40 will be considered equivocal and a repeat sample will be requested.  
 
  
          
 
 
         Figure 4.10: Youden Plot- Determination of cut-off Ct for qPCR positive results. The rectangle 
represents 2SD (standard deviation) coverage (95% CI: 25.250 to 31.721).  Anomalous bands (pale 
grey square) are found at Cts >30, No true positive results (clear circle) are found at Cts >45.   
Possible true positive results (dark grey square) i.e. samples with very little DNA may be found at 
Cts, <40. False positive samples (black square) determined by negative results for the cPCR repeat 
may also be found at Cts <45. 
Therefore the study determined that 45 amplification cycles were suitable for the qPCR assay and 
this would be a suitable introduction into the routine diagnostic workflow already in use at DCP. As 
has been previously discussed, missing a diagnosis of strongyloidiasis can have severe 










Positive control Cts at various dilutions
vs
positive clinical samples Cts












2011), the size of the anomalous bands on gel electrophoresis (145bp and 500- 525bp) does not 
indicate the formation of primer dimers (Vallone and Butler, 2004). In proven cases of 
strongyloidiasis very low DNA concentrations have been detected with a Ct >30 in this study.  
The NAAT assays for S. stercoralis detection may be required to detect very small amounts of DNA 
in cases where there has been a relevant travel history, even after a long time-scale, in patients 
who are about to undergo immune-suppressive therapy or are otherwise immunocompromised. A 
highly sensitive test with a low limit of detection is susceptible to contamination therefore, a limit 
of detection cut- off value of Ct = 40 was chosen. Any samples, with an acceptable internal control 
value, with a Ct >40 are determined to have given an equivocal result. Verweij and Stensvold (2014) 
stated that a sample demonstrating a Ct value above the limit of detection value is not necessarily 
negative and so cannot be determined to be negative.  
A limit of detection cut-off of Ct=40 does detect those samples with anomalous bands and would 
miss true positive samples with very little target DNA, however, there were very few of those 
samples in this study (n=8, Minimum Ct= 40.05, maximum Ct=48.16) One sample (266) in this study 
with a Ct=48.16 would not have been detected (Appendix 4). This sample also generated a product 
in the cPCR assay that could not be sequenced as the concentration of DNA was too low.  
The qPCR assay Ct range was: minimum = 14.98, maximum = 40.05 (n=1) for true positives and 
minimum = 27.15 and maximum = 48.16 for equivocal positive results as determined by the CRS. 
Therefore, the qPCR assay protocol was established at 45 cycles with a limit of detection cut-off at 
Ct ≥ 40. A cautionary note will be added to Ct results ≥ 40:  
 Equivocal result obtained by real-time PCR in this sample, please send a repeat sample if 
clinically indicated.  
4.7 VALIDATION OF THE INTERNAL CONTROL 
Once all the samples and controls had been tested the results of the internal control (gfp) were 
normalised (sample gfp Ct x [gfp mean Ct of all runs/sample run mean]) (Figure 4.11). All the results 
were used to generate a mean and standard deviation in a Microsoft Excel® spreadsheet. Any 
samples that had an internal control Ct reading >gfp mean Ct for the run +1.96SD (mean + 2.04) 
were diluted 10-1 and the qPCR assay was repeated to determine whether any inhibition of the 
qPCR has occurred. Inhibition of qPCR is confirmed if the gfp reading of the 10-1 diluted sample Ct > 
mean + 5.2 in the repeated sample run.  
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Thirty three samples out of a total number of 610 reactions (this includes duplicate samples and 
samples stored at 4oC or -20oC) had a gfp reading > run mean+ 2.04 and required a 10-1 dilution 
before the qPCR was repeated (i.e. only 5.4% of samples required further testing).  
The repeated 10-1 dilution results were the same as the initial qPCR results (i.e. positive or negative) 
for all samples tested. The low number of samples requiring 10-1 dilution to investigate the 
presence of inhibition of qPCR and the fact that there is very little difference between the Cts 
before and after normalisation demonstrates that the extraction and amplification methods used in 




Figure 4.11: Comparison of the internal control Cts from all runs and internal control Cts after 
normalisation of the results between runs. Normalisation was carried out so that the internal 
control data could be assessed between different qPCR runs. (Raw data in grey and normalised data 
in black). 
 
4.8 FINAL qPCR PROTOCOL FOR THE DETECTION OF S. STERCORALIS DNA IN CLINICAL SAMPLES 
All positive and negative stool controls, specificity bank samples and anonymised study samples 
(stored at 4oC or -20oC) were tested using the study protocol. The internal control was validated 
and all samples that gave a mean gfp reading greater than the run mean + 2.04 were diluted 10-1 (in 
nuclease-free water) and the qPCR assay was performed. Any 10-1 diluted samples with a gfp 
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reading greater than the run mean + 5.2 were determined to contain inhibitors for qPCR and would 
have been excluded from the study, however, no samples showed inhibition to qPCR after 10-1 
dilution and no alteration to the qPCR result (positive or negative) was demonstrated as previously 
discussed. This was performed on raw data to determine whether the individual sample contained 
inhibitors.  
Analytical verification was determined by analytical sensitivity (limit of detection) and analytical 
specificity was performed using samples in the specificity bank. Amplification efficiency affects the 
cycling threshold, which is the point where the amplification curve crosses the threshold line and is 
set above the baseline and within the exponential growth region of the curve. So investigating 
amplification efficiency is part of the analytical verification of a qPCR assay. Cn= Ci x (1 + E)
n, where  
Ci = initial copy number, Cn = copy number at cycle n, n = number of cycles, E = efficiency of target 
amplification. When E=1 (maximum efficiency) Cn=Cix2
n (two-fold increase at each cycle), the 
quantity of product generated at each cycle decreases when E is decreased, thus delaying the 
amplification plot and affecting quantitation using this assay. The Ct is inversely proportional to the 
amount of starting nucleic acid in the amplification tube. The recommended E should lie between 
90-110% (Life Technologies, 2011). 
Rotagene recommend that the results are reported as delta delta Ct (∆∆ Ct) by normalising the 
sample results to the sample reporter gene (internal control) and also to the calibrator (in this study 
the positive control at a dilution of 10-3) so that comparable results are obtained across the 
different qPCR assay runs. The reporter gene and the gene of interest must have the same 
amplification efficiency for ∆∆ Ct analysis. The formula for the calculation of amplification efficiency 
is: [10(-1/slope of the trendline)]-1. The correlation coefficient (R2) should be ≥ 0.99 and the closer 
the slope (M) is to -3.32 the closer the amplification efficiency is to 100%. (Qiagen, n.d.). The 
amplification efficiencies for the internal control and the target gene were performed (Figures 4.12 
and 4.13). E for the internal control and the target gene was calculated from the results of five 
consecutive qPCR runs where the positive control DNA had been diluted in a 10-fold dilution series. 
The mean of the Ct readings for the internal control and target DNA was calculated and this was 
used to determine the slope and correlation co-efficient from a semi-logarithmic graph to allow the 
amplification efficiency to be calculated on an Excel® spreadsheet. To determine the amplification 
efficiencies for the internal control and the target of interest a dilution series of 10-1 to 10-3 was 
chosen. While amplification efficiency for some of the 10-4 dilutions could be determined for S. 
stercoralis, the effect of dilution on the internal control meant that matching gfp Ct values were not 
always available or that the result was not in the exponential part of the curve. Therefore a 
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comparison of amplification efficiencies could only be performed using those dilutions where the Ct 
was demonstrated in the exponential part of the curve for the internal control and the target DNA. 
Figures 4.12 and 4.13 exhibit similar values for E and demonstrated that gfp was a suitable internal 
control for use in this qPCR assay. 
 
Figure 4.12: Semi-logarithmic graph for the determination of amplification efficiency (E) in the 
internal control (gfp). A negative slope is obtained if the standard curve is run in the order of most 
dilute to most concentrated and the trendline is exponential as the graph is semi-logarithmic. 
 
 
Figure 4.13: Semi-logarithmic graph for the determination of amplification efficiency (E) in target 
DNA (S. stercoralis). The trendline is exponential as the graph is semi-logarithmic. 
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Absolute ∆ Ct (another method to confirm amplification efficiency) determines the copy number of 
the target template and is used with a standard curve. However, this method was not used in this 
study as the internal control of each sample is compared to the internal control run mean plus the 
standard deviation (2SD) to detect sample inhibition or qPCR variation in the individual tube. The 
internal control (gfp) can be used to compare the qPCR assay within and between runs as it has 
been previously shown to be stable between different qPCR runs (Figure 4.9). 
Clinical samples are complex environments consisting of microbial flora, faecal matter and PCR 
inhibitors and this affects the amplification efficiency of the assay (Moghaddassani et al., 2011, 
Monteiro et al., 1997, Murphy et al., 2007). Degradation of DNA is determined by copy number 
variations which will affect amplification efficiency but not the correlation coefficient (R2) values 
(Dhanasekaran et al., 2010). Three parameters are important to determine quantification 
parameters: PCR efficiency, copy number variance and the correlation coefficient, and will reflect 
variations in pipetting and target DNA degradation (Dhanasekaran et al., 2010). 
Amplification efficiency can be performed using the Rotagene statistical analysis package (Source 
Corbett Life Sciences) and Figure 4.14 demonstrates the amplification efficiency calculated from a 
study qPCR assay run for the 10- fold dilution series of purified DNA from a positive stool control 
(standard curve) and clinical samples. The qPCR standard curve produced an amplification 
efficiency of 1.14 with a correlation coefficient R2= 0.651 and a slope of -3.028 (Figure 4.14).  
 
 
Figure 4.14: Amplification efficiency determined by qPCR standard curve (blue), clinical samples 
(red) 
 
Amplification efficiency for the qPCR assay for clinical samples.  
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To determine the effect of the variation on precision between the different qPCR amplification runs 
the percentage co-efficient of variation (% CV) was determined from 10- fold dilution series on 
different aliquots of the positive control (one incubated for 2 hours at 56oC and one incubated 
overnight at 56oC during the extraction protocol). The analysis was performed on three consecutive 
qPCR runs and the % CV was calculated as the standard deviation divided by the mean and 
multiplied by 100. An F test to compare standard deviations was performed to see if there was any 
difference between the standard deviations of the samples incubated for two hours or incubated 
overnight at 56oC.  
The % CV between runs and between different incubation times ranged from 0.3 to 3.5% i.e. <5% 
variation. As previously discussed in Chapter 3, % CV should be <15% for inter- assay runs and <10% 
for intra- assay runs (Reed et al., 2002, Salimetrics, n.d.). The F Test,a comparison of the standard 
deviations, produced no statistically significant difference in the results. The p values for the target 
DNA ranged from: 10-1 dilution (p=0.87), the 10-2 dilution (p=0.92) and the 10-3 dilution (p=0.439) 
between the samples incubated at 56oC for 2 hours or overnight. The internal control p values 
were: 10-1 dilution (p=0.39), the 10-2 dilution (p=0.33) and the 10-3 dilution (p=0.899) between the 
samples incubated at 56oC for 2 hours or overnight. This finding determined that overnight 
incubation at 56oC in tissue lysis buffer can be performed in two hours as there was no statistically 
significance difference in the qPCR assay results between the two methods. 
4.9 PERSISTENCE OF S. STERCORALIS DNA AT STORAGE TEMPERATURES OF 4oC AND -20oC 
As previously described for the LAMP assay (Section 3.7), the qPCR assay was assessed for the 
persistence of short-term storage at 4oC without a preservative as this would impact the routine 
workflow at DCP where neat stool aliquots for NAAT testing are stored at 4oC (without a 
preservative) for up to 3 weeks. To investigate the decreased sensitivity in the detection of S. 
stercoralis in samples stored at 4oC and -20oC a pilot study was set up to determine the short-term 
persistence of DNA in samples stored at 4oC or -20oC. Table 4.8 shows the results obtained using a 
positive control stool sample containing 0.1 S. stercoralis larvae/ µl, stored at 4oC or -20oC in a 10-
fold dilution series and tested at various time intervals. The DNA was extracted using a Qiagen® 
Qiasymphony SP and the extracted DNA was stored at -20oC until a qPCR assay could be performed. 



























qPCR ASSAY (final 
dilution positive) 





Week 1 01/04/2017 Negative 10-3 Negative 10-4 
Week 2 01/04/2017 Negative 10-3 Negative 10-4 
Week 3 01/04/2017 Negative 10-3 Negative 10-4 
Week 4 01/04/2017 Negative 10-2 (Ct 30.91) Negative 10
-4 
Week 5 01/04/2017 Negative 10-3 Negative 10-5 (Ct 38.7).  
Repeat 10-4 
Week 8 17/04/2017 Negative 10-3 Negative 10-4 
Week 12 17/04/2017 Negative 10-3 Negative 10-4 
 
As previously discussed in the survival study for the LAMP assay, the results from the DNA 
persistence pilot study show that storage at 4oC is not recommended even for short-term storage 
and samples requiring a qPCR assay for detection of S. stercoralis DNA in clinical samples must be 
stored at -20oC. There is a 10- fold decrease in the sensitivity of detection of S. stercoralis DNA in 
samples stored at 4oC cf. samples stored at -20oC.  
An anomalous result was seen in the week 4 sample stored at 4oC and tested on the 1st April 2017 
where the lowest positive result was detected in a dilution of 10-2 when all other samples stored at  
4oC detected S. stercoralis DNA at a dilution of 10-3. This may be attributed to poor quality DNA or 
there may have been a dilution error in the dilution series. An anomalous result was also seen in 
the sample (week 5) stored at -20oC. Although the final dilution that was positive was 10-5 (a 
dilution increase of 10- fold), the Ct of 38.7, which is just before the Ct cut-off of 40, indicates the 
presence of a small amount of DNA. This sample was repeated on the 17th April 2017 and gave a 
final positive dilution of 10-4. This does not alter the conclusion reached from the pilot study that 
storage at -20oC showed no deterioration of the DNA stored for up to 12 weeks.   
4.10 STATISTICAL ANALYSIS 
The study code was broken after all study samples had been analysed and statistical analysis was 
performed. The tests in the CRS were performed from the same sample that was sent for storage at 
4oC or -20oC. Standard McNemar’s test for the comparison of proportions and diagnostic sensitivity 
and specificity calculations were performed (MedCalc®, n.d.) and the results were recorded in Table 
4.9.  The sensitivity results were poor for the qPCR assay as an imperfect low sensitivity and low 
specificity composite reference standard was used. The CRS denoted proven disease or probable 
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disease and is, therefore, subject to bias in the sensitivity and specificity estimations (Baughman et 
al., 2008). The FDA guidelines (FDA, 2007) suggest reporting the overall percent agreement 
between the CRS and the new test when using an imperfect reference standard (Table 4.9). 
Table 4.9: McNemar’s test and 2x2 contingency table results for the qPCR assay and overall percent 
positive results (including 95% CI to determine significance) 
STATISTICAL TEST  CRS AND qPCR       -20OC MICRO/CULTURE AND 
qPCR -20OC 
  95%CI   95%CI 




  Probability p=0.0007   p=0.0013   
Fischer’s exact Significance level p=<0.000001   p=<0.000001   








  AUC 0.66 0.61-0.71 0.82 0.78-0.86 
  Positive likelihood ratio 5.44 3.18-9.32 7.95 5.18-12.20 
  Negative likelihood ratio 0.65 0.54-0.79 0.29 0.15-0.54 
  Disease Prevalence 













FDA recommendation when using an 
imperfect reference standard (FDA, 
2007) 
Positive percent agreement 
PPA (instead of sensitivity) 
40.32% - - - 
 Negative percent agreement 
NPA (instead of specificity) 
91.9% - - - 
 Overall percent agreement 






As previously discussed in Section 3.6, this study determined that the use of an imperfect reference 
standard achieved sensitivity and positive predictive values that could not be accurately assessed. 
The qPCR assay showed suitable specificity and negative predictive values. The negative percent 
agreement and the overall percent agreement values indicate that the qPCR assay will detect the 
presence of disease with a high probability, there was also a suitable negative predictive value 
determined for this test. A note of caution must be made as the negative predictive values are 
related to disease prevalence and this could not be determined in this study.  
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The overall percent agreement (OPA) will always lie between the negative and positive percent 
agreement, care must be taken with interpretation of the results as OPA does not differentiate 
between the agreement of the negatives and the agreement of the positives with an imperfect 
reference standard. Percent agreement can be used in conjunction with Cohen’s kappa where the 
expected and observed results are expressed as a fraction of the maximum difference (FDA, 2007) 
(Table 4.10). 
Table 4.10: Cohen’s kappa tables for qPCR results when the CRS is negative (0), when the 
microscopy/ culture only is positive (1), when the serology only is positive (2) and when all the CRS 
tests are positive (3) 
   qPCR RESULTS 
CRS RESULTS  0 1 2 3 TOTAL 
Negative 0 206 4 31 2 243 (85.6%) 
Microscopy/ 
culture positive 
1 11 15 10 0 36 (12.7%) 
Serology positive 2 5 0 0 0 5 (1.8%) 
Full CRS positive 3 0 0 0 0 0  
TOTAL  222 19 41 2 284 
   -78.20% -6.70% -14.40% -0.70%  
 
Kappa assumes independence this gave a weighted kappa of 0.229 with a standard error of 14.617 
(95% CI: -1.0 – 1.0). There was an 85.6% agreement between the qPCR result and the CRS when the 
CRS is negative. When the microscopy was positive there was only a 12.7% agreement and there 
was little agreement between serology positive and qPCR. The lack of agreement between 
microscopy/ culture positive samples and qPCR is due to the fact that there were very few positive 
samples and qPCR sample volumes are much smaller than the volumes used for stool cultures. 
Verweij et al., 2009 noted a similar effect with qPCR negative and Baermann test positive samples. 
The low agreement between qPCR positive and serology positive samples is due to the fact that 
serology may be positive in cases where there is no active strongyloidiasis.  
Positive predictive values for the qPCR assay cannot be determined as the disease prevalence is 
unknown in this study cohort, however negative predictive values show that qPCR can be used as a 
screening test as the detection of true negatives was above 80%. Jones and Payne (1997) stated 
that the evaluation of a new test aims for a power (sensitivity) of 80 to 95% and a probability 




As with the data described for the LAMP assay missing a true positive sample carries severe 
consequences for the patient (Pottie et al., 2011). However, a false positive, in the protocol for this 
study would be considered in the context of serology, qPCR and a clinical decision on whether 
repeat samples are required or if treatment is indicated.  
Likelihood ratios are clinically important in the determination of how many times more or less likely 
the patient will have a positive or negative result in a patient with strongyloidiasis than in a patient 
without strongyloidiasis. When the positive likelihood ratio >1, it indicates that a positive result is 
more likely in a patient with strongyloidiasis than in a patient without the disease and the same 
holds true for a negative qPCR result in a patient without strongyloidiasis. A positive qPCR assay, in 
patients with strongyloidiasis, is 7.95 times more likely than a negative result when using proven 
disease as a comparator. This indicates that qPCR assays may be used for treatment monitoring. 
The same is not true for a negative qPCR result as a negative microscopy or culture result does not 
necessarily mean that the patient does not have strongyloidiasis due to the low sensitivity of these 
methods.  
The purpose of this chapter was to ascertain the analytical sensitivity and specificity of a published 
qPCR assay to assess the suitability for diagnostic assay of strongyloidiasis in human faecal samples 
in a high- throughput specialist diagnostic well- resourced setting.  
The conclusions from this part of the study were that qPCR is a useful adjunctive test to the 
diagnostic repertoire, but cannot fully determine cases of absence of disease. It is, however, a 
suitable diagnostic test with a specificity of >90%.  






CHAPTER 5: ANALYSIS OF PATIENT 
DEMOGRAPHICS AND SAMPLE CONDITIONS 
AND COMPARISON OF LAMP AND qPCR 
RESULTS 
5.1 INTRODUCTION 
The data generated from this study was analysed after the study code had been broken and the 
results were separated into samples stored at 4oC or -20oC. The composite reference standard (CRS) 
divided the 284 samples into 17 true positive and 233 true negative for the LAMP assay and 29 true 
positive and 216 true negative samples for the qPCR assay as shown in Table 5.1.  
Table 5.1: True positive (sensitivity) and true negative (specificity) diagnostic samples: determined 
by the CRS. 















P P TP (8) The negative LAMP assay results may be 




P N TP (12). Serology negative, microscopy and/or 
culture positive may be due to early diagnosis, 
before the development of an antibody 
response or the lack of an antibody response in 
immunocompromised individuals 
5 (41.7%) 8 (66.7%) 
N P TP (42) (probable cases, positive results may be 
due to post treatment persistence of antibody) 
4 (9.5%) 9 (21.4%) 
N N TN (222) 1 (0.45%) 9 (4.1%, excluding the 2 anomalous bands 
3.2%)  
9 positive samples, two have an 
anomalous band that could not be 
identified 
*P= positive N= negative TP= true positive TN= true negative 
1 qPCR: Cts:  33.89, 28.47. (LAMP remained negative on repeated assays) 
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These results were used for the statistical analysis of the LAMP and qPCR assays to determine 
sensitivity, specificity, negative predictive values and overall percent agreement of the LAMP or 
qPCR assay with the CRS. 
Patient demographics and sample quality were examined using stepwise logistic regression to 
determine if there was any effect on the detection of S. stercoralis DNA by the LAMP or qPCR 
assays by patient demographics (gender, patient age in years and country of travel or origin) or the 
sample conditions (length of storage, temperature of storage and aliquot size). Stepwise logistic 
regression was chosen to determine the effect of multiple variables on the LAMP or qPCR assays. 
Graphical analysis of the individual variables is demonstrated by percentage positive of the total 
number of samples in the study. The y axis maximum unit was set at 100% unless the effect was too 
small to be determined at this level and the y axis was adjusted accordingly. 
Statistical analysis was performed (MedCalc®, n.d.) and the results compared between LAMP and 
qPCR to determine the efficiency and suitability of the assays for the detection of strongyloidiasis in 
a WTM clinic or in the field.  
To further determine the suitability of the use of qPCR and LAMP in a WTM clinic a costing analysis 
was performed, the results of a further costing analysis determined the suitability of the LAMP 
assay for use in resource-limited areas. The introduction of a novel NAAT for the diagnosis of 
strongyloidiasis into the diagnostic repertoire at DCP requires a business plan (Appendix 5) and the 
full cost and suitability of the test chosen is discussed in Section 5.3, this Chapter). 
5.2 PATIENT DEMOGRAPHICS 
5.2.1 GENDER 
There was no significant difference between the number of females and males in this study for the 
samples stored at 4oC or -20oC and very little difference was detected between the number of 
positive samples detected in the male and female groups in this study. Not all samples that were 
stored at 4oC (n= 285) were also stored at -20oC (n= 284). Stepwise logistic regression showed no 
difference for gender in the detection of S. stercoralis DNA by LAMP or qPCR, but this may be due 
to the small numbers of positive samples detected in this study. There were 53% (n=285) and 52% 
(n=284) males in the samples stored at 4oC or -20oC, respectively and 47% (n=285) and 48% (n=284) 
females in the samples stored at 4oC or -20oC, respectively. There was a consistent increase in the 
efficiency of detection of S. stercoralis DNA in samples stored at -20oC by both the LAMP and qPCR 
assays. The results are demonstrated in Figure 5.1 by the percentage of total number of samples 





Figure 5.1 Percentage positive of total for LAMP and qPCR assays determined by gender in samples 
stored at 4oC or -20oC. 
5.2.2. AGE (YEARS) 
The majority of patients that attended the HTD travel clinic were in the 20 to 50 year age group. 
The patient population in this study is biased towards patients (including the “worried well”) who 
seek post-travel advice with or without gastro-intestinal symptoms. Figure 5.2 shows the 
percentage of LAMP and qPCR positive results for the total number of samples in the different age 
groups in the samples stored at 4oC or -20oC. Stepwise logistic regression showed no significance in 
the age of patient for the detection of S. stercoralis DNA by LAMP or qPCR assays in the samples 
stored at 4oC. The analysis did show a small effect in qPCR assay detection of S. stercoralis DNA in 
the samples stored at -20oC (Odds ratio= 0.7128 that the qPCR assay will be positive, 95% CI: 0.5800 
to 0.8759). A larger set of positive samples might be able to further detect a significant difference in 
the detection of S. stercoralis DNA by the LAMP assay in samples stored at 4oC or -20oC or by the 
qPCR assay in samples stored at 4oC, but this was not possible in this study due to the low number 
of positive results. The findings are a reflection of unavoidable patient bias in the study cohort due 
to patient demographics. The number of study samples found in each of the age groups is shown in 
Table 5.2. The study samples were stored at 4oC or -20oC but not all of the study samples were 
stored in duplicate, therefore the study analysis was performed on the samples stored at 4oC or at -





Figure 5.2: The effect of patient age on percentage of total LAMP and qPCR assay positive in 
samples stored at 4oC or -20oC.  
Table 5.2: Number of study samples in the different age groups in samples stored at 4oC or at -20oC. 
AGE RANGE (YEARS) STORAGE AT 4
O
C STORAGE AT -20
O
C 
1920-1929 4 4 
1930-1939 12 11 
1940-1949 21 22 
1950-1959 35 34 
1960-1969 61 60 
1970-1979 61 60 
1980-1989 59 60 
1990-1999 32 33 
TOTAL 285 284 
 
 
5.2.3. COUNTRY OF TRAVEL/ RESIDENCE 
In the majority of samples travel history was not able to be determined or the travel history was 
unclear as many countries had been visited (worldwide). Where the travel history was known the 
most frequent countries visited were in Africa and Asia. Biggs et al. (2009) has previously noted that 
strongyloidiasis is common in migrants from Africa and South East Asia. Stepwise logistic regression 
showed no significance in the country travelled to, or originated from, for the detection of S. 
stercoralis DNA by the LAMP or qPCR assays in samples stored at 4oC or -20oC. However, the 
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efficiency of the detection of S. stercoralis DNA was improved in the samples stored at -20oC. The 
difficulty in ascribing a geographical region to samples from patients at HTD has been noted before 
(Sudarshi et al., 2003) as travel history may be complicated or not documented. The percentage 
positive LAMP and qPCR assay results of the total number of samples stored at 4oC or -20oC is 
shown in Figure 5.3. It must be noted that there were very small numbers of samples with a travel 
history to the Caribbean, Europe and the Middle East and the analysis of these categories must be 
interpreted with care. A comparison of data was only performed for LAMP (Figures 3.21 and 3.22) 
for those samples with a travel history to Africa (n=73, all samples) or Asia (n=73, all samples) and 
demonstrates the effect of serology results on the CRS. Anomalous band sizes were detected in this 
study but could not be explained as being due to geographical differences as the low number of 
positive results in the LAMP and qPCR assays and the complicated travel histories made this finding 
unsuitable for statistical analysis. The comparison of data to demonstrate the effects of the CRS on 
the qPCR assay is presented in Table 4.10. The total number of positive samples by geographical 
region in the study samples stored at 4oC or -20oC is shown in Table 5.3. 
 
 
Figure 5.3: Geographical effect on percentage of total LAMP and qPCR assay positive in samples 




Table 5.3: Number of positive samples in each geographical region and the number of LAMP or 















UNKNOWN 57 4 10 57 6 10 
AFRICA 65 2 7 68 2 9 
ASIA 69 1 6 69 2 5 
CARIBBEAN 8 2 3 8 3 3 
EUROPE 8 0 1 7 0 0 
LATIN AMERICA 17 2 3 16 2 4 
MIDDLE EAST 2 0 0 2 0 1 
WORLWIDE 59 1 6 57 3 11 
       
       
       
5.3 SAMPLE CHARACTERISTICS 
The quality of the samples, stored at 4oC or -20oC before DNA extraction, was investigated to 
determine if this had an effect on the detection of S. stercoralis DNA by the LAMP or qPCR assays. 
The percentage of the total number of samples that were LAMP or qPCR positive was compared to 
aliquot size, length of storage and storage temperature. 
5.3.1. LENGTH OF STORAGE 
Samples were collected and stored at 4oC or -20oC (without preservatives) from 2011- 2016. Those 
samples collected in 2015-2016 were stored for a period of less than 6 months before DNA 
extraction. The extracted DNA was stored at -20oC until the LAMP or qPCR assay was performed. 
DNA extraction on samples stored from 2011- 2014 was carried out from January 2015. Stepwise 
logistic regression did not demonstrate a statistically significant effect on the detection of S. 
stercoralis DNA by the length of time the samples were stored at 4oC or -20oC by LAMP or qPCR. 
The largest number of samples in the study was collected in 2015- 2016 and this is demonstrated in 
Figure 5.4. The y axis maximum was set at 10% to demonstrate the effect of length of storage at 4oC 




Figure 5.4: Effect of length of storage at 4oC or -20oC before DNA extraction on the percentage of 
total LAMP and qPCR assay positive.  
 
5.3.2. ALIQUOT SIZE 
Martins and De Paula (2015) suggested that the difference in the sensitivity for the detection of S. 
stercoralis DNA in true positives samples (determined in this study by composite reference 
standards of culture and microscopy only) between studies may be due to the different sizes of 
stool aliquots that were extracted. To determine if aliquot size would have an effect on this study 
this factor was included in a stepwise logistic regression and demonstrated no significant difference 
in the detection of S. stercoralis DNA. The aliquot size for DNA extraction varied due to consistency 
and hydration of the samples (Lewis and Heaton, 1997) and Figure 5.5 shows the percentage of the 
total number of samples with LAMP and qPCR positive results in the different aliquot sizes. The y 
axis has a maximum unit of 6% to demonstrate the effect that a low number of positive samples 




Figure 5.5: Effect of aliquot size on percentage of total LAMP and qPCR assay positive in samples 
stored at 4oC or -20oC. 
 
5.3.3. STORAGE TEMPERATURE 
Samples for this study were aliquoted and stored at 4oC or -20oC before DNA extraction. Samples 
stored at 4oC should be kept in ethanol to preserve the DNA or stored neat at -20oC (ten Hove et al., 
2009). This was not done during this study as the IDEA study samples were collected and stored in 
the laboratory at DCP before the start of this study. The current laboratory protocol for detection of 
DNA in stool samples states that samples are stored at 4oC without preservative (up to 3 weeks) 
until DNA extraction is performed.  
Integration of a NAAT into the current workflow required an assessment of the effect of storage 
temperature. To determine the effect that sub-optimal storage would have on the efficiency of the 
LAMP and qPCR assays to detect S. stercoralis DNA this storage method for the aliquots was 
maintained for all samples. The effect was measured after the study had been completed.  
The aliquots stored at 4oC were given a different study number to the aliquots stored at -20oC so 
that the effect of storage temperature could not be linked to the LAMP or qPCR results until the 
study code was broken. There was an increase in the percentage positive LAMP and qPCR results 
for the total number of samples stored at -20oC in comparison to the total number of positive 
samples stored at 4oC before DNA extraction. Stepwise logistic regression did not demonstrate a 
significant difference between the LAMP or qPCR assay results in the samples stored at 4oC or -20oC 
but the number of positive samples in all groups was small and this necessitates that the analysis 
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must be interpreted with care. Figure 5.6 shows the effect of storage temperature on the detection 
of S. stercoralis DNA in clinical samples. 
 
Figure 5.6: The effect of storage temperature (4oC or -20oC) before DNA extraction on percentage of 
total LAMP and qPCR assay positive. 
 
The results were analysed using Friedman’s test (with a significance level of 0.05), with the 
normalised Ct values or LAMP time in minutes as the dependent variable and temperature as the 
independent variable (Medcalc®, n.d.) (Table 5.4).  
Table 5.4: Friedman’s non-parametric test for the difference between samples stored at 4oC or -
20oC in the detection of S. stercoralis DNA using LAMP or qPCR assays. 




















P (significance P<0.05) 0.00026 0.00371 0.00007 0.00098 
 
Friedman’s test demonstrated a significant difference between the samples stored at 4oC and -
20oC. The samples were analysed by LAMP and qPCR assays for temperature (4oC or -20oC) and for 
NAAT (LAMP or qPCR) to detect any differences between the samples. 
The decrease in sensitivity of both the LAMP and qPCR assays in samples stored at 4oC and the 
significant difference demonstrated by Friedman’s test decided the final statistical analysis of LAMP 
and qPCR assays for those samples stored at -20oC only. Friedman’s test also demonstrated 
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significant difference in the detection of S. stercoralis DNA by the LAMP or qPCR assays in samples 
stored at the same temperature (4oC or -20oC). 
A separate study investigating the role of NAATs in determining point of cure after treatment is 
under way. The samples for this study are being stored at -20oC only before DNA extraction is 
performed. 
5.4 COMPARISON OF LAMP AND qPCR TO ASSESS THE SUITABILITY OF THE ASSAYS FOR 
DETECTION OF S. STERCORALIS DNA IN CLINICAL SAMPLES 
5.4.1. COMPARISON OF LAMP AND QPCR POSITIVE RESULTS AT STORAGE TEMPERATURES OF 4OC 
OR -20OC 
Determination of LAMP positive results when the qPCR is positive was performed on all study 
samples tested to determine the maximum Ct (related to decreasing amounts of target DNA in the 
sample) at which a LAMP positive result will be obtained. A comparison of all the results for LAMP 
and qPCR (including duplicates) at 4oC and -20oC (n=610) demonstrated that a LAMP positive result 
was obtained when qPCR Ct ≤ 31.46 (mean Ct = 23.25 at which a LAMP positive result is obtained). 
No samples were qPCR negative and LAMP positive. Figure 5.7 demonstrates the comparison of 
LAMP and qPCR positive results in a notched Box and Whisper plot (MedCalc®, n.d.).  
 
Figure 5.7: Box and Whisper Plot for the comparison of LAMP positive (minutes) vs. qPCR positive 










































5.4.2. THE EFFECT OF SEROLOGY ON THE COMPOSITE REFERENCE STANDARD 
The persistence of antibody, even after successful treatment, is known and may only denote 
probable or past disease (Requena-Méndez et al., 2013). The composite reference standard was 
deconstructed into the individual tests. The number of positive results (LAMP or qPCR) was 
expressed as a percentage of the total number of samples for the composite reference standard, 
microscopy/ culture or serology. The percentage of positive samples (from the total number of 
samples assayed) for the LAMP and qPCR assays was determined. The results were analysed for the 
4oC and -20oC stored samples separately to demonstrate the difference in sensitivity of the NAATs 
(Figure 5.8).  
 
Figure 5.8: Comparison of percentage of total positive results for the combined reference standard 
(microscopy, culture and serology) or microscopy, culture or serology positive and LAMP or qPCR 
positive.  
As noted previously not all samples were stored both 4oC and at -20oC so the data generated for 
microscopy, culture and serology differs slightly. Nevertheless significant results can be determined 
from the data generated. In the study samples the LAMP assay demonstrated an increase of only 
0.6 % in detection of S. stercoralis DNA when compared to microscopy percentage positive 
(definitive diagnosis) in samples stored at 4oC and at -20oC. The qPCR assay showed an increase of 
4.8 % in the detection rate for samples stored at 4oC and an increase of 7 % in the detection rate for 
samples stored at -20oC when compared to microscopy percentage positive. 
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5.4.3. COMPARISON OF TEST PERFORMANCE, TURNAROUND TIME AND COST BETWEEN LAMP 
AND qPCR 
Minetti et al. (2016) highlighted that there are three main obstacles to the uptake of diagnostic 
tests: 
I. The standard method to use for quality standards and agreement on the best approach; 
II. Cost of advanced equipment, training and reagents; 
III. Result interpretation regarding the use of molecular data to inform decision making by the 
development of suitable guidelines (Figure 6.1). 
The standard methods and study design have been previously discussed in Chapters 2, 3 and 4 and 
result interpretation has been previously discussed in Chapters 3 and 4. . 
A comparison of the cost to the laboratory and the time taken to perform LAMP and qPCR was 
performed to determine the effect of the introduction of a NAAT into the routine diagnostic 
laboratory workflow (Table 5.5). 
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Table 5.5: Comparison of test performance, turnaround time, analytical sensitivity (positive stool 
control in a 10-fold dilution series), analytical specificity and cost between LAMP and qPCR 
 LAMP qPCR 
Turnaround time: Processing (time taken) 2.5 days. 
Processing for LAMP may 
be reduced to 30 minutes 
using a manual DNA 
extraction method (e.g. 
PURE®) 
2.5 days 
Turnaround time: Testing (time taken for 
assay and analysis) 
1.5 hours 3.5 hours 
Analytical sensitivity (spiked positive stool 
samples) 
1 S. stercoralis larva x 10
-3




Analytical sensitivity (purified DNA) 117.2 x 10
-9
 ng of DNA 154.4 x 10
-9
 ng of DNA 
Analytical Specificity (cf. Specificity bank) 100 97 
% NAAT positive when serology is positive 







% NAAT positive when microscopy/ 







Cost per test (including equipment, 
reagents and staff) 
£20.18 £44.09 
 
Analytical sensitivity and specificity (previously calculated for the LAMP and qPCR assays) and the 
limit of detection for the assays were included to determine the most suitable assay for the 
introduction into the diagnostic repertoire.  The turnaround time was determined from the time 
taken to process the sample, perform the assay and analyse the data.  
The department required a business plan (Appendix 5) to be completed which included a costing 
analysis.  The cost was calculated using the time taken by a senior member of staff to perform the 
assays and the middle scale of the salary range for a senior member of staff (£10.25 per hour). DCP 
is a specialist referral laboratory and all specialist staff members are senior biomedical scientists 
with specialist parasitology training and knowledge. Processing of samples for DNA extraction was 
not added to the calculation for staff time as the extraction is an automated process. LAMP costs 
are 54% less than the costs for qPCR and the results for LAMP can be obtained from extracted DNA 
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within 1.5 hours rather than the 2.5 hours for qPCR post- processing. The business plan for assays 
at DCP must be adjusted for use in different settings where staffing and running costs in WTM or 
endemic areas will be unrelated (European Commission Directorate-General Education and Culture, 
2006). 
There was no difference in analytical sensitivity and the analytical specificities were greater than 
the 80% lower limit described by Jones and Payne (1997) for a new diagnostic test. A new 
diagnostic test ideally has a sensitivity of 100% and specificity of 100%, however, this is not the case 
in biological systems where inhibition and sampling can influence the result and a probability of a 
false positive of 5-10% and a power of 80-90% to detect true negative results is chosen to 
determine the usefulness of new diagnostic test.  
Diagnostic sensitivity and specificity, (determined from the results of the patient study, excluding 
serial and duplicate samples in the samples stored at -20oC) was 23.29% (95% CI: 14.19-34.65%) for 
sensitivity and 99.57% (95% CI: 97.63-99.99%)for specificity with the LAMP assay; 39.73% (95% CI: 
28.45-51.86%) for sensitivity and 92.70% (95% CI: 88.58-95.69%) for specificity with the qPCR assay, 
using the CRS as the reference standard. A sensitivity of 46.15% (95% CI: 26.59-66.63%) and a 
specificity of 97.86% (95% CI: 95.39-99.21%) was obtained for the LAMP assay and a sensitivity of 
74.07% (95% CI: 53.72-88.89%) and a specificity of 97.86% (95% CI: 86.64-93.82%) was obtained for 
the qPCR assay using microscopy/ culture positive as the reference standard.  
The area under the ROC curve (AUC) is a measure of the ability of the assay (LAMP or qPCR) to 
distinguish the true population from the area under the curve and the 95% CI is the interval in 
which the true population is found in the area under the ROC curve. The closer the AUC is to 1 the 
better the test is to distinguish between the two groups. The p value determines the significance 
value for the null hypothesis, when p> 0.05 there is no difference between the two tests. The AUC 
for the LAMP assay (using the CRS as the reference standard) is 0.61 (p=<0.0001) and for the qPCR 
assay it is 0.66 (p=<0.0001). The AUC assay (using microscopy/ culture positive as the reference 
standard) for the LAMP is 0.72 (p=<0.0001) and for the qPCR assay it is 0.82 (p=<0.0001). The null 
hypothesis for this study was, therefore, rejected.  
Disease prevalence was not known in this study cohort so positive predictive value was not able to 
be interpreted. The negative predictive value (NPV) or true negative value using the CRS as a 
reference standard for the LAMP assay was 83.08% (95% CI: 75.51-84.96%) and for the qPCR assay 
it was 80.56% (95% CI: 77.96-87.43%). Using microscopy/ culture positive as the reference standard 
the NPV for the LAMP assay was 95.14% (95% CI: 91.98-97.32%) and for the qPCR assay it was 
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97.31% (95% CI: 94.53-98.91%). When serology was negative (determined as part of the CRS) LAMP 
detected one extra positive result and qPCR detected four extra positive results, the LAMP positive 
(40.12 minutes) result was also qPCR positive (Ct 27.15) with a 101bp product identified on the 
agarose gel. This may be due to early infection where the specific antibodies have not yet 
developed or an immunocompromised condition where the antibody levels may not develop at all 
(Requena-Méndez et al., 2013). There was no further information in the case notes regarding this 
patient. This case was also microscopy and culture negative, indicating that the larval load was 
below the limit of detection for both microscopy and culture.  
Where the CRS was determined to be positive by serology only- LAMP was positive in 6.3% of cases 
and qPCR was positive in 18.75% of cases. This result is difficult to interpret as specific antibodies 
are known to persist up to 12 months after successful treatment. Nevertheless the risk to the 
patient may be significant if a false negative result is recorded and NAATs cannot, at present, 
replace serology as a screening test for strongyloidiasis.  
LAMP detected 0.45% and qPCR detected 1.8% of cases when all the tests in the reference standard 
were negative. NAATs will therefore be a useful addition to the diagnostic repertoire for 
strongyloidiasis at DCP as they may detect strongyloidiasis cases in individuals where the CRS is 
negative. 
The qPCR assay, which requires DNA extracted from clinical stool samples using a labour and time 
intensive method to minimise the effect of inhibition on qPCR and is 54% more costly than LAMP, 
was determined to be an improved method for the detection of S. stercoralis DNA in clinical 
samples compared with the LAMP assay.  
This study concluded that the introduction of a qPCR assay into the diagnostic laboratory workflow 
was superior to the introduction of a LAMP assay. Furthermore the qPCR assay is suitable for 
deployment into the workflow of a high- throughput automated diagnostic laboratory where 
existing technology is available. 
The same extracted DNA samples were used for the LAMP and qPCR assays and so the difference in 
the detection of target DNA and in the analytical measures might be attributed to the target 
alignment on the 18S rRNA genome (Section 6.4, Appendix 3a). The LAMP assay is 10- fold less 
sensitive than the qPCR assay and may not be able to detect all cases of strongyloidiasis. LAMP is 




There was no difference in the limit of detection between the LAMP and qPCR assays when a limit 
of detection (LOD) assay run was performed on purified DNA from a cloned insert of the cPCR 
product. The effect of stool inhibition of the LAMP assay was excluded when the limit of detection 
was performed on cloned purified DNA. The LAMP assay had an LOD of 117.2 x 10-9 ng of DNA and 
the qPCR assay had an LOD of 154.4 x 10-9 ng of DNA. This is discussed further in Section 6.4.  
A separate costing analysis was performed for the cost of the LAMP assay for use in resource-
limited areas. A method of rapid ultrapure DNA extraction was tested for use without the need for 
technical expertise and costly automated equipment and reagents. A simpler manual DNA 
extraction method was also investigated that requires only a hot block, a centrifuge (the “boil and 
spin” method). The cost of staff and equipment was not included in the costing analysis because 
epidemiological control and monitoring studies will be funded in a different way to well-resourced 
WTM departments (European Commission Directorate-General Education and Culture, 2006, FIND, 
2012) (Table 5.6). This is discussed in Section 6.5. The price for DNA extraction was calculated from 








EXTRACTION (192 tests 
per kit) 
EIKEN CHEMICAL CO., 
LTD. PURE® DNA 
EXTRACTION (90 tests 
per kit) 
BOIL AND SPIN 
MANUAL DNA 
EXTRACTION 
DNA extraction per test 3.02* (price in 2014) 2.81* (price in 2017) 0.7* 
LAMP per test 0.7 0.7 0.7 
Consumables 1.08 1.08 1.08 
Turnaround time 2 days 1.5 hours 1.5 hours 
Equipment, staff and 
running costs  
Not included Not included Not included 
TOTAL per test £4.80 £4.59 £2.48 
*The cost is reduced when large numbers of samples are processed (Eiken Chemical Co. Ltd., 2005) 
 
There is very little difference in cost using the prices quoted by the manufacturers of the PURE® and 
automated DNA extraction methods (Eiken Chemical Co. Ltd., 2005, Qiagen, 2013). The savings will 
occur in the elimination of the need for high cost and maintenance equipment and the requirement 
for highly trained staff.  
LAMP can be set up in a high throughput format which greatly reduces the cost of the assay (Perera 
et al., 2017). FIND negotiates the costs for studies in endemic areas on an individual basis (Eiken 
Chemical Co. Ltd., 2005, European Commission Directorate-General Education and Culture, 2006, 
FIND, 2012). This study demonstrated that the simple “boil and spin” method with further 
optimisation would prove a very useful simple cost- effective tool for use in resource- limited 
settings. 
5.5 COMPARISON OF REPRODUCIBILITY FOR LAMP AND qPCR ASSAYS USING PAIRED SAMPLES 
STORED AT 4oC AND -20oC AND A POSITIVE PAIRED STOOL SERIES 
Two patients had a series of stool samples stored in 2012 (archived stools not collected as part of 
the study so no details were available) only 1 patient was positive. The positive samples were 
examined as an evaluation of the replication of results where duplicate samples were stored at 4oC 




Table 5.7: Positive stool series: LAMP and qPCR results in samples stored at 4oC and -20oC 
SAMPLE COMPOSITE REFERENCE STANDARD LAMP + (-20) qPCR + (-20) LAMP + (4) qPCR + (4) 
1 Microscopy positive 0 34.61 0 33.57 
2 Microscopy positive 49.36 31.46 0 31.29 
3 Microscopy positive 0 33.65 0 35.56 
4 Microscopy positive 0 30.84 0 31.84 
 MEAN Not applicable 32.64 Not applicable 33.065 
 STANDARD DEVIATION Not applicable 1.78 Not applicable 1.93 
 
The LAMP assay detected the target DNA in only one sample (sample 2) with a Ct of 31.46 (stored at 
4oC). This sample was also stored at – 20oC with a qPCR Ct of 31.29 where the LAMP assay was 
negative. The qPCR positive (Ct of 31.29) and LAMP assay negative sample was stored at 4
oC for 
three years before DNA extraction was performed. 
The Ct is proportional to the amount of target DNA present in the sample. The LAMP assay detected 
the target DNA at the limit of detection (when qPCR Ct ≤ 31.46) and may indicate that insufficient 
target DNA was present in the rest of the samples for detection by the LAMP assay (Morrison et al., 
1998). As previously discussed the storage of samples for the LAMP assay, before DNA extraction, 
was sub- optimal and this could have influenced the results seen. No conclusions about the 
replication of results for the LAMP assay could be determined, however, the qPCR assay showed 
good replication of results in a series of duplicate samples. As for the LAMP assay, improved 
performance was demonstrated by the qPCR assay in samples stored at -20oC.  
These results support the previously discussed DNA survival study for the LAMP and qPCR assays 
which demonstrated that samples for S. stercoralis DNA detection must be stored at -20oC and 
tested as soon as possible. A further study into the optimal storage conditions of stool samples for 
the LAMP assay is required.  
The purposes of this chapter were to assess the effect of external parameters on the LAMP and 
qPCR assays and to compare the suitability and cost of the two assays for diagnosis of 
strongyloidiasis in human faecal samples in well- resourced and resource- limited settings. 
The LAMP assay has the potential to be deployed in a suitable format for use in resource- limited 
areas, however further work is required to optimise sample storage and manual DNA extraction 
methods before this assay can be recommended. 
The qPCR assay is suitable for use in a high- throughput busy WTM setting, but is too costly for, and 
requires resources that are not available in, resource- limited areas. One step qPCR kits for use with 
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purified DNA templates are available (Qiagen, n.d.) with a reaction time shortened to one hour 
making the introduction of qPCR assays for multiple parasite targets a feasible option for a 






CHAPTER 6: DISCUSSION, CONCLUSIONS 
AND FURTHER RESEARCH 
This study focussed on the development of a novel LAMP assay for use in resource- limited settings 
and the evaluation and validation of the LAMP and qPCR assays for the diagnosis of strongyloidiasis 
in a specialist parasitology referral diagnostic laboratory. There is a need for the development of 
suitably sensitive and specific tests (Requena-Méndez et al., 2013) that would be useful as an 
addition to, or a replacement for, the current diagnostic repertoire at DCP.  
The introduction of NAATs for some tropical diseases that are suitable for use in resource- limited 
areas has already been reported in the literature e.g. LAMP diagnostics for malaria (Polley et 
al.,2013, Perera et al., 2017) and for the detection of T. cruzi (Thekisoe et al., 2010). At DCP the 
introduction of qPCR for the detection of microsporidia (a group of parasitic intracellular fungi) 
(Polley et al., 2011) and a multiplex protist qPCR for the detection of E. histolytica, G. lamblia/ 
intestinalis and Cryptosporidium sp. (ten Hove et al., 2007) has enhanced the diagnosis of these 
organisms. Multiplex qPCR is available for the detection of other nematode human pathogens. 
Verweij et al. (2006) described a multiplex qPCR for the detection of Ancylostoma duodenale, 
Necator americanus, and Oesophagostomum bifurcum in faecal samples. These reports indicated 
that LAMP and qPCR assays could be successfully developed for the detection of S. stercoralis. 
Future development of these assays to detect parasitic infections in multiplex formats (Iseki et al., 
2007, Verweij et al., 2006) will enhance the diagnostic throughput for the molecular detection of 
intestinal parasites. Jaleta et al. (2017) concluded that molecular diagnosis of S. stercoralis is 
important as the clinical outcomes of different species is not yet known and may have a role to play 
in the treatment options for strongyloidiasis in humans and canines. 
The aim of this study was, therefore, to evaluate and validate nucleic amplification tests for the 
detection of S. stercoralis in clinical samples in a well- resourced specialist parasitology reference 
laboratory and to develop a LAMP assay that could be used for the diagnosis of strongyloidiasis in 
resource- limited areas with appropriate sensitivity and specificity estimations. The main objective 
was the development of a “fit for purpose” (CPA standards F1, ISO 15189:2012) (UKAS, n.d., ISO 
15189:2012, 2012) diagnostic screening strategy for introduction into the testing repertoire of a 
specialist parasitology referral laboratory to enhance clinical care for strongyloidiasis. 
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6.1 EVALUATION CRITERIA 
Peeling et al. (2007) discussed the problems associated with evaluating diagnostics. This study was 
designed to address the potential shortcomings that were highlighted in that report (Table 6.1).  
Table 6.1: Problems that may be encountered when performing diagnostic test evaluation: the 




Evaluation in an 
inappropriate 
study group 
This study examined a cohort of patients being investigated for strongyloidiasis at HTD 
and UCLH. While HTD is not in an endemic setting some bias in the choice of samples was 
introduced by the fact that patients were being investigated for strongyloidiasis due to 
previous exposure in an endemic setting. This was unavoidable for this patient cohort. 
Evaluation in an 
inappropriate 
setting 
A higher number of false positive than true positive results would be expected in a low 
prevalence setting e.g. HTD. Overall percent agreement was used to determine the 




This study was used to develop and investigate NAATs for detection of strongyloidiasis in 
asymptomatic patients. The appropriate statistical analysis was chosen to investigate the 





This was an unavoidable problem as there are no sensitive and specific tests that can be 
used as a “gold standard” however, a search of the literature found that a composite 
reference standard (CRS) could be used to eliminate bias in sensitivity estimations. A best 
possible CRS was chosen for this study and the CRS was broken down into two parts (a) 
the use of the full CRS that includes a test that indicates probable disease and (b) the use 
of the CRS with only those tests that indicate proven disease. LAMP (a novel assay 
developed at DCP) was compared to qPCR, which is a published method (Verweij et al., 
2009),  to overcome the limitations of the lack of a suitable “gold standard” 
Inadequate 
sample size 
An appropriate sample size was calculated with a significance level of 0.05 and a power 
of 0.10 to detect a difference of at least ten in the rows and columns of a 2x2 table using 
McNemar’s test for the comparison of paired data. 
Lack of blinding All samples were blinded at the start of the study by a database curator, not the 
researcher,  and the code was broken after the study was completed 
Assessing the 
quality of an  
evaluation trial 
Quality assurance was assessed by STARD (HPA UK protocols, 2013, Bossuyt et al., 2015), 




The study examined samples from patients (returning travellers and migrants) who were being 
investigated for strongyloidiasis on the basis of travel history, symptomology or screening of 
patients with compromised immunity and a relevant travel history. Spectrum bias was, therefore, 
unavoidable and overstated the sensitivity and specificity estimations (Pewsner et al., 2011). 
Nevertheless, the assays evaluated in this study are to be deployed for use in patients with a high 
index of suspicion for strongyloidiasis and the study cohort was deemed to be appropriate. The 
limitations encountered in this study for the analysis of the data are discussed in Sections 2.8, 3.9 
and 4.10. The NAAT assays (detection of specific target DNA) were compared to microscopy/ 
culture (detection of whole parasite) and serology (detection of specific antibodies) in this study. 
The selection of an appropriate assay must be considered in the context of utilisation of the assay 
and consequences of the disease (Caraguel et al., 2011).  
WHO (2013) described the selection requirements for a diagnostic test as:    
I. Screening for the disease requires a high sensitivity to confirm that the individual is free 
of disease; 
II. Diagnosing the disease in symptomatic patients requires a test with high specificity; 
III. Monitoring treatment requires a test with suitable sensitivity and high specificity. 
Culture with a sensitivity of only 70% (Requena-Méndez et al., 2013) and a requirement 
for untreated parasites is unsuitable for treatment monitoring and is not sensitive 
enough to detect low levels of parasite present in the stool samples. 
The sensitivity of a test is the true positive rate of a test and specificity is the true negative rate of a 
test. These parameters are independent of the disease prevalence and together determine the 
diagnostic power of the test (Pewsner et al., 2011). A negative result in a test with high sensitivity is 
useful for ruling out those who do not have the disease (a screening test) however this test will 
produce false positive results so it is not a useful test for diagnostic purposes. A positive result in a 
test with high specificity will determine a high probability of the disease (a diagnostic test) 
(Pewsner et al., 2011). 
In a low prevalence setting (e.g. HTD) a higher false positive to true positive results ratio may be 
detected than in endemic settings (Peeling et al., 2007). However, in a chronic disease, such as 
strongyloidiasis, where the subsequent consequences of a missed diagnosis may be fatal (Pottie et 
al., 2011, Barros and Montes, 2014, Levenhagen and Costa-Cruz, 2014) the selection of a test with a 
low level of false positive results may be deemed appropriate (Caraguel et al., 2011). At DCP, 
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microscopy, culture and serology form part of the diagnostic repertoire and the decision to treat 
patients on the basis of only a positive qPCR assay would require clinical input. 
6.2 DEVELOPMENT AND EVALUATION OF A NOVEL LAMP PCR FOR THE DETECTION OF S. 
STERCORALIS DNA IN CLINICAL SAMPLES IN RESOURCE- LIMITED AND WELL- RESOURCED 
SETTINGS 
Isothermal amplification was developed and evaluated in this study as it has a shorter turnaround 
time than cPCR and qPCR and is a simple and cost- effective assay. Moreover, the equipment 
required was already available in the laboratory at DCP for research purposes. Wong et al. (2017), 
in a review of LAMP assays, noted that LAMP has successfully been used as a diagnostic tool for 
human, livestock and plant diseases. DCP is a high- throughput, busy diagnostic specialist 
parasitology referral laboratory. LAMP has been shown to be suitable for adaptation to a high- 
throughput format (Perera et al., 2017, Wong et al., 2017) and the rapid turnaround time has made 
it suitable for the development of an individual point of care test format for urgent samples (Njiru, 
2012). However, the rigorous protocol required for DNA extraction from stool samples requires 
adaptation to a more rapid and simple method of DNA extraction before LAMP can be useful for a 
point of care test format or for use in a resource- limited setting.  
One aim of this study was to develop a novel LAMP assay for the detection of S. stercoralis DNA in 
clinical samples for use, in both, resource- limited and well- resourced settings. Novel LAMP assay 
primers were designed and evaluated for the detection of S. stercoralis DNA (Chapter 3). Raw data 
is found in Appendix 6. Sequencing of the cPCR product, generated using the forward and back 
outer LAMP primers, confirmed the detection of a 240bp sequence of the target DNA with 99% 
sequence match to S. stercoralis (Section 3.4, Appendix 3a). No non-specific DNA was detected by 
the LAMP assay. Based on the findings in this part of the study (Chapter 3), the LAMP assay was 
determined to be a potentially suitable screening test for the diagnosis of strongyloidiasis (Pewsner 
et al., 2011). Analysis of sample storage temperature demonstrated a 0.6% increase (in samples 
stored at 4oC or -20oC) in the detection of S. stercoralis when evaluated against microscopy/ 
culture. The study findings revealed that, when the LAMP assay was evaluated against serology, 
6.3% of serology positive samples were LAMP assay positive (Table 5.5). Serology may be positive in 
cases where active disease is not present (Requena-Méndez et al., 2013), nevertheless, a missed 
diagnosis can have severe consequences (Pottie et al., 2011) and the LAMP assay is unsuitable as a 
standalone diagnostic test (Section 3.8). Further evaluation of short- term DNA persistence and 
rapid manual DNA extractions methods highlighted the limitations of the assay. 
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As previously stated storage of neat stool samples at -20oC is recommended for efficient S. 
stercoralis DNA extraction (ten Hove et al., 2009). Current standard operating procedures at DCP 
entail storage of clinical samples for up to three weeks at 4oC before DNA extraction is performed 
for routine NAAT testing. To determine the standardisation of the LAMP assay required to 
harmonise with existing standard operating procedures at DCP the samples were evaluated for DNA 
persistence at storage temperatures of 4oC and -20oC.  In this study, short- term persistence of DNA 
in stored samples was superior at a storage temperature of -20oC but did demonstrate 
deterioration of S. stercoralis DNA, even at -20oC (Table 3.16). Fresh samples are required and this 
current format is not suitable for the introduction of a NAAT into the diagnostic repertoire at DCP (a 
busy well –resourced reference laboratory) where samples may arrive in the post and be several 
weeks old. This storage condition is also unsuitable in endemic areas (which may be resource- 
limited) where samples may be stored for a period of time before the LAMP assay can be 
performed. Alternative sample storage before DNA extraction is required and further work is 
planned to evaluate the storage of samples in ethanol at 4oC and sample storage on FTA cards 
(Section 3.7). 
To determine the suitability of the LAMP assay for use in resource- limited areas, or in a point of 
care test format, rapid simplified manual methods for purified DNA extraction were examined. This 
study used an automated DNA extraction method (Qiagen® Qiasymphony SP) that requires 
expensive, high maintenance equipment that is not suitable for use in resource- limited areas. The 
LAMP assay is said to be less sensitive to assay inhibition than PCR as it uses a Bst polymerase 
rather than a Taq polymerase (Notomi, 2000) so methods for direct manual extraction of DNA 
suitable for use in the LAMP assay were investigated. Rapid, simple and cost-effective manual DNA 
extraction methods have been developed for use in endemic areas (WHO, 2013, Perera et al., 2017) 
and this study evaluated the use of two rapid, simple manual DNA extraction methods that require 
only a constant power supply, a heating block and a centrifuge (Section 3.7). At DCP, the PURE® 
DNA extraction system was simple and easy to use but required more stages, and cost 54% more 
than, the “boil and spin” method (Table 5.4). DNA from both manual DNA extraction methods 
demonstrated inhibition of the LAMP assay when evaluated against the automated DNA extraction 
method (Tables 3.19 and 3.20). The demonstration of inhibition of the LAMP assay, in this study, 
when using large sample volumes for the manual extraction of DNA may indicate a possible reason 
for the reduced sensitivity of the LAMP assay when compared to the qPCR assay for the detection 
of S. stercoralis DNA in clinical samples. This study tested stool aliquots ranging from 0.01 to 0.5 
mg. In the current study inhibition was demonstrated in samples > 10µg (0.001mg). 
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This study recommends the “boil and spin” method as a rapid, simple and cost-effective method 
that is easy to use and suitable for use in resource- limited settings. However, further work on 
sample loading volumes and reproducibility is required to address the issue of inhibition of the 
LAMP assay before this method can be deployed in endemic areas or used in a point of care test 
format. 
The current study demonstrated the feasibility of a LAMP assay to detect S. stercoralis in clinical 
samples. The use of LAMP for the detection of S. stercoralis DNA in clinical samples using novel 
primers designed to target the 18S rRNA gene has not yet been reported in the literature. This 
section of the study will be published after further optimisation of storage conditions for clinical 
samples and the manual DNA extraction methods has been completed. 
6.3 REAL-TIME PCR (qPCR) FOR THE DETECTION OF S. STERCORALIS DNA IN CLINICAL SAMPLES IN 
A HIGH- THROUGHPUT SPECIALIST PARASITOLOGY REFERRAL LABORATORY. 
This part of the study focused on the evaluation and validation of a published qPCR (Verweij et al., 
2009, ten Hove et al., 2009) suitable for high-throughput processing in a well-resourced laboratory 
setting. The development of a protocol that would harmonise with existing work practices was also 
investigated. The qPCR assay was optimised for use at DCP and analytical sensitivity and specificity 
was performed using known negative and spiked positive stool samples and a bank of DNA from 
viral, bacterial and other parasitic organisms that may also be found in diagnostic stool samples 
received at DCP for strongyloidiasis investigation. Raw data from the study samples is found in 
Appendix 6. 
Sequence analysis confirmed the detection of the target 101bp DNA with a sequence match of 
100% to S. stercoralis and a sequence match of 93- 98% to Strongyloides species (Section 4.4). 
Anomalous results were detected, where the CRS was negative and the qPCR assay was positive. 
This finding may be due to increased sensitivity of the qPCR assay when compared to the 
microscopy/ culture result or to the serology result which may not be positive during acute 
infection or in immunocompromised individuals (Suddarshi et al., 2003). Repeat qPCR and cPCR 
assays were negative in some cases (Appendix 4) or were proven to be S. stercoralis by sequence 
analysis. It could not be established whether the negative repeated assays were due to small 
quantities of DNA in the sample (Morrison et al., 1998, Minogue et al., 2014), primer dimers or 
whether theoriginal tubes had been contaminated due to environmental contamination (Caraguel 
et al., 2011). The DNA extraction method and the master mix and sample loading were all 
automated procedures and only one instance of environmental contamination occurred after the 
limit of detection evaluation (Figure 4.8) had been performed. The environmental contamination 
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was determined to be at the master mix and sample loading stage as the repeat qPCR assay (after 
laboratory decontamination) did not demonstrate contamination in any of the repeated study 
samples. Once the qPCR assay had been optimised for use in the study (Section 4.3) residual 
diagnostic sample DNA from the microsporidia and Multiplex protist qPCR assays, from patients not 
being investigated for strongyloidiasis, was used to challenge the qPCR assay. These samples (n=20) 
were completely anonymised so no reference to patient data was available. A positive qPCR assay 
result was detected in three of the samples but no further action could be taken. It was, therefore, 
decided to perform gel electrophoresis on the products from the qPCR assay, including those 
samples in the specificity bank that were completely anonymised. Non-specific DNA was detected 
in three of the samples in the specificity bank. Two of the samples with Cts of 35.11 and 35.13 
(Section 4.5.2) were negative in two consecutive qPCR assays. Caraguel et al. (2011) suggest the 
reason for this may be due to primer dimer formation or environmental contamination. One 
sample with a Ct of 44.56 was detected in this study and the sample was microscopy positive for 
hookworm ova (Table 4.7). The target DNA band of 101bp was confirmed by gel electrophoresis. 
Hookworm and S. stercoralis may be found in the same geographical regions (CDC, n.d.) and this 
sample may have contained low levels of detectable S. stercoralis DNA or this result may indicate 
environmental contamination (Morrison et al., 1998, Caraguel et al., 2011). However, a cut-off Ct of 
>40 was determined in this study for qPCR positive results and Cts >40 were classified as equivocal 
results. In diagnostic samples the generation of an equivocal result would require clinical input and 
a repeat sample would be requested. The qPCR assay was repeated twice more and generated 
negative results both times. It is thought to be more likely that the qPCR result was due to 
environmental contamination in this case (Caraguel et al., 2011). 
The findings from the gel electrophoresis of the products from the qPCR assay for the study 
samples generated three anomalous qPCR products (one 145bp and two 500- 525bp- different 
patients). Only one of the qPCR products (500- 525bp) was identified. Multiple sequence alignment 
analysis (Larkin et al., 2007) demonstrated alignment with the reference strain Strongyloides 
stercoralis 18S ribosomal RNA gene, complete cds (Appendix 3b). However the products generated 
small fragments that aligned with the reference strain (M84229.1) from a 500bp query with Evalues 
of 3E-11 (39bp) and 8E-40 (90bp). While it may be possible that the detection of a 500bp product 
indicated a region of hypervariability (Jaleta et al., 2017), or a different strain, this result must be 
interpreted with care. This assay may, therefore, detect S. stercoralis from different geographical 
regions, but it was not possible to determine this as the number of positive samples with 
anomalous identifiable bands in the study was too low for data analysis to be performed.  
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Confirmation of the identity of the 500bp sequence is required before the presence of anomalous 
bands in the qPCR assay, which has not yet been reported in the literature, can be published to 
expand the knowledge base for the detection of S. stercoralis DNA. Further work is required to 
determine if there is a significant difference in the sequence of the DNA products to determine 
whether the samples contain a new species of S. stercoralis able to infect humans. Jaleta et al. 
(2017) demonstrated that S. stercoralis is more variable in the HVR I and HVR IV (Hasegawa et al., 
2009) regions of the 18S rRNA gene than other nematodes and determined that this might not, 
therefore, indicate the presence of a cryptic Strongyloides species capable of infecting humans.  
Where the sequence analysis confirmed the identity of S. stercoralis after repeated qPCR assays 
(Appendix 4) it was concluded that qPCR detected low levels of S. stercoralis DNA and indicates that 
further study into the use of the qPCR assay for treatment monitoring would be applicable as the 
disease was, detected by this assay. It was determined by this study to be 7.95 times more likely for 
S. stercoralis DNA to be present when the qPCR assay result is positive. The increased sensitivity of 
the qPCR assay may, therefore, be used to monitor treatment in studies designed to determine the 
exact dose of ivermectin required to eliminate strongyloidiasis in a patient. The findings in this 
study determined that the qPCR assay is a suitable screening test for the diagnosis of 
strongyloidiasis (Pewsner et al., 2011), but cannot replace serological diagnosis as only 21.4% of 
serology positive samples were qPCR assay positive (Table 5.5). The limitations regarding the use of 
serology (probable disease) as part of the CRS have been previously discussed (Requena-Méndez et 
al., 2013). This qPCR assay is suitable for deployment to well- resourced laboratories, with available 
expert advice, in a high- throughput format and will transform the diagnosis and clinical care of 
strongyloidiasis at DCP. 
Similar to the LAMP assay, a DNA persistence study was performed for samples stored at 4oC and  
-20oC. This determined harmonisation of standard operating procedures between the qPCR assay 
and current molecular assays for stool parasites at DCP. The findings confirmed that stool samples 
for S. stercoralis DNA detection by the qPCR assay must be stored at -20oC before DNA extraction is 
performed. 
6.4 COMPARISON OF LAMP AND qPCR ASSAYS FOR THE DETECTION OF S. STERCORALIS IN 
CLINICAL SAMPLES 
This study investigated the application of LAMP and qPCR assays for the detection of S. stercoralis 
DNA in clinical samples. The cohort demographics and the quality of the samples used in this study 
were investigated for the effect that study sample demographics or storage conditions would have 
on NAATs deployed for use on fresh clinical samples or in epidemiological study conditions 
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(Sections 5.1 and 5.2). As demonstrated in Chapter 3, further experiments are required to optimise 
sample storage conditions before the LAMP assay can be deployed to diagnostic settings (Section 
5.3.1). An improved performance for the qPCR assay cf. the LAMP assay in the detection of S. 
stercoralis DNA in clinical samples was consistently demonstrated in this study (Sections 3.8 and 
4.10). An exception for this was the demonstration of similar limits of detection for the LAMP and 
qPCR assays on purified DNA (Table 5.5) and the reasons for this may be attributed to sub- optimal 
storage of neat stool and/ or inhibition of the LAMP assay. A further reason for the difference in 
detection of S. stercoralis DNA between the LAMP and qPCR assays may be due to the fact that the 
primers detect different target regions of the 18S rRNA gene. Clustal W2 multiple sequence 
alignment (Larkin et al., 2007) was used to determine the target regions of the 18S rRNA gene for 
the LAMP and qPCR assays. The results are shown in Appendix 3a. 
Demonstration of stool inhibition for the LAMP assay was determined in this study by the 
evaluation of rapid manual DNA extraction (Notomi, 2000, Perera et al., 2017) and the automated 
Qiagen® Qiasymphony SP magnetic bead resonance technology. The automated DNA extraction 
technology had been previously validated for extraction of DNA from stool samples at DCP. The 
effect of inhibition was diminished or excluded from the LAMP assay when the DNA was diluted 
before use or smaller loading stool samples were used. Sub- optimal storage of stool samples for 
the LAMP and qPCR assays was demonstrated in this study for those samples stored neat at 4oC and 
for the LAMP assay in those samples stored neat at -20oC before DNA extraction. The reason for the 
improved performance of the qPCR assay was believed to be due to the sub- optimal storage of 
stool samples for the LAMP assay, LAMP assay inhibitors present in the DNA extracted from stool or 
a different target DNA detection site in the S. stercoralis genome for the LAMP assay. Multiple 
sequence alignment analysis demonstrated that the LAMP and qPCR primers target different 
regions in the S. stercoralis 18S rRNA gene (Appendix 3a). The similar limit of detection for purified 
DNA, suggested that further optimisation of the stool sample storage before DNA extraction and 
the DNA sample loading volume for rapid manual DNA extraction are required before the LAMP 
assay can be deployed for the detection of S. stercoralis DNA in clinical samples. 
6.5 THE INTRODUCTION OF A qPCR ASSAY FOR THE DETECTION OF S. STERCORALIS IN CLINICAL 
SAMPLES 
The information provided in this section forms part of a business plan (Appendix 5) that will be 
presented to the UCLH board of directors for the introduction of a qPCR assay for the detection of S 
stercoralis DNA in clinical samples into DCP. The algorithm described in Figure 6.1 is recommended 






Figure 6.1: An algorithm for the use of the qPCR assay in the routine diagnostic laboratory at DCP. 
Potential for future use of qPCR to monitor treatment* 
1 Stool samples for culture and FECT to be processed immediately. Stool samples that are processed 
after 24 hours are stored at room temperature for culture or 4oC for FECT 
2 Stool samples for qPCR: store an aliquot at -20oC immediately 
3 Serum samples may be stored at 4oC or at -20oC 
 
This demonstrates the use of the qPCR assay when microscopy and culture are negative and a qPCR 
assay can be requested when the clinician has determined that there is a risk of strongyloidiasis for 
the patient. Clinical input is required when the serological assay is positive and a clinical decision 
must be made to treat the patient or request qPCR confirmation. Clinical input is also required 
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when the microscopy, culture and/ or serological assay is negative when the qPCR assay is positive. 
A clinical decision can be made to request qPCR confirmation and will depend on the clinical degree 
of suspicion for strongyloidiasis.  
Microscopy will still be an integral part of the diagnostic repertoire as this assay detects all parasites 
found in stool samples. The continued inclusion of the culture assay will be evaluated six months 
after the introduction of the qPCR assay for relevance to the diagnostic repertoire. The culture 
assay remains an infection risk and the removal of this test from the diagnostic repertoire will 
positively impact on the workload and the health and safety of laboratory staff.  
Research and development for more sensitive detection methods is continuously being performed 
in the department. The removal of a time- consuming test (culture) will allow the introduction of 
more sensitive and specific assays for parasite detection to be introduced into a busy, high- 
throughput routine diagnostic department. A further improvement to the turnaround time of the 
Qiagen® Qiasymphony SP was investigated for the qPCR assay (Section 4.8), and was also 
demonstrated for the LAMP assay (Section 3.8). The current protocol requires stool samples to be 
incubated overnight in ATL buffer and proteinase k at 56oC. Parallel DNA extraction was performed 
on multiple positive and negative control stool samples and no significant difference between those 
samples incubated at 56oC for 2 hours or overnight was demonstrated. This determines that the 
automated DNA extraction method may be shortened to 1.5 days as opposed to the current 
protocol of 2.5 days. This suggests that other qPCR assays (e.g. microsporidia and Multiplex protist 
qPCR assays) may also be investigated for shorter turnaround times and will allow the further 
introduction of novel assays into the diagnostic repertoire at DCP. 
The cost analysis calculation is described in Section 5.3 and the comparison of the LAMP and qPCR 
assays, in Table 5.5, describes the factors included into the decision to introduce the qPCR assay 
into DCP. A running cost of £44.09 per qPCR assay was calculated. This amount is heavily subsidised 
as the equipment and consumables are already available at DCP. The cost of staff is also subsidised 
as the qPCR assay can easily harmonise into existing standard operating procedures and automated 
DNA extraction for the S. stercoralis qPCR assay will be performed alongside DNA extraction for 
microsporidia and Multiplex protist qPCR assays. Removal of the equipment and staff costs 
provides a cost per qPCR assay of £8.21. 
A cost analysis of the LAMP assay was performed to calculate the running costs of the assay in well- 
resourced and resource- limited areas (Table 5.5). FIND (2012), in reference to a report on the 
sustainability of international cooperation in the field of higher education and vocational training 
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(European Commission Directorate-General Education and Culture, 2006), determined that funding 
will be different in resource- limited areas where involvement of local government and non- 
governmental agencies is required to maintain funding for projects in these areas. FIND (2012) 
therefore, will supply reagents and kits with costing determined on an individual basis. Projects in 
these areas may require the supply of equipment (e.g. Loopamp- LF160, Figure 2.4) and this will be 
funded and supplied on an individual basis. The cost of staff and training is also performed based on 
the individual need of the projects. The costing analysis performed in this study was therefore 
performed on the cost of the reagents published (FIND, 2012) only. Nevertheless, based on this 
analysis the LAMP assay using the “boil and spin” method for rapid manual DNA extraction (FIND, 
2012) will be a suitable candidate for deployment to resource- limited areas for the detection of S. 
stercoralis DNA in clinical samples once further optimisation experiments have been completed. 
Based on the costing analysis (Table 5.5) the LAMP assay is potentially suitable for point of care 
testing in well- resourced settings. The LAMP assay may also be designed in a high- throughput 
format (Perera et al., 2017) and this format is suitable for both well- resourced high throughput and 
resource- limited settings. 
6.6 CONCLUSIONS 
The conclusions of this study were that the LAMP assay may be suitable for use in endemic areas 
after further optimisation has been performed. In this study LAMP assay inhibition was reduced by 
using a low sample loading volume for manual DNA extraction methods (FIND, 2012, Perera et al., 
2017) but the sensitivity of the assay was also reduced. Additional experiments are required to 
determine the optimal storage conditions for samples and to further develop manual DNA 
extraction methods. Further work is planned to investigate storage conditions and manual DNA 
extraction methods for the LAMP assay, but this is beyond the timescale for this professional 
doctorate degree (Appendix 7) and will be completed within a further study investigating the use of 
the qPCR assay for post- treatment monitoring. Once the LAMP assay has been optimised for 
suitability of use in the field the potential exists for the manufacturing of a lyophilised kit version 
(Wong et al., 2017).  
The qPCR assay is a suitable diagnostic test for use in well- resourced areas that meets the 
molecular diagnostic test standards of an internal control and quantification capability that can be 
used to detect disease and monitor therapy follow up (Kramme et al., 2011). The qPCR assay is 
suitable for introduction as an adjunctive test that requires clinical input into assay requesting and 
interpretation of results. This assay cannot be used as a first- line test but it is suitable for detecting 
cases of strongyloidiasis in patients who are about to undergo iatrogenic immunosuppressive 
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therapy where a missed diagnosis can have severe consequences. Statistical analysis of data 
demonstrated that the qPCR assay is suitable for treatment monitoring in conjunction with 
serology.  
Detection of S. stercoralis is not only a problem in humans. Reports of S. stercoralis infection 
amongst canines (Yang et al., 2013) have highlighted a need for a rapid cost-effective method for 
use in veterinary medicine as well (McNally et al., 2013, Sudhakara and Sivajothi, 2017). Dillard et 
al. (2007) reported on an outbreak in a Finnish kennel which led to the death of a 10- week old 
puppy from a naturally acquired S. stercoralis infection.  
Molecular methods for the detection of human parasites in stool samples may also be used in 
veterinary medicine. There are published reports of the techniques described in this study being 
used in veterinary medicine (Yang et al., 2013, Melville et al., 2014, Jaleta et al., 2017). Sudhakara 
and Sivajothi (2017) reviewed methods for detection of parasites in veterinary medicine and noted 
the increased sensitivity and number of molecular techniques that are available. Diagnosis in 
veterinary medicine is important to the successful control of veterinary diseases which have an 
economic impact due to loss of the animal or reduced food production. The most common 
application of molecular diagnosis in veterinary medicine is the investigation of herd health to 
determine disease strategies (Sudhakara and Sivajothi, 2017). McNally et al. (2013) described a 
method for the extraction of DNA from stool samples and a multiplex quantitative PCR to detect 
Haemonchus, Trichostrongylus and Telodorsagia infections in sheep. The techniques described in 
the current study could also be used for veterinary medicine and a LAMP assay useful for resource- 
limited areas would be beneficial to the diagnosis of strongyloidiasis in animal husbandry. New 
primers designed to target Strongyloides sp., rather than S. stercoralis, would be required for the 
utilisation of this method in veterinary medicine as the Strongyloides sp. found in animals is usually 
different to the Strongyloides sp. found in humans (Jaleta et al., 2017). Humans have been shown 
to be susceptible to infection with certain strains of S. stercoralis that infect canines (Jaleta et al., 
2017). There is, therefore, a use for the introduction of molecular techniques for epidemiological 
studies in areas where animals and humans are exposed to parasites. Jaleta et al. (2017) 
recommended that humans and associated infected dogs are treated together to eliminate the risk 
of potential zoonotic transfer. 
6.7 FUTURE RESEARCH 
A new study has been given ethical approval at DCP to investigate the usefulness of the qPCR assay 
in monitoring treatment for strongyloidiasis and determination of the correct dosage of ivermectin 
159 
 
in cases of chronic infection and hyperinfection syndrome. This work will be carried out after the 
conclusion of this professional doctorate degree and collection of samples has already begun. 
Further work is planned to determine the optimal storage temperature for the LAMP assay 
samples, it is thought that storage of samples under optimal conditions will improve the 
performance of the LAMP assay for use in endemic areas. Manual DNA extraction methods suitable 
for use with the LAMP assay in endemic regions require further development and this will also be 
performed after the completion of the Professional doctorate degree. 
Recently, cell-free DNA defined as DNA fragments found extracellularly in different body fluids has 
been investigated for the sensitive diagnosis of disease. The origin and distribution is unclear but it 
is being used with increasing success as a diagnostic biomarker (Weerakoon and McManus, 2016). 
Lodh et al. (2016) published a study where S. stercoralis DNA was detected in urine samples. 
Further work by Lodh et al. (2016) is planned to determine the sensitivity and specificity of this 
technique. Urine may be easily collected in larger volumes than stool samples and contains fewer 
inhibitors to NAATs and may be a suitable method for the detection of S. stercoralis DNA. This 
would be useful in determining where S. stercoralis DNA could be detected in humans and may be 
able to further the understanding of this parasite and its unique life-cycle. An investigation of cell-
free DNA was not performed in this study as no urine was saved on patients entered into the study. 
However, this study will be continued and a request to the treatment monitoring study co-
ordinator has been put forward for the investigation of urine samples on patients where this is 
available. Demmerdash et al. (1995) demonstrated schistosomal antigens in urine and serum that 
could be detected by monoclonal antibodies. It would be beneficial to perform a pilot study to 
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APPENDIX 1: S. STERCORALIS MODIFIED “IN- HOUSE” CHARCOAL CULTURE METHOD (MINATO ET 
AL., 2008) 
The in-house modification of the charcoal culture requires up to 5 g of faeces to be mixed with an 
equal volume of charcoal in a small petri-dish lid that has been fixed to the bottom of a medium 
sized petri-dish. The bottom of the medium-sized petri-dish is covered in enough water to reach the 
bottom of the lip of the small petri-dish but does flow into the small petri-dish. The lid of the 
medium-sized petri-dish is applied and the culture is incubated at 23oC for 10 days. The culture 
water is examined weekly under an inverted microscope (200x magnification), but may be 
examined more frequently. Distinctive S. stercoralis larvae must be differentiated from hookworm 
















APPENDIX 3a: CLUSTAL W2 MULTIPLE SEQUENCE ALIGNMENT OF LAMP AND QPCR ASSAY 
PRODUCTS (LARKIN ET AL., 2007) 
Grey= Reference sequence: M 84229 (Strongyloides stercoralis 18S ribosomal RNA gene, complete 
cds) 
Yellow= LAMP amplicon sequence. 
Red= hypervariable region sequence (Hasegawa et al., 2009). 
Blue= qPCR amplicon sequence. 
Identities are normalised by aligned length.  
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      ACCTGGTTGATCCTGCCAGTAGTCATATGCTTGTCTCAAAGATTAAGCCATGCATGTCTA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      AGTATAAACAAATTCATACTGTGAAACTGCGAATGGCTCATTAAATCAGTTATAGTTTAT 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        -------------------------------------------CTAAT------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TTGATGGTTTCTTGCTACATGGATAACTGTGGTAATTCTAGAGCTAATACATGCTKAAAA 
HVRII         ------------------------------------------------------------ 
181 
 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GCCCCGACTTCTGGAAGGGGTGTATTTATTAGATAAAAAACCAATGACTTCGGGCTCCTT 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        -------------------------------------------------------TCTCC 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        -----------------------CCTCGCTGANTTTGTTACTAAAACATACCGTATGTGT 
M84229.1      GGTGATTCATAATAACTTCTCGAATCGCATGGCCTTGCGCCGGCGATGCTTCATTCAAAT 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        GTTATCCGTCNCNNCNNTGGTAGGTAGGCCAATACCCTACCATCGAAAGTTGATAA---- 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ATCTGGTTTATCAACTTTCGATGGTAGGGTATTGGCCTACCATGGTTGTGACGGATAACG 
M84229.1      TTCTGCCCTATCAACTTTCGATGGTAGGATAGTGGCCTACCATGGTATCAACGGGTAACG 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        GAGAATTAGGGTTCGACTCCGGAGAGGGAGCCTGAGAAACGGCTACCACATCCAAGGAAG 
M84229.1      GGGAATTAGGGTTCGATTCCGGAGAGGGAGCCTGAGAAACGGCTACCACATCCAAGGAAG 
HVRII         ------------------------------------------------------------ 




184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        GCAGCAGGCGCGAAA--------------------------------------------- 
M84229.1      GCAGCAGGCGCGAAAATTACCCAATTTTAGTTAAAAGAGGTAGTGACGAAAAATGACAAC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      CAAATATTATTATTAATATTTGGATTGAAAATCTTCAAGTTTAAATMACCTTGTTGGTAA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        -------------------------------------ACC--------AGATACACATAC 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      AGGAAAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATACCAGCTTTCCAAGTGCATAAAA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        GG---------------------------------------------------------- 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TGATTGTTGTGGTTAAAAAGCTCGTAGTTGGATTATAAAGATTGTATAATGAGCATCTTG 
HVRII         ------------------------------------------------------------ 




184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        -------------------------------TTATTATAATTAGANNNNAATAATATAAT 
B3LAMP        ------------------------------------------------------------ 
HVRI          ----------AACCATTTTNAT-------------------------------------- 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GATGTTATTTAATCATTATCATCTTATATTTTTATTATATTAGAAATAATATAATAACTG 
HVRII         --TGTTATTTAATCAT-------------------------------------------- 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        NAACT------------------------------------------------------- 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TCACTTTGAATAAATCAGAGGGTTTAAACCAGACATTATATGTTTGTATGGTCTAGCATG 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GAATAACACTATAGAAAAATTTAGTGTGGTTTCACTTAATTTTTCATGATTAATAGGAAC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      AAACGGGGGCATTCGTATCGCTACGTTAGAGGTGAAATTCTTGGACCGTAGCGAGACGTC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
184 
 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      CTACTGCGAAAGCATTTGCCAAGAATGTTTTCATTAATCAAGAACGAAAGTTAGAGGTTC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GAAGGCGATCAGATACCGCCCTAGTTCTAACCGTAAACTATGCCTACTAGATGTATGAAT 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TATTAGTTATAATTATTTATGCATCTTCTCGGAAACGAAAGTCTTTCGGTTCCGGGGGAA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GTATGGTTGAAAAGCTGAAACTTAAAGGAATTGACGGAAGGCACCACCAGGAGTGGAGCC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
185 
 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TGCGGCTTAATTTGACTCAACACGGGAAAACTCACCCGGGCCGGACACTATAAGGATTGA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      CAGATTGATAGCTCTTTCATGATTTAGTGGTTGGTGGTGCATGGCCGTTCTTAGTTCGTG 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        -----------TATGTTTTAGTAAGAAAATCAGCGAGGATATTTTGAGT----------- 
HVRI          ------------------------------------------------------------ 
HVRIV         -----------------------------------------------------AAATATT 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GATATGATTTGTCTGGTTGATTCCGATAACGAGCGAGACTTTTATGTTATATTAAATATA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        -------------------------CAACCAATA------------------TAAAATGG 
HVRI          --------------------------------------------------------ATTG 
HVRIV         ATTATTTTNNNNGTTTATTTTAATATANATTT---------------------------- 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      ATTATTT----TGTTTATTTTAATATAAATAATTAATATTTTAATAACAGATTAATAGTG 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
186 
 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        TTTAATCAAAT-AAACGCACCACTAA----T--GTGG----------------------- 
HVRI          GTT--------------------------------------------------------- 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TTTAACTATTTGAGAGAGAGCGATAACAGGTCTGTGATGCCCTTAGATGTCCGGGGCTGC 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      ACGCGCGCTACAATGTAGTGATCATTATGTTCCTGTTTAGAGATAAATGGGTAAACATTG 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------------------------------ 
635           ------------------------------------------------------------ 
858           ------------------------------------------------------------ 
622           ------------------------------------------------------------ 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          -----------------------------GGCTCGAGTTTTTCAGCAAGATGAATTCCAA 
ON2           -----------------------------GGCTCGAGTTTTTCAGCAAGATGAATTCCAA 
F3LAMP        ------------------------------------------------------------ 
M84229.1      AAAACATTACGTAACTGGGAGTGAAAATTGCAATTATTTTTCATGAACGAGGAATTCCAA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           -----------------GGCTCGAGTTTTTCAGCAGATTGCCTCTGGATATTGCTCATTT 
635           ------------GGATGGCTCGAGTTTTTCAGCAAGATTGNCTCTGGATATTGCTCAGTT 
858           --------------ATGGCTCGAGTTTTTCAGCAAGATTGCCTCTGGATATTGCTCAGTT 
622           ---------------TGGCTCGAGTTTTTCAGCAAGATTGCCTCTGGATATTGCTCAGTT 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          GTAAACGTAAGTCATTAGCTTACATTGATTACGTCCCTGCCCTTTGTACACACCGCCCGT 
ON2           GTAAACGTAAGTCATTAGCTTACATTGATTACGTCCCTGCCCTTTGTACACACCGCCCGT 
F3LAMP        ------------------------------------------------------------ 
M84229.1      GTAAACGTAAGTCATTAGCTTACATTGATTACGTCCCTGCCCTTTGTACACACCGCCCGT 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           CCAGGTAACGACGGGCGGTGTGTAGAAAGGG---CAGGGACGTAATCAATGTAAGCTAAT 
635           CCGGGTAACGACGGGNGNTGTGTAGAAAGGG---CAGGGACGTGATCAATGTAAGCTAAT 
858           CCGGGCAGCGACGGGCGGTGTGTACAAAGGG---CAGGGACGTAATCAATGTAAGCTAAT 
622           CCGGGCAGCGACGGGCGGTGTGTACAAAGGG---CAGGGACGTAATCAATGTAAGCTAAT 
187 
 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          CGCTGCCCGGAACTGAGCAATATCCAGAGG------------------------------ 
ON2           CGCTGCCCGGAACTGAGCAATATCCAGAGG------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      CGCTGCCCGGAACTGAGCAATATCCAGAGGCAGGAAGAGATGTAATAAATTT-------T 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           GACTTACGTTTACTTGGAATTCA------------------------------------- 
635           GACTTACGTTTACTTGGAATTCA------------------------------------- 
858           GACTTACG---------------------------------------------------- 
622           GACTTACGTTTACTTGGAATTCA------------------------------------- 
HVRIII        ------------------------------------------------------------ 
B3LAMP        ------------------------------------------------------------ 
HVRI          ------------------------------------------------------------ 
HVRIV         ------------------------------------------------------------ 
qPCR          ------------------------------------------------------------ 
ON2           ------------------------------------------------------------ 
F3LAMP        ------------------------------------------------------------ 
M84229.1      TAATTTTTTTTATATTAAATCCTTCCAATCGCTGTTGTTTGAACCGGGCAAAAGTCGTAA 
HVRII         ------------------------------------------------------------ 
                                                                           
 
184           ------------------------------------- 
635           ------------------------------------- 
858           ------------------------------------- 
622           ------------------------------------- 
HVRIII        ------------------------------------- 
B3LAMP        ------------------------------------- 
HVRI          ------------------------------------- 
HVRIV         ------------------------------------- 
qPCR          ------------------------------------- 
ON2           ------------------------------------- 
F3LAMP        ------------------------------------- 
M84229.1      CAAGGTTTTCGTAGGTGAACCTGCAGAAGGATCATCA 
HVRII         ------------------------------------- 

















APPENDIX 3b: CLUSTAL W2 MULTIPLE SEQUENCE ALIGNMENT OF ANOMALOUS QPCR ASSAY 
PRODUCT (LARKIN ET AL., 2007) 
Grey= Reference sequence: M 84229 (Strongyloides stercoralis 18S ribosomal RNA gene, complete 
cds). 
Green= Nucleotide sequence match for the anomalous qPCR product (F- forward and B- back direct 
sequencing outer primer product, pGEM- product generated by the pGEM® T-Easy kit). 
 
F207qPCR      ------------------------------------------------------------ 0 
pGEM          ------------------------------------------------------------ 0 
M84229.1      ACCTGGTTGATCCTGCCAGTAGTCATATGCTTGTCTCAAAGATTAAGCCATGCATGTCTA 60 
B207qPCR      ------------------------------------------------------------ 0 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 0 
pGEM          ------------------------------------------------------------ 0 
M84229.1      AGTATAAACAAATTCATACTGTGAAACTGCGAATGGCTCATTAAATCAGTTATAGTTTAT 120 
B207qPCR      ------------------------------------------------------------ 0 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 0 
pGEM          ------------------------------------------------------------ 0 
M84229.1      TTGATGGTTTCTTGCTACATGGATAACTGTGGTAATTCTAGAGCTAATACATGCTKAAAA 180 
B207qPCR      ------------------------------------------------------------ 0 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 0 
pGEM          ------------------NNNNNNNNNNNNNNCNNNNNNNNNNGCGGCNGCNGNNNNNNA 42 
M84229.1      GCCCCGACTTCTGGAAGGGGTGTATTTATTAGATAAAAAACCAATGACTTCGGGCTCCTT 240 
B207qPCR      ------------------------------------------------------------ 0 
                                                                           
 
F207qPCR      -----------------------------------------------------------T 1 
pGEM          TTGNNTTCCNAGTAAACGTANNNNNNNNNNNNNNNNNNNCAGACNACNACTTCGTACCAT 102 
M84229.1      GGTGATTCATAATAACTTCTCGAATCGCATGGCCTTGCGCCGGCGATGCTTCATTCAAAT 300 
B207qPCR      ------------------------TCGTATGCCACGGTG--------------------- 15 
                                                                           
 
F207qPCR      TCGAGCAGCTTCNGGGTGCCNAGATGGAAGAGTTGAAG------------------CTTG 43 
pGEM          NNNNNNNNNTTCAGGGTGCCAAGATGGAAGAGTCGAAG------------------CTTG 144 
M84229.1      TTCTGCCCTATCAACTTTCGATGGTAGGATAGTGGCCTACCATGGTATCAACGGGTAACG 360 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      AGGA-----------AATCAAGAACAAGNTCATGAAGAATGCCCAGGAG------CGAGA 86 
pGEM          AGGA-----------AATCAAGAACAAGATCATGAAGAATGCCCAGGAG-------CAGA 186 
M84229.1      GGGAATTAGGGTTCGATTCCGGAGAGGGAGCCTGAGAAACGGCTACCACATCCAAGGAAG 420 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      ACATCATCTCCGATCA-TACCAAGATTGATGTACA---------TACCAAGGTAGCCAAC 136 
pGEM          ACATCATCTCCGATCA-TACCAAGATTGATGTACA---------TACCAAGGTAGCCAAC 236 
M84229.1      GCAGCAGGCGCGAAAATTACCCAATTTTAGTTAAAAGAGGTAGTGACGAAAAATGACAAC 480 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      GCCACC------GATGCATCAGGTAAGAACATCTTCAACTATGATGTAGATGTATCTTAT 190 
pGEM          GCCACC------GATGCATCAGGTAAGAACATCTTCAACTATGATGTAGATGTATCTTAT 290 
189 
 
M84229.1      CAAATATTATTATTAATATTTGGATTGAAAATCTTCAAGTTTAAATMACCTTGTTGGTAA 540 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      ACCGTAGATGA------------------------------------------------- 201 
pGEM          ACCGTAGATGA------------------------------------------------- 301 
M84229.1      AGGAAAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATACCAGCTTTCCAAGTGCATAAAA 600 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      ----------GGAT----------GACTCGGCCAAGGATGACTTTGCACCAGGTCGCTTC 241 
pGEM          ----------GGAG----------TACTCGGCCAAGGATGACTTTGCACCAGGTCGCTTA 341 
M84229.1      TGATTGTTGTGGTTAAAAAGCTCGTAGTTGGATTATAAAGATTGTATAATGAGCATCTTG 660 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      AAGGTAGAAGAATCCAATGCCGCTCAGGCAATGCTCGCC--------------------- 280 
pGEM          ATCACTAGTGAATTCGCGGCCGCCTGCAGGTCGACCATA--------------------- 380 
M84229.1      GATGTTATTTAATCATTATCATCTTATATTTTTATTATATTAGAAATAATATAATAACTG 720 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      -----ATCGTGA----AGAAGGCTTTGGAGGAAGATTTCGCCAAATATACCGCAGAG--G 329 
pGEM          -----TGGGAGAGCTCCCAACGCGTTGGATGCATAGCTTGAGTATTCTATAGTGTCACCT 435 
M84229.1      TCACTTTGAATAAATCAGAGGGT-TTAAACCAGACATTATATGTTTGTAT---------G 770 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      GGCAAGCAGG---------TGAAGATTCAGATTACCGGTATGGCAGA-----TGCCTTAC 375 
pGEM          AAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAC 495 
M84229.1      GTCTAGCATGGAATAACACTATAGAAAAATTTAGTGTGGTTTCACTTAATTTTTCATGAT 830 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      CATTCAGCCGCACCGTGGCATACGATGGCAGCTATGGCGACTTCGAGC------------ 423 
pGEM          AATTCCACACAAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGGTGNCTAATGA 555 
M84229.1      TAATAGGAACAAACGGGG---------GCA----------TTCGTATCGCTACGTTAGAG 871 
B207qPCR      ------------------------------------------------------------ 15 
                                                                           
 
F207qPCR      AGGAACCAGTACACAAGAACGGCGAACTGAG----------------------------- 454 
pGEM          GTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTG 615 
M84229.1      GTGAAATTCTT----------------GGACCGTAGCGAGACGTCCTACTGCGAAAGCAT 915 
B207qPCR      -----------------------------------------CGGCTGAATGGTAAGGCAT 34 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          TCGNGNNNNCTGCATTAATGAATCGGCNNACGCG-------------------------- 649 
M84229.1      TTGCCAAGAATGTTTTCATTAATCAAGAACGAAAGTTAGAGGTTCGAAGGCGATCAGATA 975 
B207qPCR      CT---------------------------------------------------------- 36 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          --------------------------CGGGGAGAGGCGGTTTGNNTATTGGGNGCTCTTC 683 
M84229.1      CCGCCCTAGTTCTAACCGTAAACTATGCCTACTAGATGTATGAATTATTAGTTATAATTA 1035 
B207qPCR      --GCCATACCGGTAATCTGAATCTTCACCTGCTTGCCCTCTGCGTATATTTGGCGAAATC 94 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          CGCTTCCTCNCTCACTGANTCGCTGCGCTCNGTCGTTCGGCTGNGGNNANNNGTANC--- 740 
M84229.1      TTTATGCATCTTCTCGGAAAC------GAAAGTCTTTCGGTTCCGGGGGAAGTATGGTTG 1089 
190 
 
B207qPCR      TTCCTCCAAAGCCT------------------TCTTCAC---GATGGCGAGCATTGC--- 130 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ---NNNNNNNCNNNAANGGNGNNNNNNNCGGTTATCCNCN-GA----NNCNNGGGGNNNA 792 
M84229.1      AAAAGCTGAAACTTAAAGGAATTGACGGAAGGCACCACCAGGAGTGGAGCCTGCGGCTTA 1149 
B207qPCR      -----------CTGAGCGG----------------------CATTGGATTCT---TCTAC 154 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          NNNCNAGGNAANNAACNNNNTGNNNCCNAAANGGNCNNCNAAANNNNNNNNNNNN----N 848 
M84229.1      ATTTGAC----TCAACACGGGAAAACTCACCCGGGCCGG-ACAC------TATAAGGATT 1198 
B207qPCR      CTTGAAG----CGACCTGGTGCAAAGTCATCCTTGGCCGAGTACTCCTCATCTACGGTAT 210 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          NNNAAANNNGNNNGNNNNNNNNGGNNNNNTNNNNNNNNNNNCCNNNNCCCCNN------- 901 
M84229.1      GACAGATTGATAGCTCTTTCATGATTTAG-TGGTTGGTGGTGCATGGCCG---------T 1248 
B207qPCR      AAGATACATCTACATCATAGTTGAAGATGTTCTTACCTGATGCATCGGTGGCGTTGGCTA 270 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      TCTTAGTTCGTGGATATGATTTGTCTGGTTGATTCCGATAACGAGCGAGACTTTTATGTT 1308 
B207qPCR      CCTTGGTATGTACATCAAT----CTTGGTATGATCGGAGATGATGTTCTGCTCCTGGGCA 326 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      ATATTAAATATAATTATTTTGTTTATTTTAATATAAATAATTAATATTTTAATAACAGAT 1368 
B207qPCR      TTCTTCATG---ATCTTGTTCTTGATTTCCT---CAAGCTTCAACTCTTCCATCT----- 375 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      TAATAGTGTTTAACTATTTGAGAGAGAGCGATAACAGGTCTGTGATGCCCTTAGATGTCC 1428 
B207qPCR      TG---------------------------------------------------GCACCCT 384 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      GGGGCTGCACGCGCGCTACAATGTAGTGATCATTATGTTCCTGTTTAGAGATAAATGGGT 1488 
B207qPCR      GAAGCTGCTCGAATGGTACGAAGTTGTCGTCT---------------------------- 416 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      AAACATTGAAAACATTACGTAACTGGGAGTGAAAATTGCAATTATTTTTCATGAACGAGG 1548 
B207qPCR      ------------------------------------------------------------ 416 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      AATTCCAAGTAAACGTAAGTCATTAGCTTACATTGATTACGTCCCTGCCCTTTGTACACA 1608 
B207qPCR      GACTCCAA---------------------------------------------------- 424 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      CCGCCCGTCGCTGCCCGGAACTGAGCAATATCCAGAGGCAGGAAGAGATGTAATAAATTT 1668 
B207qPCR      --------------------------------------------GAATGCTAATGACTT- 439 
191 
 
                                                                           
 
F207qPCR      ------------------------------------------------------------ 454 
pGEM          ------------------------------------------------------------ 901 
M84229.1      TTAATTTTTTTTATATTAAATCCTTCCAATCGCTGTTGTTTGAACCGGGCAAAAGTCGTA 1728 
B207qPCR      ------------------------------------------------------------ 439 
                                                                           
 
F207qPCR      -------------------------------------- 454 
pGEM          -------------------------------------- 901 
M84229.1      ACAAGGTTTTCGTAGGTGAACCTGCAGAAGGATCATCA 1766 


























APPENDIX 4: TABLE OF RESULTS OBTAINED FOR THE SAMPLES WITH ANOMALOUS RESULTS (CRS 





ORIGINAL CT GEL BAND 
SIZE 











296  -20oC 38.14 101 Negative N/A N/A 4oC Negative (289)  Latin 
America 
1054  4oC 40.59 101 Negative N/A N/A N/A No duplicate study sample  Bangladesh 
368  -20oC 31.36 101 Positive 101 S. stercoralis 99% 
homology 
4oC Negative (497)  Mauritius 
266  -20oC 48.16 500 Positive 500 Insufficient DNA N/A No other samples Worldwide 
331  -20oC 35.7 101 Negative N/A N/A 4oC Negative (873)  Worldwide 
1087  -20oC 36.56 101 Negative N/A N/A 4oC Negative (363)  Worldwide 
838  -20oC 35.2 101 Negative N/A N/A 4oC Negative (1064)  Worldwide 
200  -20oC 36.9 101 Negative N/A N/A 4oC Negative (310)  Unknown 
756  -20oC 35.52 101 Negative N/A N/A -20oC/ 
4oC 
Negative (716, 165 
1097, 639,369)*1  
Africa 
1127  -20oC 42.74 = equivocal result 101 Positive 101 Insufficient DNA, 
no sequence 
identity obtained 
4oC Positive (1196)  40.7= equivocal 





C 24.06 (LAMP also Positive 
for this sample) 




C Positive (358) 32.29 cPCR 
Positive 101bp gel band *2 
Africa 
994  4oC 35.84 Anomalous 
band 
Positive 101 Insufficient DNA -20oC (231) 39.5 cPCR Negative*2 Latin 
America 
800 4oC 26.76 (1in10 repeat 30.36  
LAMP also Positive) 
101 Positive 101 264 S. stercoralis 
94% homology 
-20oC Positive (264) 27.15 101bp gel 
band. LAMP also Positive *2 
Brazil 
786  4oC 35.4 101 Positive 101 Insufficient DNA -20oC Negative (415) *3  Worldwide 
677  4oC 38.91 Anomalous 
band 
Negative N/A N/A -20oC Positive (770) 38.15 anomalous 
band  cPCR Negative*4  
Worldwide 
748  4oC 34.43 101 Negative N/A N/A -20oC Negative (199) *4 Bangladesh 
214  4oC 34.26 101 Negative N/A N/A -20oC Negative (450) *4 Unknown 
1169  4oC 35.57 Anomalous 
band 
Negative N/A N/A -20oC Negative (388) *4 Spain 





Insufficient DNA -20oC Negative (999)  *4 Unknown 
1042  -20oC 36.92 101 Negative N/A N/A 4oC Negative (413)  
*4 
Worldwide 
120  -20oC 35.3 101 Negative N/A N/A 4oC Negative (823) *4 Africa 





N/A -20oC Negative (241) *5  Bangladesh 
176 4oC 35.99 101 Positive 101 Insufficient DNA -20oC Negative (1120) - *5  Worldwide 
725 -20oC 41.67 Anomalous 
band 
150bp 
Positive 101 Insufficient DNA 4oC 39.62 (213) *5*  Worldwide 
209  -20oC 35.4 101 Positive 101 S. stercoralis 
100% homology 
4oC Negative (479)  *5 Israel 
171  -20oC 35.13 (1in10 31.5) 101 Positive 101 S. stercoralis 
100% homology 
4oC Negative (1016) *5 Africa 
207   -20oC 35.29 101/ 500 Positive 500 S. stercoralis 
100% homology- 
short sequence 
4oC Negative (265) *5 anomalous 
band no sequence identity 
obtained 
Morocco 
213  -20oC 39.62 101/ 500 Positive 101 Insufficient DNA 4oC Positive (725 41.67 101/ 500 
insufficient DNA for 
sequencing)*6  
Worldwide 
*1 369 and 756 were received on the same date. False positive possibly due to contamination, no product generated by cPCR 
*2 True positive confirmed by cPCR 
*3 True positive confirmed by cPCR, discrepancy may be due to sampling error 
*4 False positive result, no product generated by cPCR 
*
5 
Possible true positive with very little DNA present 
*
6





APPENDIX 5: BUSINESS PLAN FOR THE INTRODUCTION OF A NAAT FOR THE DIAGNOSIS OF S. 




AGREEMENT AND PROPERTY 
RIGHTS 
This report is confidential and is the property of the University College London Hospitals NHS Foundation Trust (UCLH). All intellectual 
property rights belong to UCLH 
CONTACT INFORMATION Researcher: Katherine M Bowers (BMS band 7) katherine.bowers@uclh.nhs.uk 
Scientific Lead: Dr Spencer Polley spencer.polley@uclh.nhs.uk 
Clinical Lead: Prof. P Chiodini peter.chiodini@uclh.nhs.uk 
EXECUTIVE SUMMARY The introduction of a NAAT for the detection of S. stercoralis DNA in clinical samples with improved sensitivity and specificity to the 
current diagnostic repertoire on the basis of a prospective study performed at the Department of Clinical Parasitology for the fulfilment 
of a Professional Doctorate degree (with the University of Westminster) 
This study is submitted for approval to the UCLH board of Directors  
BACKGROUND 
JUSTIFICATION FOR THE 
STUDY 
Strongyloidiasis is caused by Strongyloides stercoralis (S. stercoralis) and is characterised by an array of symptoms ranging from 
asymptomatic to chronic non-specific gastro-intestinal problems in immunocompetent individuals and severe, potentially fatal, 
hyperinfection syndrome in immunocompromised individuals. The diagnosis of strongyloidiasis at the Department of Clinical 
Parasitology (DCP) is subject to low sensitivity because of a frequently low larval load and intermittent excretion of the parasite and low 
specificity where the antibodies are known to cross react with other helminthic parasites. Nucleic acid amplification techniques are 
available for the diagnosis of strongyloidiasis with reported improved sensitivity and specificity. A qPCR assay was investigated as part 
of a study for the fulfilment of a Professional Doctorate degree at the University of Westminster and a report is submitted here for 
approval 
PRODUCT REVIEW This study determined the following parameters for the qPCR assay: 
Analytical sensitivity: 100% 
Analytical specificity: 94.83% 
Limit of detection: 10-4 S. stercoralis larvae/ µl 
Overall percentage agreement with the composite reference standard: 80.63% (95% CI: 70.5-91.8) 
Precision: 0.3% within run (acceptable value < 10 % within run) 
Cost per test £8.21 
SERVICES The introduction of this test would offer an improved diagnostic service to users of DCP for the diagnosis of strongyloidiasis. 
This test is not available to routine diagnostic laboratories and as such would improve the service offered by DCP 
Further research is being carried out on the use of the qPCR assay for the determination of an appropriate treatment strategy using 
improved technology which was not available at UCLH under the current diagnostic testing regime. This will be of  benefit to patient 
care and improve clinical decision making 
MARKETING PLAN The provision of advanced technology by DCP to UCLH and referred samples from around the UK would improve the service available to 
UCLH by the introduction of a test that is not available elsewhere in the UK 
The cost of the test is presented to UCLH for developing a pricing analysis and includes turnaround time and reagents required. The 
costing analysis does not include running costs as the diagnostic service at UCLH has been privatised and the joint venture will 
determine the running costs. All equipment required is already available for diagnostic use 
GOALS AND STRATEGIES The goal is to introduce an improved diagnostic test for the diagnosis of strongyloidiasis 
The success of the new NAAT will be seen by the uptake of an improved diagnostic test for strongyloidiasis. S. stercoralis is increasingly 
being identified in Western travel medicine and the risk of severe disease in immunocompromised individuals indicates that this test 
will be of benefit to patients at UCLH and to other hospitals around the UK. 




APPENDIX 6: S. STERCORALIS DNA DETECTION- RAW DATA FOR LAMP AND QPCR ASSAYS. KEY AT 





























IDEA 4oC 115 4 2 2 0 6 Negative 0 Negative    0 
IDEA 4oC 117 1 2 7 0 4 Negative 0 33.65   101 1 
IDEA 4oC 119 1 0 7 1 6 Negative 0 Negative    0 
IDEA 4oC 125 3 1 0 1 1 47.12 1 28.97   101 1 
IDEA 4oC 130 0 0 0 0 6 Negative 0 Negative    0 
IDEA 4oC 141 3 1 3 0 2 24.24 1 22.49   101 1 
IDEA 4oC 156 1 0 2 1 5 Negative 0 Negative    0 
IDEA 4oC 157 4 0 1 0 7 Negative 0 Negative    0 
IDEA 4oC 158 4 2 5 1 6 Negative 0 Negative    0 
IDEA 4oC 161 3 0 2 1 5 Negative 0 Negative    0 
IDEA 4oC 164 2 1 2 0 4 Negative 0 Negative    0 
IDEA 4oC 165 2 0 1 0 8 Negative 0 Negative    0 
IDEA 4oC 168 1 0 1 0 6 Negative 0 Negative    0 
IDEA 4oC 172 1 0 0 0 6 Negative 0 Negative    0 
IDEA 4oC 181 3 0 1 0 7 Negative 0 Negative    0 
IDEA 4oC 196 4 2 2 1 3 Negative 0 Negative    0 
IDEA 4oC 263 0 2 7 0 6 Negative 0 Negative    0 
IDEA 4oC 285 4 0 1 0 7 Negative 0 Negative    0 
IDEA 4oC 334 3 2 1 0 4 Negative 0 30.07   101 1 
IDEA 4oC 352 1 0 2 1 7 Negative 0 Negative    0 
IDEA 4oC 359 2 0 0 0 5 Negative 0 Negative    0 
IDEA 4oC 363 3 0 7 1 6 Negative 0 Negative    0 
IDEA 4oC 364 3 0 0 0 5 Negative 0 Negative    0 
IDEA 4oC 383 1 0 1 1 4 Negative 0 Negative    0 
IDEA 4oC 402 4 0 2 0 4 Negative 0 Negative    0 
IDEA 4oC 408 3 2 0 0 2 Negative 0 Negative    0 
IDEA 4oC 413 1 0 7 1 4 Negative 0 Negative    0 
IDEA 4oC 419 1 0 1 0 7 Negative 0 Negative    0 
IDEA 4oC 470 3 2 2 0 5 Negative 0 Negative    0 
IDEA 4oC 497 1 0 1 0 2 Negative 0 Negative    0 
IDEA 4oC 515 3 0 7 0 6 Negative 0 Negative    0 
IDEA 4oC 528 2 0 2 0 2 Negative 0 Negative    0 
IDEA 4oC 536 3 0 0 0 2 Negative 0 Negative    0 
IDEA 4
o
C 576 3 1 2 0 6 Negative 0 Negative    0 
IDEA 4oC 593 1 0 1 0 5 Negative 0 Negative    0 
IDEA 4oC 666 3 0 1 0 1 Negative 0 Negative    0 
IDEA 4oC 683 3 2 1 0 2 Negative 0 Negative    0 
IDEA 4oC 684 4 2 2 0 5 Negative 0 Negative    0 
IDEA 4oC 686 3 2 4 1 4 Negative 0 Negative    0 































IDEA 4oC 792 3 2 3 0 4 Negative 0 Negative    0 
IDEA 4oC 716 2 2 1 0 1 Negative 0 Negative    0 
IDEA 4oC 810 2 0 3 0 1 Negative 0 Negative    0 
IDEA 4oC 813 1 3 1 0 4 Negative 0 Negative    0 
IDEA 4oC 828 3 0 2 0 5 Negative 0 Negative    0 
IDEA 4oC 840 4 1 2 0 4 Negative 1 29.09   101 1 
IDEA 4oC 842 0 0 1 0 5 Negative 0 Negative    0 
IDEA 4oC 858 1 2 1 1 4 32.18 1 23.63   101 1 
IDEA 4oC 893 3 1 2 0 6 Negative 0 Negative    0 
IDEA 4oC 894 1 0 2 1 7 Negative 0 Negative    0 
IDEA 4oC 896 4 2 2 0 5 Negative 0 35.25   101 1 
IDEA 4oC 923 3 0 0 1 5 Negative 0 Negative    0 
IDEA 4oC 939 3 0 2 0 3 Negative 0 Negative    0 
IDEA 4oC 951 3 2 1 1 6 Negative 0 Negative    0 
IDEA 4oC 970 3 2 2 0 4 Negative 0 Negative    0 
IDEA 4oC 1007 3 0 0 0 5 Negative 0 Negative    0 
IDEA 4oC 1024 4 0 2 1 5 Negative 0 Negative    0 
IDEA 4oC 1054 3 0 2 0 8 Negative 0 40.59   101 1 
IDEA 4oC 1060 2 0 1 1 4 Negative 0 Negative    0 
IDEA 4oC 1081 4 2 7 1 5 Negative 0 Negative    0 
IDEA 4oC 1097 2 0 1 0 8 Negative 0 Negative    0 
IDEA 4oC 1121 3 1 2 0 6 Negative 0 37.76   101 1 
IDEA -20oC 111 2 0 0 1 7 Negative 0 Negative    0 
IDEA -20oC 135 4 2 2 0 5 Negative 0 Negative    0 
IDEA -20oC 136 3 0 1 0 1 Negative 0 Negative    0 
IDEA -20oC 142 3 1 3 0 2 24.06 (21.2.16) 1 17.76   101 1 
IDEA -20oC 143 3 2 2 0 5 Negative 0 Negative    0 
IDEA -20oC 148 2 0 2 0 2 Negative 0 Negative    0 
IDEA -20oC 151 2 0 1 1 4 Negative 0 Negative    0 
IDEA -20oC 153 1 0 1 1 4 Negative 0 Negative    0 
IDEA -20oC 228 3 0 7 0 6 Negative 0 Negative Negative 
5.3.16 
  0 
IDEA -20oC 229 0 0 1 0 5 Negative 0 Negative    0 
IDEA -20oC 244 3 0 1 0 7 Negative 0 Negative    0 
IDEA -20oC 266 1 0 7 0 6 Negative 0 48.16   500 2 
IDEA -20oC 274 0 0 0 0 6 Negative 0 Negative    0 
IDEA -20oC 282 1 0 2 1 5 Negative 0 Negative    0 
IDEA -20oC 315 1 0 1 0 7 Negative 0 Negative    0 
IDEA -20oC 327 0 2 7 0 6 Negative 0 Negative    0 
IDEA -20oC 333 4 0 1 0 7 Negative 0 Negative    0 
IDEA -20oC 368 1 0 1 0 2 Negative 0 31.36   101 1 
IDEA -20oC 369 2 2 1 0 1 Negative 0 Negative    0 
IDEA -20oC 387 4 2 2 0 5 Negative 0 Negative    0 































IDEA -20oC 473 4 0 1 0 7 Negative 0 Negative    0 
IDEA -20oC 494 3 0 2 1 5 Negative 0 Negative    0 
IDEA -20oC 532 2 1 2 0 4 38.48 1 27.37   101 1 
IDEA -20oC 549 1 0 7 1 6 Negative 0 Negative    0 
IDEA -20oC 561 3 0 0 0 5 Negative 0 Negative    0 
IDEA -20oC 569 3 0 1 0 7 Negative 0 Negative    0 
IDEA -20oC 601 3 0 2 0 3 Negative 0 Negative    0 
IDEA -20oC 605 3 1 2 0 6 Negative 0 28.47   101 1 
IDEA -20oC 607 1 2 7 0 4 58.42(21.2.16) 1 26.42   101 1 
IDEA -20oC 608 1 0 1 0 5 Negative 0 Negative    0 
IDEA -20oC 625 1 0 0 0 6 Negative 0 Negative    0 
IDEA -20oC 639 2 0 1 0 8 Negative 0 Negative    0 
IDEA -20oC 669 4 0 2 1 5 Negative 0 Negative    0 
IDEA -20oC 729 3 2 1 0 2 Negative 0 Negative    0 
IDEA -20oC 756 2 0 1 0 8 Negative 0 35.52   101 1 
IDEA -20oC 790 4 2 2 1 3 Negative 0 Negative    0 
IDEA -20oC 810 2 0 3 0 1 Negative 0 Negative    0 
IDEA -20oC 829 4 0 2 0 4 Negative 0 Negative    0 
IDEA -20oC 845 2 0 0 0 5 Negative 0 Negative    0 
IDEA -20oC 860 3 2 3 0 4 Negative 0 Negative    0 
IDEA -20oC 898 4 2 2 0 6 Negative 0 Negative    0 
IDEA -20oC 931 1 0 1 0 6 Negative 0 Negative    0 
IDEA -20oC 936 1 2 1 1 4 33.48 1 20.9    1 
IDEA -20oC 950 4 1 2 0 4 33.30 (21.2.16) 1 24.58   101 1 
IDEA -20oC 955 3 1 2 0 6 Negative 0 Negative    0 
IDEA -20oC 960 3 0 2 0 5 Negative 0 Negative    0 
IDEA -20oC 980 4 2 5 1 6 Negative 0 Negative    0 
IDEA -20oC 997 1 0 2 1 7 Negative 0 Negative    0 
IDEA -20oC 1022 1 2 1 0 4 Negative 0 33.3   101 1 
IDEA -20oC 1042 1 0 7 1 4 Negative 0 36.92   101 1 
IDEA -20oC 1087 3 0 7 1 6 Negative 0 36.56   101 1 
IDEA -20oC 1132 3 2 2 0 4 Negative 0 Negative    0 
IDEA -20oC 1152 3 0 1 0 5 Negative 0 Negative    0 
IDEA -20oC 1181 1 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 102 0 0 1 1 6 Negative 0 Negative    0 
Diag 4oC 106 0 0 1 0 4 Negative 0 Negative    0 
Diag 4oC 108 3 1 0 0 7 49.36 1 31.46   101 1 
Diag 4oC 109 1 0 2 1 4 Negative 0 Negative    0 
Diag 4oC 110 1 0 2 0 5 Negative 0 Negative    0 
Diag 4oC 112 1 0 7 0 7 Negative 0 Negative    0 
Diag 4oC 113 1 0 2 0 1 Negative 0 Negative    0 
Diag 4oC 118 1 0 0 0 7 Negative 0 Negative    0 































Diag 4oC 124 0 0 7 0 3 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 123 1 0 2 0 8 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 126 1 0 1 1 5 Negative 0 Negative    0 
Diag 4oC 127 0 0 2 1 6 Negative 0 Negative    0 
Diag 4oC 128 0 0 1 1 5 Negative 0 Negative    0 
Diag 4oC 131 1 0 1 0 5 Negative 0 Negative    0 
Diag 4oC 138 0 2 2 1 4 Negative 0 Negative    0 
Diag 4oC 139 0 2 7 0 6 Negative 0 Negative    0 
Diag 4oC 144 1 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 146 0 0 1 0 2 38.3 1 24.06   101 1 
Diag 4oC 155 0 1 0 0 5 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 160 0 0 4 1 7 Negative 0 Negative    0 
Diag 4oC 162 0 0 1 1 5 Negative 0 Negative    0 
Diag 4oC 163 1 2 1 1 7 Negative 0 Negative    0 
Diag 4oC 170 0 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 173 0 2 3 0 3 Negative 0 Negative    0 
Diag 4oC 176 1 0 7 1 5 Negative 0 35.99   101 1 
Diag 4oC 185 0 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 186 0 0 0 0 7 Negative 0 Negative    0 
Diag 4oC 187 0 0 7 0 3 Negative 0 Negative    0 
Diag 4oC 190 0 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 193 0 0 1 0 7 Negative 0 Negative    0 
Diag 4oC 194 0 0 1 1 6 Negative 0 Negative    0 
Diag 4oC 201 0 0 1 1 7 Negative 0 Negative    0 
Diag 4oC 202 0 0 0 1 7 Negative 0 Negative    0 
Diag 4oC 204 0 2 2 1 4 Negative 0 Negative    0 
Diag 4oC 205 0 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 213 0 0 7 0 6 Negative 0 39.62   101 1 
Diag 4oC 214 0 0 0 0 7 Negative 0 34.96   101 1 
Diag 4oC 218 0 2 3 0 2 Negative 0 32.31   101 1 
Diag 4oC 223 0 0 1 1 3 Negative 0 Negative    0 
Diag 4oC 224 0 0 1 0 5 Negative 0 Negative    0 
Diag 4oC 239 0 3 7 0 5 Negative 0 Negative    0 
Diag 4oC 240 1 0 0 0 3 Negative 0 Negative    0 
Diag 4oC 243 0 0 1 1 8 Negative 0 Negative    0 
Diag 4oC 245 0 2 7 0 7 Negative 0 Negative    0 
Diag 4oC 249 0 0 7 1 7 Negative 0 Negative    0 
Diag 4oC 251 0 2 2 0 4 Negative 0 Negative    0 
Diag 4oC 252 0 0 1 0 7 Negative 0 Negative    0 
Diag 4oC 257 0 0 1 0 3 Negative 0 Negative    0 
Diag 4oC 258 0 0 1 0 7 Negative 0 Negative    0 
Diag 4oC 259 0 0 1 1 6 Negative 0 Negative Negative 
5.3.16 
  0 































Diag 4oC 267 0 0 7 0 6 Negative 0 Negative    0 
Diag 4oC 265 0 0 1 0 5 Negative 0 Negative    0 
Diag 4oC 268 0 0 7 1 6 Negative 0 Negative    0 
Diag 4oC 269 0 1 0 0 5 36.48(21.2.16) 1 26.05   101 1 
Diag 4oC 270 1 0 7 1 7 Negative 0 Negative    0 
Diag 4oC 272 0 0 0 0 6 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 273 1 0 0 0 4 Negative 0 Negative    0 
Diag 4oC 275 0 1 7 0 6 23.36 1 20.73   101 1 
Diag 4oC 276 1 0 5 1 5 Negative 0 Negative    0 
Diag 4oC 278 0 2 1 0 4 Negative 0 30.97   101 1 
Diag 4oC 283 0 2 7 0 3 Negative 0 Negative    0 
Diag 4oC 284 0 0 7 0 6 Negative 0 Negative    0 
Diag 4oC 286 0 0 2 0 7 Negative 0 Negative    0 
Diag 4oC 287 0 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 288 0 1 0 0 8 Negative 0 Negative    0 
Diag 4oC 289 0 0 5 0 6 Negative 0 Negative    0 
Diag 4oC 291 0 0 7 1 5 Negative 0 Repeat 
1 in 10 
Negative 
25.3.16 
  0 
Diag 4oC 292 0 1 0 0 6 45.36(21.2.16) 1 28.41   101 1 
Diag 4oC 294 0 0 0 0 4 Negative 0 40.84   101 1 
Diag 4oC 297 0 2 2 0 3 Negative 0 Negative    0 
Diag 4oC 298 0 0 1 0 8 Negative 0 Negative    0 
Diag 4oC 299 0 0 7 1 7 Negative 0 Negative    0 
Diag 4oC 301 0 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 304 0 0 1 0 7 Negative 0 Negative    0 
Diag 4oC 307 0 0 5 1 4 Negative 0 Negative    0 
Diag 4oC 309 0 2 2 0 5 Negative 0 Negative    0 
Diag 4oC 310 0 0 0 0 3 Negative 0 Negative    0 
Diag 4oC 312 0 0 2 1 6 Negative 0 Negative    0 
Diag 4oC 313 0 0 1 1 6 Negative 0 Repeat 
1 in 10 
Negative 
16.4.16 
  0 
Diag 4oC 314 0 0 1 1 3 Negative 0 Negative    0 
Diag 4oC 316 0 0 2 1 8 Negative 0 Negative    0 
Diag 4oC 318 0 0 0 0 6 Negative 0 41.6   101 1 
Diag 4oC 320 0 0 1 0 8 Negative 0 Negative    0 
Diag 4oC 323 0 0 0 1 8 Negative 0 Negative    0 
Diag 4oC 324 0 0 2 0 5 Negative 0 Negative    0 
Diag 4oC 325 0 1 5 1 8 27.24(21.2.16) 1 18.14   101 1 
Diag 4oC 326 0 2 5 0 3 Negative 0 Negative    0 
Diag 4oC 328 3 1 0 0 7 Negative 0 33.65   101 1 
Diag 4oC 336 1 0 1 1 3 Negative 0 Negative    0 
Diag 4oC 353 1 0 7 1 8 Negative 0 Negative    0 
Diag 4oC 356 0 0 3 1 7 Negative 0 Negative    0 
Diag 4oC 357 0 0 7 1 6 Negative 0 Negative    0 































Diag 4oC 384 0 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 380 1 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 385 0 0 7 1 6 Negative 0 Negative    0 
Diag 4oC 391 0 0 0 1 5 Negative 0 Negative    0 
Diag 4oC 410 0 0 2 1 4 Negative 0 Negative    0 
Diag 4oC 416 0 0 1 1 6 Negative 0 Negative    0 
Diag 4oC 420 0 2 0 0 5 Negative 0 Negative    0 
Diag 4oC 444 0 0 7 0 5 Negative 0 Negative    0 
Diag 4oC 446 1 2 0 0 3 Negative 0 Negative    0 
Diag 4oC 449 0 2 2 1 7 Negative 0 Negative    0 
Diag 4oC 451 0 0 1 0 6 Negative 0 Negative    0 
Diag 4oC 454 0 0 0 1 6 Negative 0 Negative    0 
Diag 4oC 455 2 1 0 0 5 Negative 0 32.35   101 1 
Diag 4oC 456 0 2 1 0 4 Negative 0 Negative    0 
Diag 4oC 457 0 0 1 1 7 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 458 0 0 0 1 5 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 460 0 0 0 0 7 Negative 0 Negative    0 
Diag 4oC 464 0 0 0 1 8 Negative 0 Negative    0 
Diag 4oC 474 1 0 2 0 5 Negative 0 Negative    0 
Diag 4oC 476 0 0 1 1 8 Negative 0 Negative    0 
Diag 4oC 479 0 0 6 1 5 Negative 0 Negative    0 
Diag 4oC 482 0 2 7 1 8 Negative 0 Negative    0 
Diag 4oC 486 1 0 7 0 7 Negative 0 Negative    0 
Diag 4oC 488 0 0 7 1 8 Negative 0 Negative    0 
Diag 4oC 493 1 0 1 1 7 Negative 0 Negative    0 
Diag 4oC 496 0 0 7 1 6 Negative 0 Negative    0 
Diag 4oC 498 1 0 5 1 7 Negative 0 Negative    0 
Diag 4oC 500 0 0 1 1 8 Negative 0 Negative    0 
Diag 4oC 502 0 2 7 0 3 Negative 0 Negative    0 
Diag 4oC 503 0 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 504 0 0 1 0 4 Negative 0 Negative    0 
Diag 4oC 506 1 2 2 0 5 Negative 0 Negative    0 
Diag 4oC 507 0 0 7 1 8 Negative 0 Negative    0 
Diag 4oC 510 0 2 1 1 6 Negative 0 Negative    0 
Diag 4oC 511 0 0 2 0 5 Negative 0 Negative    0 
Diag 4oC 514 0 0 7 1 6 Negative 0 Negative    0 
Diag 4oC 516 0 0 5 0 8 Negative 0 Negative    0 
Diag 4oC 523 0 0 7 0 7 Negative 0 Negative    0 
Diag 4oC 524 1 0 0 1 6 Negative 0 Negative    0 
Diag 4oC 525 1 0 2 1 5 Negative 0 Negative    0 
Diag 4oC 526 1 2 1 0 3 Negative 0 Negative    0 
Diag 4oC 534 
 
2 1 0 1 6 Negative 0 31.71   101 1 
Diag 4oC 540 
 































Diag 4oC 548 0 0 2 0 5 Negative 0 Negative    0 
Diag 4oC 550 0 0 7 1 5 Negative 0 Negative    0 
Diag 4oC 555 0 0 5 0 6 Negative 0 Negative    0 
Diag 4oC 556 0 0 2 0 8 Negative 0 Negative    0 
Diag 4oC 570 0 0 0 1 8 Negative 0 Negative    0 
Diag 4oC 579 1 0 2 0 3 Negative 0 Negative    0 
Diag 4oC 581 1 0 2 1 8 Negative 0 Negative    0 
Diag 4oC 582 1 0 4 1 7 Negative 0 Negative    0 
Diag 4oC 612 0 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 614 1 0 5 1 6 Negative 0 Negative    0 
Diag 4oC 624 0 0 7 0 7 Negative 0 Negative    0 
Diag 4oC 635 0 1 3 0 4 24.54(21.2.16) 1 17.07   101 1 
Diag 4oC 641 1 0 1 1 7 Negative 0 Negative    0 
Diag 4oC 643 0 0 0 0 4 Negative 0 Negative    0 
Diag 4oC 650 0 0 1 1 4 Negative 0 Negative    0 
Diag 4oC 653 0 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 656 0 0 1 0 8 Negative 0 Negative    0 
Diag 4oC 660 2 0 2 0 7 Negative 0 Negative    0 
Diag 4oC 668 0 0 0 1 7 Negative 0 Negative    0 
Diag 4oC 677 0 0 7 1 7 Negative 0 38.91   ? 2 
Diag 4oC 691 0 0 7 1 5 Negative 0 Negative    0 
Diag 4oC 696 1 0 5 1 5 Negative 0 Negative    0 
Diag 4oC 701 0 0 5 0 6 Negative 0 Negative    0 
Diag 4oC 708 1 0 2 1 3 Negative 0 Negative    0 
Diag 4oC 719 0 0 4 1 6 Negative 0 Negative    0 
Diag 4oC 723 0 0 0 1 5 Negative 0 Repeat 
1 in 10 
Negative 
25.3.16 
  0 
Diag 4oC 725 0 0 7 1 5 Negative 0 Negative    0 
Diag 4oC 727 0 2 2 0 1 Negative 0 Repeat 
1 in 10 
Negative 
26.12.15 
  0 
Diag 4oC 739 1 0 7 1 4 Negative 0 Negative    0 
Diag 4oC 741 0 2 7 1 8 Negative 0 Negative    0 
Diag 4oC 743 1 0 0 1 5 Negative 0 Negative    0 
Diag 4oC 746 0 0 4 0 5 Negative 0 Negative    0 
Diag 4oC 748 0 0 2 1 8 Negative 0 34.43   101 1 
Diag 4oC 757 0 0 3 0 6 Negative 0 Negative    0 
Diag 4oC 767 0 0 1 1 5 Negative 0 Negative    0 
Diag 4oC 778 0 0 0 1 4 Negative 0 Negative    0 
Diag 4oC 780 0 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 781 0 0 0 1 7 Negative 0 Negative    0 
Diag 4oC 786 1 0 7 1 7 Negative 0 35.4   101 1 
Diag 4oC 788 0 0 2 0 7 Negative 0 Negative    0 
Diag 4oC 797 3 1 0 0 7 Negative 0 30.84   101 1 
Diag 4oC 799 0 0 7 0 7 Negative 0 Negative    0 































Diag 4oC 815 0 2 0 0 5 Negative 0 Negative    0 
Diag 4oC 816 0 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 821 0 0 4 1 7 Negative 0 Negative    0 
Diag 4oC 823 0 0 1 0 5 Negative 0 Negative    0 
Diag 4oC 827 0 0 7 0 6 Negative 0 Negative    0 
Diag 4oC 852 0 0 2 0 8 Negative 0 Negative    0 
Diag 4oC 859 0 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 862 0 1 1 1 6 Negative 0 35.71    1 
Diag 4oC 868 0 0 4 0 8 Negative 0 Negative    0 
Diag 4oC 873 0 0 7 0 8 Negative 0 Negative    0 
Diag 4oC 886 1 3 1 1 7 Negative 0 Negative    0 
Diag 4oC 889 0 0 4 1 4 Negative 0 Negative    0 
Diag 4oC 893 0 0 7 1 5 Negative 0 Negative    0 
Diag 4oC 903 0 2 0  6 Negative 0 35.92   101 1 
Diag 4oC 908 0 0 6 1 6 Negative 0 Negative    0 
Diag 4oC 919 0 0 1 0 8 Negative 0 Negative    0 
Diag 4oC 925 0 0 5 1 7 Negative 0 Negative    0 
Diag 4oC 929 1 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 935 0 2 7 1 4 Negative 0 Negative    0 
Diag 4oC 943 0 0 2 0 8 Negative 0 Negative    0 
Diag 4oC 946 0 0 0 0 4 Negative 0 Negative Negative 
5.3.16 
  0 
Diag 4oC 961 1 0 5 1 2 Negative 0 Negative    0 
Diag 4oC 965 3 1 0 0 7 Negative 0 34.61   101 1 
Diag 4oC 984 0 0 0 1 8 Negative 0 Negative    0 
Diag 4oC 992 0 2 2 0 2 Negative 0 Negative    0 
Diag 4oC 994 0 0 5 1 6 Negative 0 35.84   ? 2 
Diag 4oC 1002 0 0 2 0 5 Negative 0 37.53   101 1 
Diag 4oC 1006 0 2 1 1 7 Negative 0 35.27   101 1 
Diag 4oC 1016 0 0 1 0 3 Negative 0 Repeat 
1 in 10 
Negative 
25.3.16 
  0 
Diag 4oC 1025 0 0 7 1 5 Negative 0 Negative    0 
Diag 4oC 1027 0 0 7 1 7 Negative 0 Negative    0 
Diag 4oC 1035 1 0 0 0 5 Negative 0 Negative    0 
Diag 4oC 1056 1 0 0 0 7 Negative 0 Negative    0 
Diag 4oC 1061 0 0 0 1 7 Negative 0 Negative    0 
Diag 4oC 1064 0 0 7 1 8 Negative 0 Negative    0 
Diag 4oC 1067 0 2 1 0 5 Negative 0 Negative    0 
Diag 4oC 1075 0 0 0 1 3 Negative 0 Negative    0 
Diag 4oC 1084 0 0 0 0 7 Negative 0 Negative    0 
Diag 4oC 1088 1 0 7 0 3 Negative 0 Negative    0 
Diag 4oC 1090 1 0 0 1 3 Negative 0 Negative    0 
Diag 4oC 1091 1 0 7 1 7 Negative 0 Negative    0 
Diag 4oC 1092 0 0 1 1 8 Negative 0 Negative    0 































Diag 4oC 1101 0 0 7 1 4 Negative 0 Negative    0 
Diag 4oC 1108 0 0 1 0 7 Negative 0 Negative    0 
Diag 4oC 1112 0 0 7 0 7 Negative 0 Negative    0 
Diag 4oC 1136 0 0 0 1 6 Negative 0 Negative    0 
Diag 4oC 1145 1 0 7 1 6 Negative 0 Negative    0 
Diag 4oC 1151 0 2 2 0 6 Negative 0 Negative    0 
Diag 4oC 1154 0 0 0 0 6 Negative 0 Negative    0 
Diag 4oC 1163 1 1 2 1 5 Negative 0 Negative    0 
Diag 4oC 1164 0 0 1 1 8 Negative 0 Negative    0 
Diag 4oC 1168 0 0 1 0 6 Negative 0 Negative    0 
Diag 4oC 1169 0 0 4 1 2 Negative 0 35.57   101 2 
Diag 4oC 1179 0 0 7 1 4 Negative 0 Negative    0 
Diag 4oC 1180 1 0 5 1 5 Negative 0 Negative    0 
Diag 4oC 1183 1 0 2 0 6 Negative 0 Negative    0 
Diag 4oC 1183 0 0 2 1 6 Negative 0 Negative    0 
Diag 4oC 1187 0 0 7 1 2 Negative 0 Negative    0 
Diag 4oC 1189 0 0 2 1 7 Negative 0 Negative    0 
Diag 4oC 1194 0 0 2 1 4 Negative 0 Negative    0 
Diag 4oC 1196 0 0 1 1 7 Negative 0 40.7   ? 2 
Diag -20oC 103 0 2 7 0 7 Negative 0 Negative    0 
Diag -20oC 104 0 0 0 1 5 Negative 0 Negative    0 
Diag -20oC 120 0 0 1 0 5 Negative 0 35.3   101 1 
Diag -20oC 130 1 0 1 1 3 Negative 0 Negative    0 
Diag -20oC 133 0 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 137 1 0 2 1 7 Negative 0 Negative    0 
Diag -20oC 146 0 2 0 1 6 38.3 1 24.06   101 1 
Diag -20oC 149 0 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 152 0 0 1 1 3 Negative 0 Negative    0 
Diag -20oC 167 0 2 1 0 4 Negative 0 Negative    0 
Diag -20oC 169 1 0 2 0 8 Negative 0 Negative    0 
Diag -20oC 171 0 0 1 0 3 Negative 0 35.13 31.5(25.3.16) 0 0 0 
Diag -20oC 175 2 1 2 1 3 Negative 0 Negative    0 
Diag -20oC 177 0 0 7 1 6 Negative 0 Negative    0 
Diag -20oC 178 0 0 3 1 7 Negative 0 Negative    0 
Diag -20oC 179 0 0 1 0 7 Negative 0 Negative    0 
Diag -20oC 183 0 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 184 0 1 3 0 4 29.48(21.2.16) 1 20.93   101 1 
Diag -20oC 186 0 0 2 1 6 Negative 0 Negative    0 
Diag -20oC 191 1 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 192 0 0 4 0 5 Negative 0 Negative    0 
Diag -20oC 197 1 0 1 0 5 Negative 0 Negative    0 
Diag -20oC 198 0 2 2 1 4 Negative 0 40.05   101 1 































Diag -20oC 200 0 0 0 0 3 Negative 0 36.9   101 1 
Diag -20oC 207 0 0 1 0 5 Negative 0 35.29   500 2 
Diag -20oC 208 0 2 2 0 3 Negative 0 Negative    0 
Diag -20oC 209 0 0 6 1 5 Negative 0 35.4   101 1 
Diag -20oC 215 0 0 2 1 8 Negative 0 Negative    0 
Diag -20oC 220 0 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 226 0 0 2 1 6 Negative 0 Negative    0 
Diag -20oC 227 0 2 3 0 2 47.42 1 26.21   101 1 
Diag -20oC 231 0 0 5 1 6 Negative 0 39.5   ? 2 
Diag -20oC 232 0 0 1 0 4 Negative 0 Negative    0 
Diag -20oC 233 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 234 0 0 0 0 6 Negative 0 Negative    0 
Diag -20oC 235 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 237 0 0 1 1 3 Negative 0 Negative    0 
Diag -20oC 237 0 0 5 0 6 Negative 0 Negative    0 
Diag -20oC 238 0 2 2 0 6 Negative 0 Negative    0 
Diag -20oC 241 0 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 242 1 0 5 1 5 Negative 0 Negative    0 
Diag -20oC 247 0 0 7 1 2 Negative 0 Negative    0 
Diag -20oC 248 0 0 1 1 6 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 250 0 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 256 0 0 1 0 3 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 264 0 0 5 1 8 40.12(57.12 1:10) 1 27.15 30.48  101 1 
Diag -20oC 271 0 0 7 0 6 Negative 0 Negative    0 
Diag -20oC 277 0 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 279 0 0 2 1 7 Negative 0 Negative    0 
Diag -20oC 281 0 2 7 0 6 Negative 0 Negative    0 
Diag -20oC 290 0 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 296 0 0 5 0 6 Negative 0 38.14   101 1 
Diag -20oC 305 0 2 3 0 3 Negative 0 Negative    0 
Diag -20oC 308 2 1 0 0 5 52.24 (Negative 1:10) 1 27.49   101 1 
Diag -20oC 330 0 0 1 1 7 Negative 0 Negative    0 
Diag -20oC 331 0 0 7 0 8 Negative 0 35.7   101 1 
Diag -20oC 332 0 0 7 1 6 Negative 0 Negative    0 
Diag -20oC 335 0 0 1 0 7 Negative 0 Negative    0 
Diag -20oC 337 0 1 7 0 6 29.54 1 14.98   101 1 
Diag -20oC 340 0 0 7 0 6 Negative 0 Negative    0 
Diag -20oC 342 0 0 1 1 8 Negative 0 Negative    0 
Diag -20oC 344 0 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 345 0 0 7 0 3 Negative 0 Negative Negative   0 
Diag -20oC 346 0 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 348 0 0 4 1 7 Negative 0 Negative    0 































Diag -20oC 350 0 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 351 1 2 2 0 5 Negative 0 Negative    0 
Diag -20oC 354 0 2 2 1 7 Negative 0 Negative    0 
Diag -20oC 358 0 0 1 0 2 Negative 0 32.29   101 1 
Diag -20oC 360 1 0 2 0 1 Negative 0 Negative    0 
Diag -20oC 365 0 2 2 0 5 Negative 0 Negative    0 
Diag -20oC 370 0 0 4 1 7 Negative 0 Negative    0 
Diag -20oC 372 0 0 1 1 8 Negative 0 Negative    0 
Diag -20oC 374 0 0 7 1 6 Negative 0 Negative    0 
Diag -20oC 375 0 1 5 1 8 32.54 1 17.9   101 1 
Diag -20oC 376 0 0 5 1 7 Negative 0 Negative    0 
Diag -20oC 377 1 0 1 1 5 Negative 0 Negative    0 
Diag -20oC 378 0 0 2 1 6 Negative 0 Negative Negative 
30.1.16 
  0 
Diag -20oC 379 0 0 4 0 8 Negative 0 Negative    0 
Diag -20oC 381 1 2 1  7 Negative 0 Negative    0 
Diag -20oC 383 0 0 0 1 7 Negative 0 Negative    0 
Diag -20oC 388 0 0 4 1 2 Negative 0 Negative    0 
Diag -20oC 389 0 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 390 0 2 7 0 3 27.24(21.2.16) 1 24.2   101 1 
Diag -20oC 392 0 0 0 0 4 Negative 0 Negative    0 
Diag -20oC 394 0 2 1 1 6 Negative 0 Negative    0 
Diag -20oC 396 0 0 0 1 4 Negative 0 Negative    0 
Diag -20oC 401 0 0 1 0 8 Negative 0 Negative    0 
Diag -20oC 403 0 0 2 0 8 Negative 0 Negative    0 
Diag -20oC 404 0 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 406 0 0 1 1 6 Negative 0 Negative    0 
Diag -20oC 407 1 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 412 0 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 414 0 0 2 1 7 Negative 0 Negative    0 
Diag -20oC 415 1 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 416 0 0 1 1 6 Negative 0 Negative    0 
Diag -20oC 417 0 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 418 0 0 0 1 5 Negative 0 Negative    0 
Diag -20oC 421 0 0 1 1 6 Negative 0 Negative    0 
Diag -20oC 425 0 2 0 0 5 Negative 0 Negative    0 
Diag -20oC 426 0 0 1 0 6 Negative 0 Negative    0 
Diag -20oC 427 0 2 7 1 8 Negative 0 Negative    0 
Diag -20oC 428 0 2 1 0 4 Negative 0 Negative    0 
Diag -20oC 430 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 431 1 2 0 0 3 Negative 0 Negative    0 
Diag -20oC 432 0 2 0 0 5 Negative 0 32.27   101 1 
Diag -20oC 433 0 0 1 0 6 Negative 0 Negative    0 































Diag -20oC 435 0 0 0 1 5 Negative 0 Negative    0 
Diag -20oC 437 1 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 438 0 0 1 1 5 Negative 0 Negative    0 
Diag -20oC 439 1 0 2 1 4 Negative 0 Negative    0 
Diag -20oC 441 0 0 0 1 6 Negative 0 Negative    0 
Diag -20oC 443 0 0 0 1 8 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 445 1 0 7 1 8 Negative 0 Negative    0 
Diag -20oC 447 1 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 448 1 0 7 0 6 Negative 0 Negative    0 
Diag -20oC 450 0 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 452 1 0 0 0 4 Negative 0 Negative    0 
Diag -20oC 453 0 0 0 0 4 Negative 0 Negative    0 
Diag -20oC 459 1 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 462  1 2 0 7 Negative 0 Negative    0 
Diag -20oC 463 0 0 2 1 8 Negative 0 Negative    0 
Diag -20oC 465 0 0 6 1 6 Negative 0 Negative    0 
Diag -20oC 480 2 1 0 0 4 Negative 0 29.35   101 1 
Diag -20oC 480.2 2 1 0 0 4 42 1 27.6    1 
Diag -20oC 483 0 0 1 0 8 Negative 0 Negative    0 
Diag -20oC 495 0 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 501 1 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 505 2 1 0 1 6 33.36 1 24.43   101 1 
Diag -20oC 508 0 0 5 0 6 Negative 0 Negative    0 
Diag -20oC 521 0 0 1 0 7 Negative 0 Negative    0 
Diag -20oC 529 1 0 0 1 3 Negative 0 Negative    0 
Diag -20oC 530 0 0 1 1 8 Negative 0 Negative    0 
Diag -20oC 542 0 0 1 1 7 Negative 0 Negative    0 
Diag -20oC 552 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 558 0 0 2 0 7 Negative 0 Negative    0 
Diag -20oC 580 0 0 0 0 7 Negative 0 Negative    0 
Diag -20oC 584 0 0 1 1 5 Negative 0 Negative    0 
Diag -20oC 588 0 0 2 0 8 Negative 0 Negative    0 
Diag -20oC 595 0 0 1 1 4 Negative 0 Negative    0 
Diag -20oC 595 0 0 0 1 8 Negative 0 Negative    0 
Diag -20oC 598 0 0 4 1 6 Negative 0 Negative    0 
Diag -20oC 599 0 1 0 0 7 Negative 0 31.84   101 1 
Diag -20oC 613 0 0 2 1 4 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 622 0 1 0 0 7 Negative 0 31.29   101 1 
Diag -20oC 632 1 0 0 0 3 Negative 0 Negative    0 
Diag -20oC 632.2 1 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 636 1 2 1 0 3 Negative 0 Negative    0 
Diag -20oC 645 0 0 2 1 7 Negative 0 Negative    0 































Diag -20oC 647 0 1 1 1 6 53 Positive didn't 
reach threshold 
1 26.78   101 1 
Diag -20oC 651 0 0 0 1 8 Negative 0 Negative    0 
Diag -20oC 657 0 0 1 1 5 Negative 0 Negative    0 
Diag -20oC 658 0 0 1 0 7 Negative 0 Negative    0 
Diag -20oC 671 0 0 5 1 4 Negative 0 Negative    0 
Diag -20oC 672 1 1 2 1 5 Negative 0 33.89   101 1 
Diag -20oC 673 0 0 0 1 3 Negative 0 Negative    0 
Diag -20oC 680 1 0 0 1 5 Negative 0 Negative    0 
Diag -20oC 688 1 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 693 0 0 1 1 6 Negative 0 Negative    0 
Diag -20oC 698 1 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 703 0 1 0 0 8 Negative 0 Negative    0 
Diag -20oC 709 1 0 2 0 3 Negative 0 Negative    0 
Diag -20oC 725 0 0 7 0 6 Negative 0 41.67   ?150 0 
Diag -20oC 732 1 0 7 1 6 Negative 0 Negative    0 
Diag -20oC 744 0 0 1 1 8 Negative 0 Negative    0 
Diag -20oC 751 1 0 2 1 3 Negative 0 Negative    0 
Diag -20oC 753 0 3 7 0 5 Negative 0 Negative    0 
Diag -20oC 755 0 0 1 1 8 Negative 0 Negative    0 
Diag -20oC 761 0 1 2 1 3 Negative 0 Negative    0 
Diag -20oC 764 0 0 1 0 5 Negative 0 Negative    0 
Diag -20oC 770 0 0 7 1 7 Negative 0 38.15   ? 2 
Diag -20oC 779 1 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 785 1 0 5 1 6 Negative 0 Negative    0 
Diag -20oC 791 0 0 2 1 7 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 793 0 2 1 1 5 Negative 0 Negative    0 
Diag -20oC 805 0 0 5 0 8 Negative 0 Negative    0 
Diag -20oC 833 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 835 0 0 7 0 3 Negative 0 Negative    0 
Diag -20oC 838 0 0 7 1 8 Negative 0 35.2   101 1 
Diag -20oC 847 0 0 0 0 6 Negative 0 Negative    0 
Diag -20oC 851 0 0 0 1 6 Negative 0 Negative    0 
Diag -20oC 854 1 0 2 1 8 Negative 0 Negative    0 
Diag -20oC 865 0 0 2 0 7 Negative 0 Negative    0 
Diag -20oC 869 0 1 0 0 7 Negative 0 35.56    1 
Diag -20oC 872 0 0 7 1 4 Negative 0 Negative    0 
Diag -20oC 874 0 0 0 1 7 Negative 0 Negative    0 
Diag -20oC 890 0 0 2 1 7 Negative 0 Negative    0 
Diag -20oC 895 1 0 2 1 5 Negative 0 Negative    0 
Diag -20oC 897 0 0 1 0 7 Negative 0 Negative    0 
Diag -20oC 905 0 0 7 1 4 Negative 0 Negative    0 
Diag -20oC 913 0 0 1 1 8 Negative 0 Negative    0 































Diag -20oC 924 0 0 2 0 7 Negative 0 Negative    0 
Diag -20oC 930 0 0 7 1 8 Negative 0 Negative    0 
Diag -20oC 941 0 1 0 0 5 34.12 1 19.15   101 1 
Diag -20oC 949 1 0 5 1 2 Negative 0 Negative    0 
Diag -20oC 962 1 3 1 1 7 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 963 0 0 7 0 7 Negative 0 Negative    0 
Diag -20oC 966 0 2 1 0 5 Negative 0 Negative    0 
Diag -20oC 983 0 0 0 0 4 Negative 0 Negative    0 
Diag -20oC 986 0 2 2 1 4 Negative 0 Negative    0 
Diag -20oC 988 0 0 2 1 4 Negative 0 Negative    0 
Diag -20oC 989 1 0 0 1 6 Negative 0 Negative    0 
Diag -20oC 995 0 0 1 1 7 Negative 0 Negative    0 
Diag -20oC 998 0 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 999 0 0 0 0 6 Negative 0 Negative    0 
Diag -20oC 1001 0 2 2 0 4 Negative 0 Negative    0 
Diag -20oC 1003 1 0 7 0 3 Negative 0 Negative    0 
Diag -20oC 1010 0 0 1 0 8 Negative 0 Negative    0 
Diag -20oC 1023 1 0 5 1 7 Negative 0 Negative    0 
Diag -20oC 1033 0 0 0 1 8 Negative 0 Negative    0 
Diag -20oC 1041 0 0 2 1 4 Negative 0 Negative    0 
Diag -20oC 1043 0 2 7 1 8 Negative 0 Negative Negative 
5.3.16 
  0 
Diag -20oC 1055 0 2 2 0 1 Negative 0 Negative    0 
Diag -20oC 1058 0 0 1 1 6 Negative 0 Negative    0 
Diag -20oC 1059 2 1 0 0 5 Negative 0 Negative    0 
Diag -20oC 1063 0 2 2 0 2 Negative 0 Negative    0 
Diag -20oC 1069 1 0 1 1 7 Negative 0 Negative    0 
Diag -20oC 1073 0 0 0 1 7 Negative 0 Negative    0 
Diag -20oC 1080 0 0 0 0 5 Negative 0 Negative    0 
Diag -20oC 1089 0 2 7 1 4 Negative 0 31.29   101 1 
Diag -20oC 1095 3 1 0 0 7 Negative 0 33.57   101 1 
Diag -20oC 1099 0 0 3 0 6 Negative 0 Negative    0 
Diag -20oC 1107 0 2 1 1 7 Negative 0 Negative    0 
Diag -20oC 1120 1 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 1125 0 0 7 0 6 Negative 0 Negative   0 0 
Diag -20oC 1126 2 1 1 1 6 Negative 0 Negative    0 
Diag -20oC 1127 0 0 1 1 7 Negative 0 42.74   ? 2 
Diag -20oC 1141 0 0 7 1 8 Negative 0 Negative    0 
Diag -20oC 1142 0 0 1 0 8 Negative 0 Negative    0 
Diag -20oC 1157 0 0 7 1 7 Negative 0 Negative    0 
Diag -20oC 1158 0 0 0 0 3 Negative 0 Negative    0 
Diag -20oC 1165 1 0 1 1 7 Negative 0 Negative    0 
Diag -20oC 1171 1 0 5 1 5 Negative 0 Negative    0 































Diag -20oC 1176 1 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 1193 0 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 1200 0 0 1 0 4 Negative 0 Negative    0 
Diag -20oC 212/489 0 0 3 1 5 Negative 0 Negative    0 
Diag -20oC 519a 0 0 2 0 5 Negative 0 Negative    0 
Diag -20oC 520a 0 0 2 0 8 Negative 0 Negative    0 
Diag -20oC 522a 0 0 7 1 6 Negative 0 Negative    0 
Diag -20oC 527a 0 0 7 1 5 Negative 0 Negative    0 
Diag -20oC 531a 0 0 2 0 6 Negative 0 Negative    0 
Diag -20oC 533a 0 2 5 0 3 Negative 0 Negative    0 




  0 
Diag -20oC 538a 0 2 7 0 3 Negative 0 Negative    0 
 
KEY TO CODES FOR APPENDIX 6: 
LENGTH OF STORAGE 2011=4, 2012=3, 2013=2, 2014=1, 2015/ 2016=0 
REF STD (COMPOSITE REFERENCE STANDARD) CRS negative= 0, Microscopy/ culture positive only = 1, Serology positive only = 2, 
CRS positive = 3 
TRAVEL Unknown=0, Africa=1, Asia=2, Caribbean=3, Europe=4, Latin America=5, Middle 
East=6, Worldwide=7 
GENDER Male=0, Female=1 
AGE (YEARS) 1920-1929=1, 1930-1939=2, 1940-1949=3, 1950-1959=4, 1960-1969=5, 1970-
1979=6, 1980-1989=7, 1990-1999=8 





APPENDIX 7: GANTT CHART FOR PROGRESS TO A PROFESSIONAL DOCTORATE DEGREE 
 
